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Hydrocarbon stapling is a method of constraining a short polypeptide 
through the incorporation of alkenyl alanine unnatural amino acids,1, 2 which 
are metathesised during peptide synthesis to afford a covalent crosslink on one 
face of the peptide. The purpose of 'stapling' is to improve the therapeutic 
properties of a peptide by improving transport properties and resistance to 
proteolysis.2, 3 Stapling also reduces the conformational plasticity of a peptide, 
which in turn, should improve the potency of the crosslinked peptide with its 
binding partner.  
Alkenyl glycine ('monosubstituted') derivatives of amino acids have 
been previously synthesised, but overlooked for peptide stapling experiments.4 
This project investigated the utility of monosubstituted amino acids as 
surrogates for hydrocarbon stapling with a therapeutically relevant family of 
proteins, the apoptosis regulator Bcl-2 family and p53 proteins.5, 6 This led onto 
an investigation of the foundations of hydrocarbon stapling, to assess the extent 
that hydrocarbon stapling modulates potency through various biophysical and 
structural experiments.  
Hydrocarbon stapled peptides are classified as peptidomimetics within 
the field of foldamers,7, 8 which aims to construct scaffolds from synthetic 
oligomers which can replicate the three dimensional topography and 
functionality of native proteins.7, 8 Since the de novo design of synthetic proteins 
is out of reach, regions of proteins with distinct architecture have been 
replaced with mimetics to afford semi-synthetic proteins in a technique 
described as 'protein prosthesis'.9, 10  
The project also aimed to chemically synthesise a protein with four 
distinct helical regions, colicin immunity protein Im7,11 with the view to replace 
one of the helical regions with a stapled peptide or an oligobenzamide helix 
mimetic12 to afford a semi-synthetic protein to add to the growing field of 
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1.1  Protein Prosthesis: Replacing Sections of Native 
Proteins 
1.1.1 Proteins - A definition 
Proteins are diverse biological macromolecules that are comprised of a 
specific sequence of amino acids (primary structure), which fold into a three-
dimensional structure (known as its native conformation) to govern many 
intra- and extracellular biological functions.13 Sections of the polypeptide chain 
within a protein can adopt architectural features, known as secondary 
structures, which commonly are α-helices, β-strands, and turns;14, 15 all of 
which are stabilised by intramolecular hydrogen bonding networks. The folded, 
functional protein, which is composed of secondary structure is referred to as 
its tertiary structure.16 Finally, quaternary structure comprises multiple 
subunits of tertiary structure (which are not functional in isolation) that 
function as a complex. Conversely, with protein-protein interactions,17, 18 
tertiary protein subunits associate to form functional complexes that are more 
transient in nature.     
1.1.2 Protein Synthesis - Biological Machinery 
The unique sequences of proteins are genetically encoded within DNA, 
which commences polypeptide biosynthesis through a regulated pathway 





Figure 1.1 - Cartoon representation of the biosynthesis of a protein, demonstrating the 
key steps of transcription and translation before the full protein detaches from tRNA 
after a Stop codon is read by tRNA.  
The first process, transcription, is the unfolding of the double-helical 
structure of DNA followed by the recognition of the canonical nuclear bases of 
DNA by a complementary strand of 'messenger' RNA (mRNA), which passes into 
the cellular cytoplasm. During the second process, translation, mRNA is bound 
to a ribosome complex. Meanwhile, 'transfer' RNA (tRNA) is specifically 
acylated with an amino acid. Within the ribosome, translation of mRNA begins 
at a specific 'start' codon - a unique combination of three ribosomal bases (AUG 
in eukaryotic cells). The trinucleotide codon is then recognised by a 
complementary anticodon on amino-acylated tRNA, which has the first amino 
acid covalently bound to it. The next codon on mRNA is then 'read' by the 
ribosome, matched with a complementary amino-acetylated tRNA 
macromolecule and the amino acids translocated to form a dipeptide. This 
chain elongation continues until a 'stop' codon is reached on the mRNA, 
whereby the polypeptide detaches from the final tRNA unit and either 
undergoes posttranslational modification and/or folding into its functional 
tertiary structure.  
Typically, ribosomal protein expression is widely used in biology to 
synthesise native proteins using an 'overexpression' technique in different 




1.1.3 Modification of proteins - a mutagenesis approach 
Site-directed mutagenesis23 is widely used to mutate the DNA coding 
and therefore sequence of a protein of interest prior to its overexpression as 
outlined above (1.1.2). Mutagenesis systematically varies the protein sequence 
and the changes in the properties of the mutant protein - such as its activity, 
folding or recognition - are correlated with the changes in the amino acid 
sequence to identify 'key' residues.24, 25 Whilst this protein engineering 
technique is useful for studying mutations between the 20 proteinogenic amino 
acids, it does not allow the direct incorporation of unnatural amino acids in a 
specific position. 
To address this, Schultz and coworkers developed the 'Amber 
Suppression Method' which can allow the specific incorporation of unnatural 
amino acids into a polypeptide sequence (Figure 1.2a).26 The Amber 
Suppression Method utilises site directed mutagenesis by altering the codon at 
the desired position to a nonsense 'Amber Stop' codon. This codon recognises a 
complementary tRNA macromolecule within the ribosome that is 
aminoacylated with an unnatural amino acid, for its addition into a protein 
using biological machinery. Indeed, the toolkit of amino acids incorporated 
(Figure 1.2b)27 by these means have allowed the sequence specific installation 





Figure 1.2 - a) Cartoon representation of the Amber Suppression Method, which 
combines site-directed mutagenesis and chemical tRNA amino acylation to selectively 
incorporate unnatural amino acids; b) examples of interesting amino acids with light 
activated functionalities 1, 2;32, 33 click handles 3, 4;30, 33 fluorophores 533 and biotin 
tags 6.31   
Amber Suppression Methods have been recently expanded to allow 
installation of multiple unnatural amino acids by using other nonsense stop 
codons34-36 and expansion of the genetic code to quadruplet recognition.37 The 
culmination of the Amber Suppression Method has allowed the introduction of 
photocages and fluorophores into living cells32, 38, 39 and finally in vivo by 
fluorescently labelling Caenorhabditis elegans nematode worms.40     
However, there are limitations. Firstly, the fidelity of incorporation 
decreases as more unnatural residues are installed. Whilst this has been 
reported to be effective for five individual amino acids,34 this represents an 
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outlier. In addition, there are limitations to the use of quadruplet codons to 
expand the genetic code, whereby ribosomes also require mutagenesis to 
recognise quadruplet stop codons.37 Finally, suppression methods do not allow 
the placement of unnatural residues that are not α-amino acids, since the 
translocation site of the amino acids in the growing peptide chain are governed 
by the ribosome. Essentially, β-amino acids (where a methylene unit is added to 
the amino acid backbone) and other non α-amino acids are too sterically 
hindered to be effectively accommodated. 
1.1.4 Modified Proteins Through Chemical Synthesis 
1.1.4.1 Solid Phase Peptide Synthesis (SPPS) Methods 
 Mutagenesis-based modifications of proteins have become an elegant 
tool in protein engineering, but to overcome the limitations of the ribosome, 
synthetic chemistry is required to feasibly exchange any native amino acid, or 
sections of a protein with no limit to the number of mutations. 
Solid Phase Peptide Synthesis, established by Merrifield,41 allows 
peptide elongation on resin, where excess reagents are employed in couplings 
and are washed out after coupling is finished.  
 
Figure 1.3 - Steps of solid phase peptide synthesis using the Fmoc protection strategy. 
The common adaptation of SPPS is the use of Fmoc protecting strategies 
(Figure 1.3),42 where amino acid side chains are orthogonally protected by 
acid-labile protecting groups and peptide elongation is performed under basic 
conditions. It is using these methods that the majority of unnatural amino acids 
are incorporated into a polypeptides, but the caveat of SPPS is that coupling 
efficiency decreases as the peptide chain length increases. Since proteins, with 
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only a few notable exceptions,43 are generally accepted to compromise more 
than 50 residues, stepwise synthesis of a protein is considered inefficient. As a 
result, a convergent method for the total synthesis of proteins is required. 
1.1.4.2 Native Chemical Ligation Approach to Protein Synthesis 
Kent and coworkers devised an elegant route to the total chemical synthesis of 
proteins by their discovery of Native Chemical Ligation (NCL).44 Essentially, 
two peptides, one functionalised with a C-terminal thioester and the other with 
an N-terminal cysteine can be chemoselectively coupled (Figure 1.4a). Under 
denaturing buffer with neutral pH, the thiol of cysteine attacks the C-terminal 
thioester prior to an acyl switch to furnish a native peptide bond.45  
One apparent disadvantage of the NCL method is the requirement of a native 
cysteine to be present in the peptide sequence, but this can be circumvented by 
the conversion of Cys to Ala by reduction with Raney Nickel.46 Elaboration of 
the NCL pathway to Auxiliary Mediated Ligation obviates the use of cysteine 
entirely on the N-terminus of a peptide (Figure 1.4b & c). 
Similarly, methodologies have advanced to allow C-terminally activated 
peptides to be constructed and cleaved on modified resins, which alleviates the 
requirement for a solution phase chemoselective activation of a C-terminal 




Figure 1.4 - Examples ligation methods after their synthesis. a) is the classic 
thioester/cysteine native chemical ligation;45 b) utilises an auxiliary to afford a native 
peptide bond without cysteine, similar to c) which is the traceless Staudinger 
reaction;48-50 d) is the installation of a trizole moitey into a polypeptide from 




With NCL being an efficient and convergent pathway, peptides are 
generally built in sections of less than 30 residues before being ligated together. 
It is even possible to have a one-pot ligation strategy of more than two 
fragments by the use of a protected cysteine residue (Figure 1.5 Ligation 2),45, 52 
which can be deprotected after the first ligation has completed.  
 
Figure 1.5 - Simplified version of the total chemical synthesis of Sortase A which 
required several elegant chemoselective steps.53 Ligation 1 demonstrates the kinetic 
ligation product of a mixture of aryl and alkyl thioesters. Ligation 2 shows the use of a 
masked cysteine residue, thiazolidine (Thz), which is deprotected before Ligation 3. 
Desulfurisation followed ligation 3 to convert all non-endogenous cysteine residues to 
alanine.  
The elegance of NCL has been proven in the total chemical synthesis of 
several proteins that maintain full enzymatic activity and are of a size that is 
out of reach by a single step-wise synthesis on solid phase. Of particular 
interest are proteins that have required four peptide fragments and a 
succession of native chemical ligations and protection strategies, such as in the 
total synthesis of HIV-1 protease (203 residues)54 and Sortase A (148 residues, 
Figure 1.5).53 NCL has also been combined with microbial expression, where 
polypeptide thioesters are expressed and ligated with a chemically synthesised 
peptide and is termed 'Expressed Protein Ligation'.55-57  This particular 
methodology is related to the biochemistry of inteins,58 which are segments of 
proteins that undergo self-excision after expression through a related 
mechanism to native chemical ligation.59 Over the past 20 years, the range of 
techniques that are available to chemically synthesise proteins have provoked 
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studies into the replacement of secondary structure inducing residues or entire 
sections of proteins.  
1.1.5 'Posttranslational' Chemical Modification of Proteins 
Following translation on the ribosome, some amino acid residues can be 
further altered to expand the functionality of the protein.60 The possible 
modifications range from oxidation of cysteine residues to disulfides,61 to the 
introduction of larger molecules such as carbohydrates and lipids.62-64 Whilst 
biological machinery has evolved to efficiently and selectively modify 
polypeptide residues, replicating this chemically is a challenge.  
In addition to using Amber Suppression or total synthesis methods to 
install modified amino acids, Davis and coworkers have described a 
'tag-modify' approach where glycosylation can be chemoselectively introduced 
into proteins and polypeptides through the appropriate combination of 
reagents.65  
 
Figure 1.6 - a) Cartoon of the 'tag-modify' approach to the modification of proteins and 
b) the 'bio-orthogonal' groups66 that are used in the tag-modify system, with examples 
of their targets for glycosylation and phosphorylation.  
An elegant improvement to the tag-modify system utilises two 
mutations to install a nucleophilic Cys residue and an azide tag, has been used 
to chemoselectively add two modifications through nucleophilic attack and 
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click cycloadditions respectively,67 which has proven effective for the addition 
of oligosaccharides and photo-inducible moities.68   
  The final pertinent 'tag-modify' strategy is the chemical conversion of 
Cys using mesitylenesulfonyl-hydroxylamine (MSH) to dehydroalanine (Dha),69 
which is an electrophilic tag. Dha allows access to phosphorylation and 
glycosylation by nucelophilic moieties.69, 70  
Whilst the 'post-translational modification' approach does not lead to 
the significant alteration of the polypeptide backbone (vide infra, 1.1.6), it is 
nonetheless an essential technique in the biochemist's toolkit for introducing 
modified residues that cannot be easily installed through orthogonal tRNA or in 
cases where total protein synthesis is inefficient.    
1.1.6 Protein Prosthesis: Combining chemical protein synthesis  
and unnatural residues   
 'Protein prosthesis' is the replacement of components of the covalent 
structure of a protein with a suitable mimetic to afford a semi-synthetic 
analogue.9 Typically, the synthetic components are introduced through solid 
phase synthesis methods (1.1.4) and are designed to recapitulate native 
secondary structure without perturbing the tertiary structure and function of 




Figure 1.7 - Representation of the two different approaches to the creation of designed 
proteins with synthetic mimetics. 
Protein prosthesis is tangential to the 'foldamer' field of research. 
Foldamers are unnatural oligomers that are designed to mimic protein 
structure,71, 72 with the long term goal of synthesising fully functional, synthetic 
protein-like scaffolds.7 Foldamer science is generally observed as designing 
synthetic scaffolds using a 'bottom-up' approach (Figure 1.7), this is the 
opposite to protein prosthesis, which replaces secondary protein structure 
with a mimetic (known as a  top-down approach).    
A popular choice of protein secondary structure to replace is the β-turn, 
since β-turns may be induced by amino acids that favour the cis conformation, 
such as proline. Indeed, the introduction of a 5,5-dimethyl proline (dmP) 7 
derivative (which exists purely in the cis isomer) into 113NP turn section of 
RNase A resulted in no loss of catalytic activity and an increase in the 




Figure 1.8 - Structures of a) RNase A with the turn and loop regions replaced by β-turn 
mimetics highlighted in orange (PDB:3I7W); b) the Pin1 WW domain with a β-turn 
mimetic installed (PDB:2KBU)74 c) β-turn mimetics incorporated into RNase A 7 - 10 
and Pin-1 rotamase 11 & 12. 
The leading research groups in the field of 'protein prosthesis', Kelly and 
Raines, have identified several candidates for β-turn mimetics based on their 
intrinsic conformations (Figure 1.8 7-12).9, 73-76 These scaffolds, in turn, have 
been incorporated into loop regions of Pin-1 rotamase76 and RNase A,9, 73 
without hindering protein activity. Building from dmP 7, Raines and coworkers 
succeeded in the covalent linkage of two polypeptides with 'click' handles to 
afford a triazole proline mimetic 9 within the RNase A sequence,77 with no loss 
in activity compared to the wild type RNaseA. Click ligations have also been 
demonstrated in the total chemical synthesis of Cystatin A,51 where the triazole 
containing semi-synthetic protein did not have a weaker activity compared to 




Figure 1.9 – Bicyclic β-turn mimetic Hot=Tap 13 incorporated into the turn region of 
fibritin foldon (PDB: 2KBL and 2WWL).78, 79  
A contrast to the previous β-turn mimetics incorporated into proteins 
came from the laboratory of Geyer.79 Using a bicyclic 'Hot=Tap' motif 13 
promoted the formation of β-turns within a 29 residue miniprotein domain of 
T4 phage fibritin (Figure 1.9). However, the Hot=Tap molecule includes a pair 
of hydroxyl groups that are purposefully designed to interact with the tertiary 
environment of the protein, in contrast to previously examined β-turn mimetics 
which are designed to avoid disturbing the proximal environment. 
 
Figure 1.10 - a) Illustration of the loop sections of GB1 replaced by polyethylene glycol 
chains, highlighted in orange, (PDB: 2QMT)80 and b) cartoon of the installation of 
unnatural amino acids (red) in regions of secondary structure. 
The overlap between protein prosthesis and foldamer research was 
made evident by the research of Horne and coworkers.81, 82 Rather than 
attempting to rigidify turn regions with a conformationally locked unit, Horne 
and coworkers introduced a flexible polyethylene glycol (PEG) chain in the 
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place of three residues within a surface exposed loop section of the B1 domain 
of immunoglobulin G protein (GB1, 56 residues, Figure 1.10a).81 Whilst the 
prosthetic protein maintained the same fully folded architecture and activity of 
the native protein, the PEG chain decreased the prosthetic protein's folded 
stability. In another attempt, the same group returned to GB1 to demonstrate 
the effect of replacing individual amino acids within secondary structure 
(Figure 1.10b),82 culminating in a 56-mer protein composing of 20% unnatural 
residues whilst retaining the folded behaviour of the native protein. Whilst 
replacing 20% of the native backbone resulted in an unstable protein, it was a 
rare example of attempting to mimic native tertiary interactions, which has 
implications in future research into the design of fully functional synthetic 
tertiary scaffolds. However,  the overzealous introduction of artificial building 
blocks can have a detrimental effect, as found with a prosthetic RNaseA that 
had its activity reduced to 1% of the wild type.83 In this instance, native 
residues in an N-terminal helix of RNase A were replaced by peptoids - where 
the amino acid side chain branches from N rather than Cα - which arrested 
catalytic activity when 3 out of 13 residues were switched.      
An obvious candidate for replacing sections of α-amino acid sequences 
with unnatural oligomers are β-peptides, which are comprised of repeating 
units of β-amino acids (α-amino acids with an extra methylene unit within the 
backbone).84  
 
Figure 1.11 - Polypeptides compromised of α- and β- amino acids. β-Amino acids have 
additional nomenclature, where β3 amino acids have the side chain adjacent to the N-
terminus and β2 have the side chain adjacent to the C-terminus.  
β-Peptides are of interest in the foldamer research field because of their 
increased flexibility and improved resistance to proteolytic degradation, in 
addition to being able to achieve some biomimetic functions.8, 85 Tailoring an 
oligomeric chain with different repeating units of α and β amino acids can lead 
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to mimicry of α-peptide secondary structure, but with different folding and 
stability properties.86, 87 
Raines and coworkers recently evaluated and compared the use of a 
β-dipeptide 10 in the turn region of RNase A (Figure 1.8b), which displayed no 
pertubation in the function of RNaseA akin to the other β-turn inducing 
residues that had been previously incorporated.75   
 
Figure 1.12 – Solution NMR structure of hIL-8, displaying its secondary structure and 
electrostatic surface. The parent red helix was replaced with a β-peptide, which 
reversed its handedness. (PDB: 1IL8).88 
An ambitious introduction of secondary structure mimetics into a 
protein sequence came from Beck-Sickinger and coworkers.89 Here, a C-
terminal α-helix of human interleukin-8 (hIL-8) was replaced by a β-peptide 
oligomer (Figure 1.12).  The extra methylene unit in the β-peptide backbone 
promoted a 14-helix90 with opposite handedness to the native hIL-8 α-helix. In 
spite of this, the functionality of the semi-synthetic protein did not differ from 
the wild type, since the β-peptide oligomer projected key side chains in the 




Figure 1.13 - a) Cartoon of the assembly of the hdCM heterodimer. The green helical 
N1 region was replaced by αααβ peptides b) and c). SPPS and native chemical ligation 
was performed to furnish the semi-synthetic N1-Z polypeptide, followed by 
introducing hdCM enzyme cofactor that was microbially expressed. The heterodimeric 
complex is spontaneously formed and stabilised through a leucine zipper (blue Z 
ovals), and the red active site arises from the juxtaposition of N1 and three other 
helices (white ovals). 
Recently, Hilvert and coworkers succeeded in building fully functional 
prosthetic enzymes based on the heterodimeric chorismate mutase (hdCM).91 
Utilising α/β peptides with a repeating unit of αααβ 14, which have been 
previously shown as effective α-helix mimetics, an N-terminal α-helix was 
replaced to afford seven prosthetic enzyme sections (Figure 1.13). 
The prostheses then formed a heterodimer with another enzyme 
fragment to form an active site, which allowed the evaluation of the effect of 
introduction of a foldamer helix on tertiary stucture by observing the loss of 
enzymatic activity. Of the seven prosthetic enzymes, three demonstrated 
enzymatic activity close to the wild type, and variants using conformationally 
locked amino acids 15 abolished activity. This is particularly profound, as this 
is the first example of a designed foldamer replicating a tertiary environment. 
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The last 10 years have been fruitful in the development of prosthetic 
proteins to verify the capability of designed molecules and oligomers to mimic 
regions of proteins without detriment to activity. The fascinating result with 
hdCM particularly demonstrates the progress made towards the overall goal of 
the synthesis of fully functional tertiary structure mimetics.   
Aside from the construction of a fully synthetic and functional protein, 
one the remaining challenges of protein prosthesis methodology is the 
replacement of  α-helical or β-strand architecture that is not located at either 
terminus. Replacement of internal sections of a native protein could have a 
greater impact on the stability of a semi-synthetic protein and therefore alter 
its function. However, with the technology available for protein total synthesis 
and effective mimetic scaffolds having been identified, this challenge is not out 
of reach.    
1.2 Towards Therapeutic Peptides: Constrained 
Peptides 
The de novo design of secondary structure mimetics prior to replacing 
architecture of a native protein is a difficult challenge in both chemical 
synthesis and structural biology. However, it is possible to take inspiration 
from Protein-Protein Interactions (PPIs) that have regions of secondary 
structure at a binding interface. In mimicking the secondary structure with a 
synthetic scaffold, foldamer science can diversify into the production of 
molecules that are capable of recapitulating native protein architecture and 
inhibit a PPI. Secondary structure mimetics that have demonstrated inhibitory 
potency could therefore be reconsidered as potential prostheses for its parent 
protein.   
PPIs are ubiquitous in biological systems and are responsible for a 
variety of signalling and regulation pathways.85 Unlike an enzyme-substrate 
interaction, which has a well defined binding cavity (Figure 1.14),92 PPIs 
generally form contact over large surface areas (>800 Å2) which are often 




Figure 1.14 - Cartoons of two models in the design of inhibitors for enzyme/substrate 
(top) and protein-protein interactions (bottom). 
Fortunately, a PPI usually involves only a few key residues (known as 
hot-spots) which contribute to the majority of the binding affinity.94 Thus, to 
design inhibitors of PPIs, replication of the projection and proximity of the hot 
spot residues is critical. One starting point for the design of inhibitors of PPIs is 
that some have secondary structure on their binding interface, the secondary 
structure being vital to orienting key binding side chains to interact with a 
complementary region (Figure 1.15a, b). The full protein can therefore be  
theoretically reduced to a polypeptide that is involved in the binding 
interaction, without the hinderance of chain entropy.93 
One particular class of PPIs that have gathered interest are those 
mediated by an α-helix at the binding interface, where side chains are projected 
at the i, i + 4, i + 7 (and i + 11) positions in the same direction to interact with a 
complementary (often hydrophobic) groove.95-97 Foldamer scientists have 
therefore produced oligomers and small molecules that are capable of 
recapitulating the spatial orientation of the key binding residues of an α-helix 




Figure 1.15 - a), b) Examples of protein-protein interactions that are driven by the 
recognition of an α-helix from one protein into a complementary binding pocket (PDB: 
a) 2KBW; BID bound to Mcl-1;98 b) 1YCR; p53 bound to mDM2.99 c) Considering that α-
helix mediated PPIs are dependent on a few key side chains, a 'mimetic' strategy 
replaces the native polypeptide scaffold with one that maintains the orientation of the 
key side chains.  
1.2.1 Constraining Peptides - Rationale 
Since the interacting regions of α-helix mediated PPIs are based on a 
sequence of α-amino acids that are folded in an α-helical conformation, one 
starting point could be to utilise the peptide sequence in isolation to inhibit the 
PPI. Unfortunately, short, isolated peptides are therapeutically undesirable due 
to their lability towards proteases and their poor transport properties.100, 101 
However, small molecules cannot completely recapitulate all of the functions of 
an active helical peptide, so a compromise is needed to improve the therapeutic 
potential of peptides. 
Small, isolated peptides are generally unstructured, since secondary 
structure requires the tertiary environment to remain stable.102 Entropy 
therefore favours an infinite number of random conformations of a small 
molecule over a single, organised conformation. Thus, the introduction of 
synthetic residues to constrain a peptide into one conformation could reduce 
the entropic penalty of preorganisation prior to binding.103 This, in turn, should 




1.2.2 Native Peptide Constraints 
Constraints can be introduced into a peptide without extensive 
modification to the native peptide sequence. The simplest constraint can be 
furnished through the oxidative bridging of cysteine residues (Figure 1.16a),104 
which had been effective for the inhibition of the oestrogen receptor α/co-
activator interaction,105 in spite of the peptide having minimal helical content in 
an aqueous environment.  
 
Figure 1.16 -Examples of 'native' constrained peptides: a) Cysteine bridged peptides; 
b) Lactam bridges formed by the bridging of Asp→Lys; c) Photoinduced constrained 
peptides using cysteine linked azobenzene moities.  
A different measure for controlling the conformation of the peptide via 
cysteine residues was the installation of an azobenzene crosslink, which can 
undergo a cis/trans isomerisation upon irradiation (Figure 1.16c).106, 107 The 
upshot was the ability to alter the conformation of a peptide from random coil 
to stabilised α-helix at will.108 In addition to this, when incorporated into the i, 
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i + 7 positions, the cis isomer stablises a helical conformation, whereas the 
same isomer destabilises the peptide conformation when incorporated at the i, i 
+ 11 position. In vitro, stabilised helical peptides (In this case, a BID peptide 
mimetic) bound to their partner (Bcl-xL, an anti-apoptotic protein) with an 
improved affinity over their destabilised variants.106    
A more permanent approach to constraining native residues was 
initially reported from Rosenblatt and coworkers, who stabilised peptides by 
forming a lactam bridge between lysine and aspartic acid in the i,  i + 4 position 
(Figure 1.16b). Fairlie and coworkers have since expanded on this methodology 
by producing a pentapeptide with an 1Lys→5Asp lactam bridge with 
exceptionally high α-helical content.109 Using a double lactam bridged peptide 
maintained high α-helicity in the aqueous environment and furnished 
inhibitors that surpassed the native affinity for the picomolar inhibition of 
respiratory syncitial virus (RSV) fusion and picomolar activity of the NOP/NOR 
nociceptin opioid receptor.110, 111 Recently, the same group have evaluated 
different methods for the constraining of pentapeptides, some of which shall be 
described below.112 
1.2.3 Hydrogen-Bond Surrogates 
Whilst the lactam bridges and the photo-induced constraints have been 
effective in affording potent inhibitors of protein-protein interactions, one 
disadvantage is that the constraint interferes with one face of the helix. 
Hydrogen bond surrogates (HBS) are therefore an attractive method to 
introduce a covalent constraint to a peptide without blocking any recognition 
features of the helix (Figure 1.17).113-115 In addition to an improved α-helical 
character, HBS endowed a 60-fold proteolytic resistance to a BAK peptide, 
which bound to Bcl-xL in the low nanomolar range. HBS peptides have since 
been applied to p53/hDM2,116 HIF-1α/p300117 and an in cellulo inhibition of 





Figure 1.17 - a) Structural represenation of a native peptide α-helix which can be 
modified by hydrogen-bond surrogate methodologies developed by: b) Alewood;113 c) 
Satterthwait114 and d) Arora.115  
1.2.4 Hydrocarbon Stapling  
The 'hydrocarbon staple' was introduced initially by Grubbs by 
covalently linking O-allyl serine residues through Grubbs metathesis to afford a 
permanently linked, constrained peptide.1 Verdine and coworkers improved on 
this by the synthesis of an α,α-disubstituted unnatural amino acid with an 







Figure 1.18 - Toolbox of α,α-disubstituted unnatural amino acids that are used for 
'hydrocarbon stapling'. Varying the length of the olefin tether allows the crosslink to 
span between i, i + 4 or i, i + 7 positions in the peptide.  
Using RNase A as a model system, the combination of amino acid 
stereochemistry and crosslink lengths was assessed to afford peptides with 
enhanced helical character and proteolytic resistance over the unmodified 
peptide.2 The breakthrough in hydrocarbon stapling technology was the 
synthesis of ligands based on the BID BH3 pro-apoptotic domain, where a 
stapled BID peptide had demonstrated tumour suppression and regression in 
leukaemia xenografts.3 In addition to this, 'stapled' BID BH3 showed  6-fold 
increase in binding affinity over an unmodified peptide.  The Walensky group 
have since used hydrocarbon stapled peptides to understand the Bcl-2 (B-Cell 
lymphoma) family and to identify selective binding partners within this family 
of proteins.119-122  
The application of hydrocarbon stapling technology has spread to 
numerous α-helix mediated protein-protein interactions, including the NOTCH 
pathway,123 HIV-integrase pathways124 and hepatitis C membrane fusion 
inhibitors.125 Double-stapling of peptides by Walensky and coworkers 
demonstrated that long peptides can be maintained in a helical conformation, 
which in turn enhanced antiviral activity against neutralisation resistant 
HIV-1.126 Pertinent research into the hydrocarbon stapling of p53 afforded 
peptides that were capable of activating the tumour suppressor p53 protein in 
vivo.127 This led to the first reported crystal structure of a hydrocarbon stapled 
peptide, in this instance stapled p53 bound to mDM2 (Figure 1.19a).128 
Crystallographic trials with a stapled oestrogen receptor/coactivator 
interaction revealed that the hydrocarbon crosslink was responsible for 
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binding into the hydrophobic pocket and not the key binding side chains on the 
α-helix (Figure 1.19b,c).129 This was an important result to prevent the over-
interpretation of helicity-potency relationships with stapled peptides. 
 
Figure 1.19 – X-Ray crystal structures of a) hydrocarbon stapled p53 bound to mDM2 
(PDB:3V3B)128; b) Wild-type oestrogen receptor/coactivator interaction (PDB: 
2QGT)130 and c) hydrocarbon stapled oestrogen receptor/coactivator interaction 
(PDB: 2YJD).129 The key binding side chains are coloured green, and the hydrocarbon 
staple coloured blue. In c) the staple binds onto the hydrophobic surface of the protein, 
causing two Leu side chains to move from their binding pocket.     
Concerns have been raised through the research of Czabotar and 
coworkers,131, 132 who have attempted the hydrocarbon stapling of a BIM 
peptide in the same sequence position as Walensky122, 133 but found that there 
is marginal improvement of helical content and no improvement in activity or 
cellular uptake. The analysis of Czabotar and coworkers into why hydrocarbon 
stapling affords a less affine ligand rigorously states that interactions of other 
side chains within the peptidomimetic must not be ignored when designing 
effective hydrocarbon stapled peptides. Czabotar has therefore highlighted that 
the rationale behind stapled peptides being improved ligands as a direct 
consequence of improved α-helicity requires more detailed analysis.   
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In spite of this, hydrocarbon stapling methodology has been one of the 
most successful methods for inhibiting α-helix mediated PPIs, culminating in 
the founding of Aileron Therapeutics, who have entered stapled peptides into 
Phase I clinical trials.134, 135  
1.2.5 From Peptidomimetics to Proteomimetics 
Peptidomimetics are designed to recapitulate the secondary structure of 
a section of a protein with the goal of furnishing effective peptide-based 
therapeutics.8 On the other hand, proteomimetics are designed to emulate the 
topography of residues that are essential for recognition and binding.136 Since 
proteomimetics consist of synthetic, oligomeric scaffolds, they also belong to 
the foldamer family but generally deviate from α- and β-amino acid monomers 
that are utilised in peptidomimetic research.72, 137  
α-helix proteomimetics are designed to target protein-protein 
interactions that are driven by key binding side chains residing in an α-helix 
segment.95 Oligoamide based α-helix mimetics are currently a popular choice of 
scaffold,97 which allows the synthesis of rigid oligomers that are capable of 




Figure 1.20 - Examples of α-helix proteomimetics from a) terphenyl scaffolds;138 b) 
oligourea scaffolds139, 140; c) oligopyridylamide139 and d), e) oligobenzamide scaffolds 
that are amenable to library generation12, 141 and f) pyridyl-pyridone scaffold that is 
capable of mimicking two faces of an α-helix.142 
From the first reported terphenyl α-helix mimetic 18,138 the range of 
oligoamide scaffolds has developed with variations to the backbone and 
installation of interacting side-chains 19-22. Figure 1.20 shows that a rigid 
backbone, reinforced through restricted rotation, forces side chains to be 
projected into one face and recapitulate i, i + 4 and i + 7 spacings whilst 23 is 
suitable for mimicking protein-protein interactions that bind through i, i+3 and 
i + 4 recognition.140 Whilst the above α-helix mimetics have been applied to the 
inhibition of pertinent protein-protein interactions, such as p53/hDM2,12, 141 
the Bcl-2 family138, 139 and ER-CoA,142 there is also potential for future 
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development into the production of semi-synthetic proteins using protein 
prosthesis methodology.   
1.3 Project Aims 
The Wilson laboratory has specialised in the design and synthesis of 
potent oligobenzamide α-helix mimetics capable of inhibiting protein-protein 
interactions that are relevant to the survival and proliferation of cancerous 
cells (Figure 1.20 d & e).12, 141 Allied with the overall goal of producing tertiary 
structure mimetics, it was envisaged to incorporate hydrocarbon stapled 
peptides and eventually  oligobenzamide α-helix mimetics into a protein, 
analogous to the research performed by Beck-Sickinger.89  
 
Figure 1.21 – Summary of the aim of the protein prosthesis investigation 
The first goal of the project was to design a strategy for the total protein 
synthesis of a colicin immunity protein, Im7, through an appropriate native 
chemical ligation strategy (Figure 1.21). Im7 possesses four helical regions, 
which have the potential for the production of several chimeric Im7 variants. In 
addition to this, an investigation with stapled peptides was started to expand 
the Wilson group repertoire of secondary structure mimetics. With the 
synthesis of the unnatural amino acid for peptide stapling in hand, stapled 
helical regions of Im7 were to be investigated, before moving onto more 




Figure 1.22 - Disubstituted and Monosubstituted unnatural amino acids that are 
applied to hydrocarbon stapling experiments. 
Of particular interest to us was an olefinic amino acid that does not 
possess the α-methyl group that has been reported by Verdine and Walensky.2, 
3 This des-methyl amino acid had been overlooked for investigations with 
stapled peptides (Figure 1.22), but can be attained by modifying a synthetic 
approach that has been developed elsewhere in the Wilson group.143 Thus, we 
were in a prime position to discover whether des-methyl amino acids are 
suitable surrogates for hydrocarbon stapling and if there is any biophysical 
contrast between the well characterised and used α,α-disubstituted unnatural 




Chapter 2  
Towards the total chemical 





The term 'foldamer' is used to describe a synthetic oligomeric scaffold 
that has a tendency to adopt specific compact conformations, which assemble 
through their replication of protein secondary structure.7, 137 As the field has 
grown, various oligomers have been characterised to replicate the secondary 
structure of proteins and have been applied for potential therapeutic 
strategies.95 However, foldamers resembling tertiary structure, which rely on 
folding patterns to provide an active site based on the three-dimensional 
arrangement of the oligomeric network are currently out of reach. The next 
milestone in foldamer research is therefore the production of tertiary structure 
mimetics to furnish fully functional synthetic scaffolds.  
There are two possible approaches to the synthesis of effective tertiary 
structure mimetics. The first is analogous to the design of secondary structure 
mimetics, through de novo design. The second is to replace secondary structure 
of proteins using characterised secondary structure mimetics to afford semi-
synthetic proteins, which would allow the evaluation of secondary structure 
foldamers within a tertiary protein environment, which is known as the 
prosthesis approach.9, 76 
One of the aims of the project was the incorporation of stapled amino 
acids and oligobenzamide helix mimetics into a protein,12, 141 replacing an α-
helical region, and evaluating the folding properties and activity of the resultant 
semi-synthetic proteins. Prosthesis has been limited to the replacement of a 
small number of β-turn inducing residues,73, 75, 79 with one example of a C-
terminal α-helix replaced by a β-peptide oligomer.89 Replacing internal protein 





Figure 2.1 – An overview of the ‘prosthesis’ strategy for the synthesis of tertiary 
structure mimetics. a) X-Ray structure of Im7 (PDB:1AYI)144 and b) sequence of Im7 
where the  native numbering system begins from 2E, the red underlined 29A and 59D are 
the cysteine mutation points. The coloured regions correspond to Helix 1 (orange), 
Helix 2 (red), Helix 3 (green), Helix 4 (blue) and the His purification tag is highlighted 
in purple; c) cartoon of the prosthesis strategy, where a suitable helical region of a 
native protein is replaced by a secondary structure mimetic to afford a semi-synthetic 
protein.  
The target protein for replacing α-helical segments was colicin immunity 
protein Im7 (Figure 2.1a), which is responsible for binding with high affinity to 
a colicin toxin E7.145 E7 is an indiscriminate toxin which is secreted by an E. coli 
cell to its surroundings; Im7 therefore protects the host cell from its own toxin 
by neutralising E7.    
Im7 was chosen for total chemical synthesis because its folding pathway 
has been previously characterised at atomic resolution by Radford and 
coworkers at the University of Leeds,11, 146-148 thus providing in-house 
knowledge for comparing semi-synthetic varieties of Im7 with the wild type. 
Im7 also has the benefit of possessing four α-helical regions, which could all be 
potential targets of replacement with α-helix mimetics (Figure 2.1c). Im7 has 
been previously glycosylated at different positions,148, 149 which required a 
semi-chemical synthesis approach using intein mediated ligation. In order to 
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access all helical regions for replacement, a total synthetic strategy was 
devised. 
2.1 Strategy for the total synthesis of Im7 
After a bold attempt of the total synthesis of wild type Im7 (93 residues) 
in one continuous synthesis using the CEM® automated peptide synthesiser 
was unsuccessful, a total chemical synthesis strategy of Im7 was devised based 
on previously established methods of Im7 semi-synthesis (Figure 2.2),148, 149 
where the protein was divided into three fragments for two successive native 
chemical ligation steps.45 The non-endogenous cysteine residues have also been 
previously shown to have no effect on the folding characteristics of the 
protein,148 and the N-terminal His6 tag was included to assist purification. 
Figure 2.2 represents the ligation methodology for the total chemical synthesis 








Figure 2.2 – Cartoon representation of the synthetic strategy for Im7, with the 
coloured ovals representing the helical regions as defined in Figure 2.1. Here, the 
fragments of Im7 are synthesised using SPPS methods, with Fragment 2 functionalised 
with a masked cysteine residue and a C-terminal thioester. After one native chemical 
ligation to form Fragment 2-3, deprotection of the Thz group to cysteine precedes the 
second native chemical ligation to afford complete Im7.   
Fragments 1 and 2 required their syntheses to use highly acid labile 
trityl based resins, which could cleave the peptide from the resin with 0.5 % 
TFA in CH2Cl2 with all of the side chain protecting groups left intact. 
Consequently, the C-terminal carboxylic acid of Fragment 2 could then be 
chemoselectively modified to a thioester, which activates the fragment to native 
chemical ligation with a peptide that possesses an N-terminal cysteine residue. 
Fragment 2 required an additional protecting group, with its N-terminal 
cysteine protected with a thiazolidine (Thz), which prevents the formation of 






2.1.1     Synthesis of Fragment 3 
 
Fragment 3, the C-terminal fragment was synthesised first, based on 
there being no requirement for any modifications to its functionalities after 
cleavage. Table 2.1 summarises the synthetic approaches for Fragment 3. 















 R76 and R61 360 mg 
(329 mg) 
N/A 





R61, I68, V69, 
K70, E71, I72, 
R76, N79  
107 mg  
(136 mg) 
35 mg  
25% 











      
Table 2.1 – Synthesis attempts of Fragment 3, the capacity of the resin is given as 
mmol g-1.  
 The first attempt, using microwave assistance for amino acid couplings 
and Fmoc deprotections afforded an inseparable mixture of deletion sequence 
peptides. As a result, the synthesis was performed by manual solid phase 
peptide synthesis, where each step was monitored by colour tests, at the 
expense of additional time required for synthesis. In particular, the manual 
solid phase synthesis allowed periodical LCMS test cleavages to ensure that 
deletions were avoided, especially in the region of 60NRDDSP, which gave 
ambiguous results to colour tests. The N-terminal Cys residue was coupled in a 
modified manner, using a reduced polarity solvent system (1:1 DMF:CH2Cl2) 
and 2,4,6 trimethylpyridine to obviate racemisation during the coupling.150  
Using TGT resin and employing double couplings for residues that failed 
to couple effectively in the first synthesis attempt, Fragment 3 was effectively 
synthesised on a 0.04 mmol scale to afford 107 mg of crude peptide (78% crude 
recovery). Purification of the peptide by reversed phase HPLC did afford 35 mg 
of Fragment 3 (25% yield).  
Since TGT was a low-loading resin, the synthesis of Fragment 3 was 
attempted using a higher-loading and more versatile resin, with the aim of 
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affording a higher quantity of Fragment 3. Thus, Fragment 3 was built on Gly-
loaded Wang resin on a scale of 0.08 mmol, to afford 48 mg (19% yield) of 
Fragment 3 after purification by HPLC.  
2.1.2 Synthesis and Thioesterification of Fragment 2 
 
Fragment 2 was not previously synthesised in the literature, but 
required the functionalisation of the N-terminus with a thiazolidine protecting 
group to prevent dimers of Fragment 2 forming during native chemical ligation. 
The fragment was built using TGT resin, which was necessary to afford a fully 
protected peptide after cleavage with 0.5% TFA in CH2Cl2 followed by the 
conversion of the C-terminus to a thioester. 
The fragment was built manually using double couplings for each amino 
acid in order to provide a suitable quantity of peptide for characterisation free 
of deletions. Manual SPPS was effective, with a 96% crude recovery (208 mg) of 
the fully protected peptide on a 0.05 mmol scale, with the identity of the 
peptide confirmed after a small-scale deprotection, since the fully protected 













1 Manual (0.05) Novasyn 
Fmoc-Ser-
TGT (0.20) 
All 208 mg 
(216 mg) 
96% 



























F41 & P57 333 mg 
(432 mg) 
77% 
      
Table 2.2 – Summary of the pertinent attempts of the synthesis of Im7 Fragment 2, 
where ‘recovery’ means the quantity of crude material obtained after low-acidic 
cleavage.   
Following the success of the manual method, the Fragment synthesis 
was trialled for automated synthesis using the synthesiser, since double 
couplings under manual conditions were expensive in terms of time and 
reagents. The first attempt at automation used microwave irradiation which 
resulted in no peptide afforded after the synthesis; the frailty of the resin 
resulted in cleavage of the peptide from the resin at every irradiation step 
(Table 2.2, Entry 2). 
Subsequently, the peptide was synthesised without microwave 
irradiation on scales of 0.05 mmol, which proved to be effective with the double 
couplings of 57Pro and 41Phe required, since small deletions of these residues 
had been observed in the first attempt of non-microwave automation. One 
apparent downside to this was the lower crude recovery of the peptide from 
the resin, which came from acidic contaminants within the reactor, behaviour 




2.1.2.1 C-terminal thioesterification of Fragment 2. 
 
Scheme 2.1 - Scheme for the conversion of the C-terminal carboxylic acid of Fragment 
2 to a thioester. 
Thioesterification of Fragment 2 was carried out by using benzyl 
mercaptan as the thiol, in the presence of PyBOP as an activator. A particular 
disadvantage of the thioesterification reaction was that large quantities of 
protected Fragment 2 were required to monitor the reaction by LCMS, which 
could only be done by deprotecting the side chains with TFA in order for the 
peptide to ionise.   
The thioesterification required several optimisations (Table 2.3), where 
appropriate concentration of the solution was essential for the 
thioesterification to proceed, without the solution emulsifying. The order of the 
reagent addition was also optimised, where adding additional PyBOP and 







1 0.019 12.6 A No Reaction 
2 0.019 38 A 60% conversion 
3 0.027 108 B 100% conversion 
4 0.023 115 B Emulsion, no reaction 
5 0.023 58 B 100% conversion 
     
Table 2.3 – Summary of the optimisation of the thioesterification of Fragment 2. 
Condition A is 20 eq. BnSH, 3 eq. PyBOP, 3 eq. DIPEA under N2 for 18 h. Condition B is 
the same as A, but an extra 2 eq. of DIPEA and PyBOP were added after 2 h. The 
conversion of the thioesterification was determined after global deprotection and was 
quantified by integration of the LCMS peaks of the starting material versus the target 
peptide.  
Optimisation of the reaction conditions did not remove the problem that 
the peptide required full deprotection with TFA in order to quantify the extent 
of thioesterification, since mass spectrometry of small aliquots of the reaction 
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mixture were saturated by PyBOP and its byproducts, which ionised 
considerably better than that of the full peptide.  
Furthermore, purification of Fragment 2 thioester by HPLC was not 
trivial, since the PyBOP byproducts coeluted with the peptide, but 10 mg (15%) 
of Fragment 2 was afforded cleanly.  
2.1.3 Synthesis and thioesterification of Fragment 1 
 
Fragment 1 was synthesised using the same methodology as Fragment 
2, utilising TGT resin to afford side-chain protected peptides for 
thioesterification. The first attempt of peptide synthesis was manual SPPS on a 
scale of 0.04 mmol with each residue double coupled. Pleasingly, this was 
effective and afforded 225 mg of peptide (72% recovery) without any deletion 
sequences (Table 2.4). 









1 Manual (0.04) Novasyn 
Fmoc-Ala-
TGT (0.21) 























Table 2.4 – Summary of the optimisations of the synthesis of Im7 fragment 1 on TGT 
resin. Calculation of recovery for Entry 2 was not possible due to a complex mixture of 
deletion sequence peptides. 
The synthesis was then transferred to automated methods without 
microwave irradiation, where the best results were obtained when double 
couplings of the His6 region were carried out, where the possible entanglement 
of the side chains of the residues made each successive coupling less effective. 
In spite of this, the crude recovery of the peptide after cleavage was poorer 
than that of Fragment 2, which suggested that the limit of the peptide was being 
reached for this particular trityl resin. 
40 
 
With the optimisations of the thioesterification in place using Fragment 
2 (2.1.2.1), the C-terminal thioesterification of Fragment 1 was attempted. 
However, no reaction was observed for the optimised conditions, with addition 
of further reagents, lengthening reaction time and elevating the reaction 
temperature all ineffective. Considering that thioesterification attempts needed 
deprotection with TFA to quantify the success of the reaction, the failed 
attempts could not have been resubmitted to the reaction conditions, which 
was proving prohibitive in terms of time. As a result, a new method of 
activation was sought.  
2.1.4 Fragment 1 synthesis using Dawson methodology 
'Dawson' methodology47, 50 allows the synthesis of C-terminally 
activated peptides for native chemical ligation with the peptide activated on 
resin prior to cleavage and deprotection, which avoids the use of the highly 
labile TGT resin. Dawson resin utilises a diaminobenzoic acid (Dbz) linker that 
is activated to N-acylbenzimidazolinone (Nbz) by p-nitrophenyl chloroformate 
after the peptide elongation is complete (Scheme 2.2). The function of the Nbz 
is to be displaced by thiols in ligation buffer during native chemical ligation, 
which obviates a functional group transformation that had been arduous in 







Scheme 2.2 - Scheme for the synthesis and activation of Dawson resin, which starts as 
a diaminobenzoic acid (Dbz) linker before its activation to N-acylbenzimidazolinone 
(Nbz).  
Since Dawson resin was a relatively new innovation, there was no 
formally established protocol for its use, so the initial coupling of 28Ala was 
done using several different coupling methods to strike a balance between 
achieving an effective coupling of the amino acid without overacylation of the 
Dbz moiety, which would have rendered the Dbz defunct at the end of the 
synthesis (Table 2.5). 
Entry Activation Repeats Outcome 
1 HCTU 3 ~50% diacylation 
2 HBTU 3 ~25% diacylation 
3 HATU 2 ~40% diacylation 
4 HBTU/HOBt 2 No diacylation 
Table 2.5 – Trials of the loading of the Dawson Dbz resin using 5 eq. of activator, DIPEA 
and Fmoc-Ala-OH for 1 h.  
A double coupling using HBTU and HOBt proved to be effective, since 
HATU and HCTU promoted some diacylation of Dbz, and resultingly the peptide 
was synthesised using HBTU and HOBt activation without microwave 
irradiation.  
Some further optimisation was required for the synthesis of the peptide, 
where couplings were less effective at the His6 region, even with the 
employment of double couplings and the use of HATU. Finally, the peptide was 
effectively synthesised using a lower loading variant of the Dawson Resin 
(which was unavailable for the first attempts), where the complete peptide was 
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synthesised with no deletions using HBTU/HOBt activation on a 0.05 mmol 






1 HCTU 8 N-
terminal 
residues 
Complex mixture, traces of target 
peptide observed 
2 HCTU* 8 N-
terminal 
residues 
Complex mixture, traces of target 
peptide observed 
3 HBTU/HOBt None Complete peptide, quantitative crude 
recovery 
Table 2.6 – Synthesis attempts of Fragment 1 on Dawson resin after the loading of the 
first residue with HBTU/HOBt. HCTU* is where the 8 N-terminal residues were 
coupled with HATU. The scale of synthesis was 0.05 mmol for all attempts.  
The subsequent activation of the peptide on resin was achieved by 
spinning the resin in a solution of p-nitrophenyl chloroformate overnight, 
followed by treatment with DIPEA for one hour. The peptide was then cleaved 
from the resin to provide a quantitative recovery of the peptide in remarkably 
high purity, surprising considering that the activation method of HBTU/HOBt is 
milder than that of HATU and HCTU. 
 Purification by HPLC afforded 10 mg (25% from 40 mg purified)  of 
activated Fragment 1, but evaporation of the eluent had to be performed 
immediately as hydrolysis of the Nbz moiety to the C-terminal carboxylic acid 
was observed. 
2.2 Native Chemical Ligation 
With the peptide fragments in hand, native chemical ligation was 
attempted initially with Fragment 3 and the thioester of Fragment 2. Native 
chemical ligation (NCL) occurs by the in situ activation of a C-terminal 
thioesterified peptides in buffer of neutral pH in the presence of an excess of 
thiols and reducing agents.  
NCL was first attempted using thiophenol and benzyl mercaptan present 
in buffer, based on the previous Im7 semi synthesis established by Imperiali 
and coworkers.149 However, there were only trace amounts of Fragment 2-3 by 
inspection of LCMS. The ligation may have been arrested by the change of the 
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pH of the buffer as the partially miscible thiols began to precipitate from the 
mixture.  
To improve on this, the ligation conditions were altered to 6M 
Guanidinium buffer, which would denature any secondary structure formed by 
either peptides and improve the rate of reaction. Also, mercaptophenyl acetic 
acid (MPAA) substituted benzyl mercaptan and thiophenol since its aqueous 
solubility allowed an improved control of pH. 
 
Figure 2.3 - Products from the Native Chemical Ligation of Fragment 2 thioester 24 
and Fragment 3 25, which afforded ligated peptide Fragment 2-3 26 and its 
intermolecular disulfide adduct 27. Unreacted Fragment 3 25 also formed 
intermolecular disulfides 28 and the hydrolysed Fragment 2 29 was also observed.  
Whilst LCMS indicated an improved conversion of Fragments 2 and 3 to 
the ligated product, hydrolysis of the thioester of Fragment 2 was observed, 
despite repeating the ligation ensuring that the pH of the fragment solutions 
was 7.0 prior to their addition. In addition to this, the MPAA formed 
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intermolecular disulfides with the ligated Fragment 2-3 and unreacted 
Fragment 3, but this was reversed by adding a further 5 equivalents of TCEP.  
Since the native chemical ligation was envisaged to proceed in a one-pot 
reaction, the Thz protecting group was deprotected using methoxyamine 
hydrochloride. Initially, the Thz did not deprotect after 3 days which was due to 
the pH of the buffer being at 7.0. Altering the pH of the buffer to ~3 allowed the 
complete deprotection of Thz after 48 hours. 
Dialysis of the ligation mixture to remove the methoxyamine from the 
solution followed by the addition of Fragment 1 Nbz moitey for the final 
ligation was not observed to be successful, since the rate of hydrolysis of the 
C-terminal activating group was faster than that of the rate of acyl transfer.    
2.3 Concluding Remarks   
 The investigation into the total synthesis of Im7 allowed the 
optimisation of the synthesis of the three polypeptide fragments on solid phase, 
which could be reproduced for future investigations. The dynamic nature of the 
study was highlighted through the change of total synthesis strategy, where 
Dawson activating methodology was investigated in addition to C-terminal 
thioesterification. After trouble-shooting the first couplings onto Dawson resin, 
the synthesis of 36-mer peptides and on resin activation was more efficient and 
higher yielding than attempts with thioesterification, which is useful for future 
work.     
The native chemical ligation steps require some optimisation to 
minimise the hydrolysis of the C-terminal activating group of peptides, which 
can be achieved through altering the activating group or through a judicious 
control of the ligation buffer pH and components. Whilst time constraints 
prevented the complete isolation of Im7 and ligation fragments, the attention of 
the project was shifted to the investigation of the prostheses, rather than the 
methodology of total protein synthesis. Nevertheless, the Im7 total synthesis 
investigation has substantial foundations laid for future studies.   
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Chapter 3  
Chapter 3a: Investigation of 
constrained peptides using 
monosubstituted unnatural amino 
acids 
The work described in this chapter features in the manuscript Yeo, D.J., 




3.1  Introduction and context 
The study of constrained peptides as potential therapeutics has grown 
rapidly in recent years, with a diverse range of methodologies established to 
target protein-protein interactions (PPIs).95 A subset of the constrained peptide 
family are the hydrocarbon 'stapled' peptides, which furnish an all-
hydrocarbon bridge on one face of a helical peptide by incorporation of olefin 
containing unnatural amino acids and their subsequent metathesis on solid 
phase (1.2.4).1, 2 All prior work with respect to hydrocarbon stapling has 
utilised an α, α-disubstituted unnatural amino acid 16, which includes a methyl 
group on the α-carbon in addition to a side chain with a terminal alkene. The 
length of the side chain can be tailored depending on the chosen positions of 
unnatural amino acid incorporation, to afford i, i+4 or i, i+7 crosslinked 
peptides, whose utility in vitro and in vivo has been demonstrated across a 
range of targets.3, 4, 119, 120, 122, 124, 127, 151, 152  
It was apparent that a des-methyl ('monosubstituted') unnatural amino 
acid had been overlooked for investigation as a stapling reagent, and it was 
therefore decided to examine the use of this amino acid crosslink for the 
inhibition of protein-protein interactions.12, 141  
Reported syntheses of the required unnatural amino acids have mostly 
employed a chiral auxiliary, to enable asymmetric installation of the alkenyl 
side chain. Such auxiliaries include morpholinones,153, 154 bis-lactims,155 156, 157 
oxazolidinones,124, 151 and transition metal complexes.158, 159  
The current investigation utilised two different synthetic methods for 
amino acid synthesis, based on prior research,154, 160 and utilised two well 
known α-helix mediated protein-protein interactions; p53/hDM2 and the Bcl-2 





3.2 Small molecule chemical synthesis 
3.2.1 Synthesis of α,α-disubstituted amino acids 
 α,α-disubstituted amino acids were synthesised to enable comparison 
with monosubstituted amino acids. Synthesis proceeded via a morpholinone 
auxiliary 35 as reported by Verdine and coworkers (Scheme 3.1).2, 3 From 
benzoin 30, formation of the oxime 31 and its subsequent reduction to racemic 
amino alcohol 32 afforded excellent yields (quantitative and 96% respectively). 
The following step, a chiral resolution with successive recrystallisations with 
different aqueous ethanol mixtures was abandoned after several attempts. 
Essentially, the recrystallisation was profligate and the enantiopurity of the 
resultant amino alcohol 33 and its antipode was not guaranteed, which would 
have a profound effect on the overall enantiopurity of the amino acid after the 
synthesis was complete. Therefore, the synthesis was continued using 




Scheme 3.1 – Synthetic route for the synthesis of α,α-disubstituted unnatural amino 
acids. a) Synthesis up to the aborted chiral resolution;163 i) NH2OH·HCl, NaOAc, 
EtOH:H2O (6:1), Δ, quant.; ii) H2 Pd/C, EtOH, 1.5% (v/v) aq.HCl, 96%; iii) L-Glu, 
EtOH:H2O. b) Synthesis from (1R, 2S)-1,2-diphenyl-2-aminoethanol 33 to Fmoc-
protected (S)-α,α-disubstituted unnatural amino acid 16;153 i) 39, Et3N, THF, Δ, 92%; 
ii) Boc2O, Tol., Δ, then TsOH, Tol., Δ, 81%; iii) MeI, NaHMDS, THF, –78 °C, 78% one 
diasteroisomer; iv) 40, KHMDS, THF, –40 °C, 49% one diastereoisomer; v) Li0, NH3 
(l), –78 °C, 84%; vi) TFA, CH2Cl2 then Fmoc-OSu, NaHCO3, H2O:Acetone (1:1), 62%. c) 
Proposed intermediate of the alkylation of 35. 
Formation of the morpholinone auxiliary 35 was straight-forward, 
where amination to 34 with ethyl bromoacetate afforded only the secondary 
amine with no evidence of further alkylation. Boc protection and cyclisation to 
35 was a one-pot procedure, cyclisation occurred when the reaction 
temperature was elevated to 120 °C, to afford 35 in reliable yields of 85% after 
recrystallisation.  
The diastereoselective alkylations followed the production of 
morpholinone 35, with diastereoselectivity of the alkylations driven by the syn 
49 
 
configuration of the two phenyl groups, which block one face of the auxiliary 
from incoming electrophiles (Scheme 3.1c).153, 154 The first alkylation with 
methyl iodide gave only monosubstituted product 36, which was completely 
diastereoselective. However, the auxiliary was found to be prone to 
decomposition during reaction, work-up and purification by flash 
chromatography. This unwanted decomposition was suitably mitigated by 
temperature control during the reaction and quenching, followed by altering 
the published purification to trituration. The second alkylation with 1-
iodopent-4-ene 40 was more challenging to initiate and control. After a 
succession of tests of conditions, whereby the halide, base cation, solvent and 
temperature were modified, a modest yield of 49% was afforded, and not 
improved upon. Incidentally, the order of addition of reagents was vital to the 
reaction proceeding successfully, since the addition of 1-iodopent-4-ene 
followed by KHMDS gave a successful reaction, but reversal of these additions 
promoted decomposition of the morpholinone auxiliary. The lower yield of the 
second alkylation step can be attributed to the weaker acidity of the α-proton of 
the auxiliary and a competing elimination pathway of the alkyl iodide. 
Dialkylated auxiliary 37 was cleaved using dissolving metal reduction to 
afford Boc protected amino acid 38, which remained Boc-protected after an 
acidic extraction. Finally, Fmoc-protected α,α-disubstituted amino acid 16 was 
furnished in yields of 62% after in situ Boc deprotection with trifluoroacetic 
acid, followed by protection with Fmoc-OSu under mildly basic conditions.  
3.2.2 Synthesis of α-monosubstituted amino acids 
The difficult nature of the synthesis of the α,α-disubstituted unnatural 
amino acid made the route described in 3.2.1 unsuitable to follow for 
α-monosubstituted amino acids. Therefore, Schiff-base complex 454, 160 was 
employed to furnish des-methyl amino acid 48 (Scheme 3.2).  
 To this end, L-proline 41 was converted to N-benzyl proline 43 with 
potassium hydroxide and the dropwise addition of benzyl chloride. It is notable 
that attempting this reaction using sodiated bases resulted in the reaction 
mixture emulsifying, and the use of benzyl bromide or benzyl iodide promoted 
the formation of a mixture of quaternary ammonium salts and benzyl esters. 
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Any N-benzyl proline benzyl ester 42 was extracted with chloroform and 
hydrogenolysed using a poisoned palladium support to afford N-benzyl proline 
as the free acid. Coupling N-benzyl proline 43 with 2-aminobenzophenone 49 
required a modification of the published procedure from using thionyl chloride 
to a dropwise addition of mesyl chloride in the presence of N-methyl imidazole, 
since the former gave no reaction. With (S)-N-
(benzylprolyl)aminobenzophenone (BPB, 44) in hand, complexation to 
tetradentate nickel complex 45 with glycine gave excellent yields.  
 
Scheme 3.2 – Reaction scheme of the synthesis of Fmoc-protected monosubstituted 
unnatural amino acid 48;158 i) BnCl, KOH, iPrOH, 55%; ii) H2 Pd/BaSO4, EtOH, 60%; iii) 
49, MsCl, NMI, CH2Cl2, 86%; iv) Glycine, NaOMe, Ni(NO3)2·6H2O, 96%; v) 50, MeCN, 
NaOH, –22 °C, 70% one diastereoisomer; vi) 3M HCl(aq) MeOH, Δ, 95%; vii) Fmoc-
OSu, Na2CO3, H2O:Dioxane (1:1), 53%.    
Alkylation with 1-bromopent-4-ene or 1-iodopent-4-ene gave good 
yields after optimisation of the reaction conditions, where allowing an extra 24 
hours for the reaction to proceed gave a better conversion to the singly 
alkylated product 46, with only minimal dialkylated complex observed. 
51 
 
Pleasingly, the diastereomeric ratio of the alkylation was at worst 98:2, by 
inspection of the 1H-NMR spectra and comparison with  the literature 
precedent.158 The stereochemistry of complex 46 was confirmed in the solution 
state by extensive NOESY analysis, in conjunction with COSY, HMQC and HMBC 
data. In addition to this, 46 was crystallised from toluene:pentane and single 
crystal X-ray diffraction confirmed the absolute stereochemistry in the solid 
state (Figure 3.1).   
Hydrolysis of complex 46 followed by ion-exchange chromatography 
furnished free amino acid 47 in high yields (>90%), with the additional 
advantage of the BPB ligand 44 being extracted with chloroform and recycled 
for further use. Fmoc protection to 48 generally afforded modest yields (50-
60%), without racemisation. This synthetic route has been found to be 
amenable to scale. The initial steps of the production of N-benzyl proline 43 
and BPB 44 were performed on 50 gram scales, with the complexation to 45 
performed on a 22 gram scale.I This afforded a total of 6.2 grams of Fmoc amino 
acid 48, which has been provided to Sigma-Aldrich; under a commercialisation 
agreement. 
 
Figure 3.1 – X-ray crystal structure of alkylated complex 46, confirming the absolute 
stereochemistry of the alkylation. Hydrogen atoms other than at the α-position have 
been omitted for clarity. (Colour code: Grey = C, Blue = N, Red = O, Silver = Ni). a) top 
perspective; b) lower perspective.        
 
                                                        
I It was observed in the up-scaled procedure that significant quantities (~3 g) of 
Fmoc-β-Alanine was isolated as a side product, from a suspected Lossen 
rearrangement of OSu under basic conditions. 
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3.3 Peptide Synthesis 
3.3.1 p53/hDM2 
p53 has a pivotal role in the regulation of cells. It prevents cancer 
through initiation of DNA repair of damaged cells, cell cycle arrest or through 
signalling the apoptosis of cells whose DNA cannot be repaired.5, 164 The 
binding of p53 to its negative regulators, hDM2 and hDMX has been well 
studied and characterised,5, 99 where the key binding region is an α-helical 
transactivation domain spanning residues 15-31 (Figure 3.2a, b).  
 
Figure 3.2 – Images of the binding of p53 to mDM2; a) The helical region of p53 with 
the key side chains displayed; b) Visualisation of the transactivation domain of p53 
binding into a complementary hydrophobic cleft on mDM2 (PDB:1YCR)99; c) Crystal 
structure of a stapled p53 peptide bound to mDM2 (PDB:3B3V)128  
Three hydrophobic side chains, 19Phe, 23Trp and 26Leu, oriented on one 
face of the α-helix, contribute to the majority of the binding energy by burying 
into a complementary hydrophobic pocket on the surface of hDM2. 
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Recapitulation of the key side chains has therefore been pivotal for inhibition of 
p53/hDM2 by small molecules and proteomimetics.85, 161 Constrained peptides 
improve affinity by the preorganisation of the peptide into an active 
conformation that is suitable for binding, with the key side chains oriented 
correctly for efficient binding to their complementary partner. For the purposes 
of this investigation, the p53/hDM2 PPI has been targeted in-house,12, 141 as 
well as targeted in the field of hydrocarbon stapling by Verdine and coworkers, 
culminating in a crystal structure of a stapled p53 peptide bound to the murine 
equivalent, mDM2 (Figure 3.2c).127, 128 
3.3.2 Nomenclature of p53 peptides 
The discussion of the synthesis and biophysical analysis of stapled p53 
will use the following abbreviations: p53 WT, p53 MM and p53 MU. Wild type is 
the unmodified transactivation domain peptide (residues 15-32). p53 MM is 
monosubstituted metathesised (stapled) where monosubstituted amino acid 
48 has been incorporated. p53 MU is monosubstituted unmetathesised 
(unstapled).   
 
Figure 3.3 –The synthesised sequences of the p53 transactivation domain. The key 
hydrophobic binding residues are coloured green, with the chosen sites of 
incorporation of alkenyl amino acids coloured red. The abbreviations of the peptides 
are Monosubstituted Metathesised (MM) and Monosubstituted Unmetathesised (MU).   
3.3.3  Peptide Synthesis of p53 
Sites for the incorporation of monosubstituted amino acids within the 
peptide sequence, were chosen at 18Thr and 22Leu (red in Figure 3.3), on the 
basis that these residues are suitably spaced and modification should not 
interfere with the orientation of the key hydrophobic side chains.127 This 
substitution also does not replace any charged residues that may have 
implications for solubility or disrupt stabilising salt bridges. The peptides were 
synthesised on Rink Amide MBHA resin on a 0.05 mmol scale, in order to afford 
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C-terminally amidated peptides that are equivalent to the transactivation 
domain of p53.  
 
The synthesis was carried out using well established Fmoc solid phase 
peptide synthesis (SPPS), with HCTU, HOBt and DIPEA as the activating 
reagents for peptide elongation.42 Double couplings were required for the 
coupling of 29Asn and 30Asn, since small scale test cleavages had revealed these 
couplings to be cumbersome and incomplete after 2 hours. In spite of this, the 
monosubstituted unnatural amino acid 48 was incorporated completely with 
no special considerations or modifications, with the Kaiser test165 being 
conclusive for their couplings and deprotections.  
The alkenyl side chains of the unnatural amino acids were metathesised 
using the first generation Grubbs catalyst in degassed dichloroethane, which 
gave >98% conversion of the alkenyl side chains into an 8-carbon crosslink 
after two treatments with the catalyst. Optimal cleavage and global 
deprotection of the peptide from the resin was found to require Cleavage 
Reagent K, which contains ethanedithiol and thioanisole as its scavengers, to 
prevent disulfide oxidation of 32Cys and the irreversible alkylation of 
nucleophilic side chains by tBu cations. Generally, the stapled and unstapled 
p53 peptides were the dominant species present in the LCMS of the crude 
precipitate and deletion sequences were not observed. Purification of the 
stapled and unstapled p53 peptides was performed using reverse phase 
preparative HPLC, which in spite of using TCEP in the loading solution, gave 
poor recoveries of 13% and 11% of pure stapled and unstapled p53 based on 
crudes of 100 mg. 
3.4 Biophysical evaluations of the p53 peptides  
3.4.1 Circular Dichroism 
In order to evaluate the effectiveness of the hydrocarbon crosslink to 
promote a particular conformation and to reduce conformational plasticity in 
aqueous solution, circular dichroism was employed to probe the type and 
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extent of secondary structure of peptides and proteins. CD provides distinct 
spectral profiles depending on the secondary structure present.166  
 
Figure 3.4 – Representative example of circular dichroism spectra for unstructured, 
random coil peptides (red) and α-helical peptides (black). 
In the context of investigating α-helical peptides and peptidomimetics, 
the amplitude at 222 nm is used to quantify the percentage α-helicity of a 
polypeptide.103, 167 CD is therefore a fundamental tool in the design and 
optimisation of stapled peptides.1, 2 
3.4.1.1 Circular Dichroism of the Stapled p53 Peptides 
The monosubstituted p53 peptides were examined for their helical 
character using circular dichroism to compare the unstapled and the stapled 
variants. The peptides were dissolved in an acetonitrile:water solvent mixture - 
the acetonitrile was necessary to solubilise the peptides and was chosen over 





Peptide % Helicity (no 
TFE) 
% Helicity (TFE) 
p53 MU 27% 54% 
p53 MM 32% 32% 
Figure 3.5 - Expansion of the circular dichroism spectra of p53 MU (black) and p53 MM 
(red) peptides. Solid lines are spectra of peptides dissolved in acetonitrile:water, with 
dashed lines the spectra of the peptides dissolved in 3:7 TFE:H2O. The % helicity of 
wild type p53 has been reported as 11%.127 
p53 MM appeared to have a modest increase in its helical character 
compared to reported wild type values,127 but its CD profile suggested a 
predominantly random coil character. Whilst p53 MU had a similar % helicity, 
its CD profile suggests a greater proportion of random coil character. 
Employing trifluoroethanol (TFE) in the solvent, which promotes the formation 
of α-helical structure in short peptides,168, 169 provided a benchmark for the 
maximum helicity p53 MU and p53 MM could attain. p53 MU had a dramatic 
change in its % helicity and its CD profile, which matches an α-helical 
conformation. Meanwhile, p53 MM also displayed a change in its CD profile, but 
had no change in its % helicity, which suggests that the hydrocarbon staple 
greatly reduces the conformational flexibility of the peptide.  
3.4.2 Fluorescence Anisotropy  
The potency of the p53 peptides was evaluated using fluorescence 
anisotropy competition assays previously developed within the Wilson 
laboratory.12, 141 The principle of fluorescence anisotropy as a measure of 
potency is underpinned by the binding of a fluorescently labelled tracer to a 
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larger binding partner. As the concentration of the unlabelled partner, typically 
a protein, increases, a greater fraction of the tracer is bound. Once the labelled 
species is bound, the tumbling rate of the complex is reduced and, upon 
excitation of the fluorophore, an increase of anisotropy signal (r) is observed 
(Figure 3.6).II Plotting the fraction bound of the tracer against the concentration 
of the unlabelled partner allows the extraction of a Kd value for this interaction. 
 
Figure 3.6 – Overview of the fluorescence anisotropy assay, with anisotropy signal 
increasing as a protein binds to a fluorescently labelled species (left) and the decrease 
of anisotropy signal (right) as an inhibitor competes out the labelled species.  
With the Kd of an interaction of a fluorescently labelled species and its 
partner established, it is possible to extract information of potencies of 
inhibitors of the tracer:protein interaction. Fixing the concentration of protein 
and tracer, and titrating the inhibitor of interest results in the release of the 
tracer from the protein binding site in lieu of the inhibitor. The release of the 
tracer allows it to tumble freely in solution, causing a decrease in the 
anisotropy signal. Plotting of anisotropy signal against the concentration of the 
                                                        
II Anisotropy is inversely proportional to the rate of tumbling of a species 
compared to its fluorescence lifetime.  
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inhibitor allows a Ki or IC50 to be extracted - the inhibitory equilibrium constant 
and the half inhibitory concentration point respectively.  
3.4.2.1 Fluorescence Anisotropy Competition Assays of Stapled p53 peptides 
The stapled and unstapled p53 peptides were evaluated for their 
potencies against a fluorescein-labelled p53 peptide (p53*), using procedures 
analogous to those previously reported.12, 141   
 
Peptide IC50 (µM) 
p53 WT 1.2 
p53 MU 17.8 ± 1.7 
p53 MM 10.4 ± 1.0 
Figure 3.7 – Fluorescence anisotropy competition curves of the inhibition of 
p53/hDM2 using stapled (red) and unstapled (black) p53 peptides.  
The results were somewhat disappointing, considering that the IC50 of 
p53 WT has been previously established as 1.2 µM in the Wilson laboratory. 
Interestingly, there was a marginal improvement of binding affinity between 
p53 MM and p53 MU, which could lead to the conclusion that restricting the 
conformation of the peptide mitigated a penalty in the installation of amino 
acid 48. Constraining a peptide prevents the entropic penalty of organisation of 
the peptide into its binding conformation; therefore stapling of this p53 peptide 
suggests a reduction of the entropic penalty. Nevertheless, the reduced potency 
relative to the wild type leads to the conclusion that the positioning of this 




3.4.3 Concluding remarks of the stapling of p53 
It was evident that the use of the p53 peptide was not appropriate for 
the evaluation of des-methyl amino acids for peptide stapling. Inspection of the 
circular dichroism data suggests that, whilst the p53 MM peptide has been 
conformationally rigidified, the lack of α-helical character suggests that the 
positions chosen for the incorporation of the amino acids were inappropriate. 
This hypothesis was further reinforced by the inhibitory potency of p53 MM 
versus p53 WT, which was lower by an order of magnitude. In spite of the fact 
that p53 MU was a weaker inhibitor than MM, possibly from the additional 
entropic penalty of the peptide folding into its active conformation, the position 
of the crosslink was insufficient to promote improved inhibitory activity. 
In some respects this is unsurprising, considering preceding work on the 
stapling of p53 identified optimal crosslinks to bridge the i, i+7 positions and 
using an (S)-pentenyl amino acid with an (R)-octenyl partner,127 the latter 
which had not been synthesised using our current methodology.   
It was therefore necessary to explore a different interaction with the 
monosubstituted stapled peptides, which had precedent with the use of two 
(S)-pentenyl amino acids in an i, i+4 configuration.   
3.5 Investigation with the Bcl-2 family of proteins 
 The B-Cell Lymphoma (Bcl-2) family of proteins are a series of 
homologous proteins that regulate the apoptosis of cells through a balance of 
pro- and anti-apoptotic proteins. After the discovery of the eponymous anti-
apoptotic Bcl-2 protein,170 several family members with homologous sequences 
have been found, of which some are involved in the promotion of apoptosis.6, 
162, 171-173 The four homologous sequences are all α-helical and are termed as 
BH (Bcl-2 homologous) regions, which allowed the subdivision of the Bcl-2 
family based on the presence of the BH regions and the function of the protein. 
Anti-apoptotic (Bcl-2, Mcl-1, Bcl-xL) and pro-apoptotic executioner (BAK, BAX) 
proteins contain up to four BH regions, with a third class of 'BH3 only' 
modulation proteins (BID, BIM, BAD, NoxaB) that contain only the BH3 helical 




Figure 3.8 – Schematic representation of the three classifications of the Bcl-2 family 
and their complementary interactions). The illustrated proteins are Bcl-xL (green, PDB: 
1BXL)174; BAK (blue, PDB: 2M5B)175 and BID (red, PDB: 2BID).98  
  
Regulation by the Bcl-2 family occurs in the mitochondrial outer 
membrane where, in healthy cells, anti-apoptotic proteins sequester BAK and 
BAX.6, 172 In the event of cellular stress, signalling pathways regulate the 
expression of the BH-3 only modulation proteins, which in turn relay the pro-
apoptotic signals to the multiple domain members (Figure 3.9). Signalling 
occurs either by the direct activation of BAK or BAX,176-178 or by sequestering of 
anti-apoptotic proteins on the mitochondrial membrane by the BH-3 only 
proteins,6, 162 resulting in the oligomerisation of BAK or BAX, permeabilisation 
of the mitochondrial membrane and the release of cytochrome c, triggering 




Figure 3.9 – Illustration of the association of proteins within the Bcl-2 family and their 
roles in triggering apoptosis by the caspase cascade. 
The promiscuity of the BH3 'death domain', which binds into the 
juxtaposition of the BH1, BH2 and BH3 domains of the multiple domain family 
members has given rise to numerous studies on the use of BH3 peptides as 
potential therapeutics, notably hydrocarbon stapled BH3 peptides.3, 119, 120, 133, 
178, 179  
 
Figure 3.10 – Representations of BID bound to Mcl-1. a) The key side chains within the 
BH3 region that are essential for binding; b) ribbon diagram of BID BH3 (red helix) 
and Mcl-1, with the BH1 (yellow), BH2 (green) and BH3 regions of Mcl-1 coloured; c) 
surface representation of the BID BH3 (red helix) binding into the hydrophobic pocket 
of Mcl-1, formed by the juxtaposition of BH1, 2 and 3. PDB: 2KBW.  
In the context of this investigation, the constrained BID BH3 sequence 
which has been shown to be effective in killing leukaemia xenografts in mice 
was used.3 The BID protein is an indiscriminate binder to all multi-domain 
proteins and binds into the hydrophobic groove of its partner by projection of 
86Ile, 90Leu, 93Val and 97Met along one face of the α-helical BH3 domain (Figure 
3.10). The preceding work provided a foundation for the study of 
monosubstituted unnatural amino acids as surrogates for stapling, as well as 
62 
 
potential studies on the selectivity of stapled peptides across anti-apoptotic 
family members.       
3.5.1 Peptide synthesis of unlabelled BID peptides  
The peptides synthesised for the study of stapled BID peptides 
encompass the BH3 region of the BID pro-apoptotic protein, utilising the 
peptide sequence used by Walensky and coworkers (Figure 3.11b, BID-DM).3 A 
direct replacement of the disubstituted amino acid positions optimised for the 
most helical constrained peptide with monosubstituted amino acids allowed a 
comparison of the two stapling methodologies. In addition, a peptide with 2-
aminoisobutyric acid (Aib) was synthesised as a further control, since Aib is 
known to promote helical character.180  
The nomenclature of the BID peptide series is similar to that described 
with the p53 series (3.3.2), with the addition of disubstituted metathesised 
(DM) and disubstituted unmetathesised (DU) which used α,α-disubstituted 
amino acid 16.  
With respect to the modifications of the peptide sequence, tryptophan 
was added at the C-terminus to assist purification and for accurate 
determination of concentration. In addition, the native methionine residue was 
exchanged to norleucine which prevents interference of the thioether moiety 




Figure 3.11 – a) The BH3 region of BID (residues 80-102) with the key hydrophobic 
side chains coloured green; b) sequences of the BID BH3 peptides used in the 
investigation of mono- and disubstituted unnatural amino acids for peptide stapling. 
MM and MU retain their definitions from Figure 3.3, and Disubstituted Metathesised 
(DM) and Disubstituted Unmethesised (DU) are also used in further discussions.    
BID WT was synthesised on Rink Amide MBHA resin manually on a 
0.1 mmol scale to establish which couplings in the sequence were troublesome 
before using automated peptide synthesis. The first attempt afforded a poor 
crude recovery of peptide and several deletion sequences in the sterically 
encumbered 82IIRN region close to the N-terminus. The following repeated 
synthesis ensured that these residues were double coupled, and the peptide 
built on a LL (low loading) variant of the resin, which prevented aggregation of 
the peptide during synthesis and afforded a greater quantity of crude peptide. 
Purification afforded 24 mg (11%) of pure BID WT, with the low yield 





Crude Yield Outcome 
0.1 None 40% 82IIRN deletions 
0.1 82IIRN, 103W 82% Purified. 11% yield 
Table 3.1 - Summary of synthesis attempts of BID WT 
Conversely, synthesis of the BID peptide using the unnatural amino 
acids required several rounds of optimisation before a reliable synthesis and 





 Peptide Couplings Outcome 
1 BID DU A Deletion of 91A, 95D; acetyl capping 
2 BID DU  B Trace deletion of 91A, 95D; acetyl capping 
3 BID DU C Successful & purified. 5% yield 
4 BID MU C Acetyl capping & complete peptide 
5 BID MU C Successful & purified. 5 % yield  
Table 3.2 - Summary of the optimisation of the BID MU and BID DU peptides. Coupling 
Condition A was double coupling of  82IIRN and 103W; B was double couplings of 82IIRN, 
91A, 95D and 103W; C was the same coupling strategy as B, but with 10 equivalents of 
HATU employed for 91A and 95D and with Fmoc deprotection of the unnatural amino 
acids extending to 30 minutes.  
     The most common deletion sequences observed for BID DU were 91A 
and 95D, which can be rationalised by the hindered N-terminus of a 
disubstituted amino acid being less efficient during standard coupling 
conditions. Trial cleavages also identified that the Fmoc protecting group of the 
disubstituted unnatural amino acid was not fully removed after 10 minutes. 
Therefore, using HATU as the coupling reagent instead of HCTU and extending 
the Fmoc deprotection time prevented these deletion sequences from 
occurring.  
 
Figure 3.12 – Deletion sequences and acetyl capping of the BID DU/MU peptides 
described in Table 3.2.  
Table 3.2 entries 1, 2 and 4 also had unexpected incorporations of an 
acetyl cap in the sequence. The acetyl capping in the place of the unnatural 
amino acids in BID DU and BID MU was attributed to traces of acetic acid that 
were present in the purification of the Fmoc protected monomers. Removal of 
acetic acid from purification completely eliminated the capping. 
On-resin Grubbs metathesis of BID DU and MU was effective, with a 
>98% conversion in both BID DU and MU to BID DM and BID MM. Cleavage and 
deprotection using Reagent K afforded respectable crude yields of peptides 
(typically ~90% for BID DU and MU; ~75% for BID DM and MM), which led to 
the purification of the stapled BID peptides to afford 7 mg (7%) and 13 mg 
(10%) of BID DM and BID MM respectively. 
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The crude peptides typically contained a species with a mass of 44 Da 
heavier than expected, due to incomplete decarboxylation of the Boc protecting 
group on 103W. Decarboxylation was completed by repeated lyophilisation of 
the crude peptides with 0.1% formic acid added to a mixture of dioxane and 
water.  
 The disappointing yields of the purified peptides after HPLC were 
attributed to the broad UV chromatogram of the crude peptides, which 
required small injections and shallow solvent gradients to afford peptides of 
acceptable purity. 
Finally, BID Aib was synthesised using a mixture of automated and 
manual methods, with the region of 91A(Aib)VGD(Aib)NL coupled manually 
with Coupling Strategy C (Table 3.2) and the other residues coupled using 
automated, non-microwave-assisted conditions. Ultimately, BID Aib was 
purified to afford 9 mg (10%) on a 0.05 mmol scale. 
3.5.2 Protein Expression of Bcl-xL (no loop) 
One of the basic biophysical experiments of the BID BH3 peptide series 
is calculating inhibitory potency by distrupting a Bcl-xL PPI. Bcl-xL 'no loop' is a 
construct of Bcl-xL that omits an unstructured region of Bcl-xL with little effect 
on its binding potency. Removing the flexible loop region of Bcl-xL can promote 
a more crystalline packing behaviour, which would be useful for future 
structural studies. From a 10 L growth, 19.1 mg of GST–Bcl-xL was afforded, of 
which 10 mg of GST–Bcl-xL was subjected to PreScission Protease to remove 
the GST tag, which furnished 4.9 mg of Bcl-xL 'no loop' for binding assays after 
gel filtration chromatography (4.6 & Appendix IV).  
3.6 Biophysical evaluations of BID BH3 peptides 
3.6.1 Circular Dichroism of the BID peptides 
The secondary structure of BID BH3 peptides was examined in solution 
by circular dichroism. In order to prevent precipitation and to ensure that the 
concentration was accurate - an essential factor in circular dichroism - the 
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peptides were dissolved in 30 % acetonitrile in phosphate buffer (40 mM, pH 
7.50).   
 
Peptide % Helicity 
BID WT 12 
BID MM 73 
BID DM 80 
BID Aib 31 
BID MU 17 
BID DU 20 
Figure 3.13 – Circular dichroism spectra and the table of % helicities of the BID BH3 
peptides investigated. The spectra that have been plotted are emboldened on the table. 
The normalised ellipticities of the peptides were converted into a percentage of 
helicity as described by Baldwin and coworkers, and for consistency, by the original 
stapled BID investigation.3, 103, 167 
Pleasingly, the DM and MM peptides gave a characteristic α-helix signal, 
whilst the Aib and wild type peptides displayed minimal helical character. The 
random coil profile of the wild type peptide confirmed that the quantity of 
acetonitrile in the buffer was not contributing to promotion of secondary 
structure. The results are consistent with respect to the DM percentage of 
helicity (Figure 3.13), but also demonstrated that the monosubsituted amino 
acid was capable of promoting an α-helical conformation in solution to the 
same extent. The profiles of the unmetathesised peptides appeared to have a 
mixture of character - random coil and α-helix - but the amplitude of the signal 
at 222 nm was insufficient for an α-helical character to dominate (See Appendix 
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II, 6.1). The exciting CD results provided the first validation of monosubstituted 
amino acids as hydrocarbon staples, which led into further biophysical 
investigations. 
3.6.2 Enzymatic Degradation 
One of the key biophysical markers of the effectiveness of stapled 
peptides as therapeutic ligands is their resistance to enzymatic degradation. 
Essentially, the peptide must be unfolded in order to be accommodated into the 
active site of a protease.181 Therefore, rigidifying a peptide would decrease its 
enzymatic lability allowing the peptide to reach its target and perform its 
function. In order to investigate the effect of the novel monosubstituted amino 
acid stapling methodology, a degradation study with trypsin was performed.  
Trypsin selectively digests at the carboxyl side of positively charged residues, 
such as lysine and arginine.182 With the BH3 region of BID possessing three 
arginine residues, trypsin was an ideal protease to monitor the degradation of 
the peptide by HPLC, and to provide insight on the mechanism of degradation 
(Figure 3.14).   
A suitable ratio of substrate:enzyme of 10,000:1 was established, 
ensuring that digestion was slow enough to obtain data points over 90 minutes 
by HPLC. Integration of the UV trace of the undigested peptide and conversion 




Peptide Half Life (mins) 
BID WT 20 
BID MM 38.3 
BID DM 46.5 
BID Aib 30 
BID MU 25.1 
BID DU 25.6 
Figure 3.14 – Results of the enzymatic degradation study with BID WT (black), MM 
(blue), DM (red) and Aib (purple) shown and the cleavage sites of BID when subjected 
to proteolytic digestion.  
It was gratifying that the DM and MM peptides displayed a marked 
improvement in their protease resistance over the wild type and Aib peptides, 
but it was also an excellent result that the MM peptide had a half life that was 
similar to that of the literature DM stapled peptide. The unstapled peptides 
displayed slight improvements in their resistance over the wild type, which 
allows the conclusion that constraining the peptide with a hydrocarbon 
crosslink gives rise to a greater enzymatic resistance for both of the alkenyl 
amino acids. 
HR-LCMS confirmed the mechanism of trypsin digestion of BID BH3 
peptides. Regardless of modification, the site at 89R is the most labile position, 
followed by 99R. Hydrocarbon stapling slows the rate of digestion of the full 
peptide at all of the positions, but the mechanism of fragmentation is the same 
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regardless of modification to the peptide. Indeed, the site at 85R is the least 
labile site, since the peptide corresponding to Fragments I-II remains after 
Fragment III-IV has been completely digested.  
3.6.3 Fluorescence Anisotropy of BID BH3 peptides 
The BID BH3 only proteins are known to bind to all members of the anti-
apoptotic Bcl-2 family proteins, as well as to the BAK and BAX effector proteins 
(Figure 3.15).6, 172, 183 As such, for assessment of the binding affinity of the BID 
BH3 peptides using fluorescence anisotropy, the assays with a labelled species 
and the available protein Bcl-xL required establishment under direct binding 
conditions before competition assays could be used.  
 
Figure 3.15 –a) Schematic of the binding selectivities of the BH3 only modulator 
proteins with two of the anti-apoptotic proteins used in the following binding assays; 
b) sequences of the BAK peptide that was used in the assays for screening of Bcl-xL 
inhibitors (synthesised by Dr. P. Prabhakaran).   
3.6.3.1 Establishing direct binding Bcl-xL assays with BODIPY-BAK 
The potency studies for BH3 peptides with anti-apoptotic Bcl-xL were 
established by utilising the BH3 region of effector protein BAK, which was 
functionalised with an N-terminal BODIPY TMR fluorophore analogous to 
studies from the laboratory of Gellman (Figure 3.15).184, 185  
Optimisation of the protein titration experiment found that 100 nM of 
BAK* was required to accelerate equilibration at low protein concentrations. 
The slow equilibration had been previously observed,184 and after 20 h, a Kd 





Figure 3.16 – Protein titration of Bcl-xL with BODIPY-BAK; a) Anisotropy data after 2 h 
incubation at rt; b) Anisotropy data after 20 h incubation at rt; c) Kd determination of 
BAK*/Bcl-xL with [BAK*] set at 100 nM; d) Raw intensity of the data in the direct 
binding experiment.  
It was noticeable that there was a large change in intensity upon binding 
(Figure 3.16d) which suggests that the fluorophore environment is altered at 
higher concentrations of Bcl-xL. In addition, the rmin value of unbound BAK* was 
unexpectedly high in the protein titration experiment, which could point to 
aggregation of BAK*.   
To confirm the Kd value from the protein titration, the conditions were 
reversed and the Bcl-xL concentration was fixed at 50 nM (henceforth described 
as a peptide titration experiment). This assay gave a lower rmin value than that 
of the protein titration but despite this, a Kd value of 12.5 ± 3.2 nM was 






3.6.3.2 Competition assays of the Bcl-xL/BAK* interaction 
 
Peptide IC50 (μM) 
BID WT 1.44 ± 0.05 
BID MM 0.62 ± 0.02 
BID DM 1.14 ± 0.04 
BID Aib 1.15 ± 0.04 
BID MU 2.48 ± 0.11 
BID DU 2.94 ± 0.10 
Figure 3.17 – Inhibition curves for a selection of BID BH3 peptides against the 
Bcl-xL/BAK* interaction, showing BID WT (black), MM (blue), DM (red) and Aib 
(purple).  
With the direct binding assay of Bcl-xL/BAK* established, the 
competition mode of the assay was set with [Bcl-xL] and [BAK*] at 131 nM and 
43 nM respectively. The IC50 values calculated for the inhibition of Bcl-xL/BAK* 
were within a surprisingly narrow range, with the stapled peptides being 
marginally better inhibitors compared to the wild type peptide. As observed 
with p53/hDM2, unstapled MU and DU were poorer inhibitors compared to 
MM and DM, which suggests that the alkenyl amino acid is an unfavourable 
incorporation, which is mitigated by constraining the peptide. The slopes of the 
curves were unexpectedly steep, which suggests there may be association of 
unbound inhibitor and BAK*.   
3.7 Discussion and Conclusions 
In terms of the synthesis of the different amino acids for peptide 
stapling, it was found that the route for α,α-disubstituted scaffolds was 
challenging to optimise, but has the potential for the synthesis of either (S) or 
(R) amino acids. In contrast, the nickel complex synthetic route in its current 
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form only allows access to the (S) amino acid since performing two successive 
alkylations affords racemic amino acids.158 Whilst the (S) amino acid was 
sufficient for effective crosslinking at i, i+4 positions, future investigations with 
stapling at i, i + 7 requires an (R) amino acid.2 One potential future investigation 
could focus on the use of an analogous complex and stereoselective alkylations 
mediated through phase transfer catalysis.159  
Initial studies with the p53 peptide were unfortunately insufficient to 
provide evidence for whether des-methyl amino acids were suitable for use in 
stapled peptides. The circular dichroism data does not show an effective 
promotion of a helical structure of the peptide after stapling. The reduced 
potency of p53 MM compared to p53 WT was also insufficient to demonstrate 
the utility of monosubstituted amino acids as suitable staples. 
The BID BH3 investigation provided conclusive evidence that the des-
methyl amino acids were capable of recapitulating the results of their widely 
reported disubstituted analogues, since a direct comparison of BID DM and BID 
MM peptides was available in this investigation. CD and enzymatic degradation 
data demonstrated the utility of des-methyl amino acids as monomers for 
hydrocarbon stapling for structural constraint, whilst the slight improvement 
of Bcl-xL/BAK* inhibition compared to BID WT was pleasing.  
Walensky and coworkers have previously reported that BID DM is >10 
fold more potent than BID WT in binding studies with homologous Bcl-2.3 Thus, 
it would have been expected that BID DM would bind more strongly to Bcl-xL 
than BID WT. Since this was not observed to such a magnitude, an investigation 
into potential selectivity of stapled peptides against a homologous series of 
targets could be opened.  




Chapter 3b: Investigation into the 
modulation of potency of 




Chapter 3a proved that des-methyl amino acids were suitable as 
monomers for hydrocarbon stapling, matching the helix promotion and 
enzymatic resistance characteristics of widely used disubstituted amino acids 
in a BID BH3 peptide. Interestingly, the IC50 values of the inhibition of 
Bcl-xL/BAK* were similar for constrained and unmodified BID BH3, which 
appears to counter previous hypotheses that an increase in helical character of 
a peptide results in an increase of potency of the peptide with its binding 
partner.3, 127 
Given the results of the otherwise overlooked monosubstituted stapled 
peptides, it was necessary that further evaluation of both monosubstituted and 
disubstituted stapled peptides was required to rigorously challenge the original 
hypotheses of stapled peptides. The required experiments were to establish a 
direct binding method for BID BH3 peptides, firstly to directly calculate Kd and 
secondly to provide a handle on the thermodynamic factors associated with the 
binding of stapled peptides with their receptors - experiments which are 
lacking in the literature.  
In addition to this, the selectivity of the stapled BID BH3 peptides with 
the other members of the Bcl-2 family has not been previously examined. BID 
DM and BID MM would provide further data on whether there is a difference in 
potency with a homologous anti-apoptotic protein, Mcl-1, in comparison to 
Bcl-xL as well as differences in potencies between mono- and disubstituted 
amino acids. 
Furthermore, the monosubstituted amino acids can be applied to other 
disubstituted stapled peptides in the Bcl-2 family that have already been 
proven effective ligands, to further assess the application of des-methyl amino 
acids in stapled peptides. Finally, structural and in cellulo experiments were 
required to formally supplement the data obtained from circular dichroism and 
test the hypothesis that hydrocarbon stapled peptides impart an improvement 




3.8 Peptide synthesis of BIM BH3 and FITC-labelled 
BID BH3 peptides 
3.8.1 FITC-BID Peptide Synthesis 
One particular limitation of the fluorescence anisotropy competition 
assay performed in 3.4.2.1 and 3.6.3 is that a direct inhibition constant (Ki) 
could not be calculated from the data. This was due to the fluorophore unbound 
anisotropy plateau in the competition assay being lower than the unbound 
anisotropy plateau in the direct binding experiment, which may arise from 
BAK* aggregating with the titrated inhibitor upon displacement (Appendix II, 
6.2.1). Therefore, functionalising the BID peptides with a fluorescein label could 
allow access to direct binding fluorescence anisotropy experiments and thus 
calculation of Kd.   
The sequences of the peptides for labelling are identical to those used in 
Figure 3.11, with the exception of further functionalisation of the N-terminus 
with either 6-amino hexanoic acid (Ahx, in the case of the wild type)6 or β-
alanine (for MM*, DM* and Aib*)3 followed by coupling with fluorescein 
isothiocyanate (FITC). The linkers were chosen based on literature precedent 
and were necessary to prevent excision of the FITC tag.186 The abbreviations of 
the peptides are the same as those used in Figure 3.11 and fluorescently 
labelled peptides are denoted with an asterisk.   
 
Figure 3.18 – a) Sequences of the FITC labelled stapled peptides, which is the same for 
MM*, DM* and Aib*. The wild type (WT*) uses a 6-aminohexanoic acid linker. B) 
Fluorescein isothiocyanate (FITC).   
The peptide synthesis, based on all of the optimisations outlined in 3.5.1 
used low loading rink amide MBHA resin. In order to prevent any complications 
between Grubbs' catalyst and the FITC label, the metathesis was performed 
before the final Fmoc deprotection and coupling of FITC. Cleavage, deprotection 
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and purification of the peptides was complicated by the hydrophobic nature of 
the peptide and label to cause streaking during HPLC, but the four peptides 
were afforded after synthesis on a 0.05 mmol scale with yields of 6.5 mg (7%), 
9.9 mg (10%), 23 mg (21%) and 9.25 mg (10%) for WT*, Aib*, MM* and DM* 
respectively. Whilst the purified yields of these peptides were low, the 
quantities of peptide that were afforded were sufficient for in vitro and 
preliminary in cellulo experiments.   
3.8.2 BIM BH3 Peptide Synthesis 
After having successfully established the use of des-methyl amino acids 
with the BID BH3 peptide, the methodology was expanded into another area of 
investigation within the Bcl-2 family of pro-apoptotic proteins to investigate 
the possibility of selectivity of stapled BH3 ligands with Bcl-2 family proteins.   
The BIM BH3 region is analogous to that of BID, matching its binding 
promiscuity by binding to all of the anti-apoptotic proteins in the Bcl-2 family.6, 
172 Areas of sequence redundancy are evident when comparing the BH3 regions 
of BID and BIM, with the key binding residues oriented along the i, i+4, i+7 and 
i+11 face of the BH3 helix.  
 
Figure 3.19 – Sequences of the BIM BH3 peptides that have been studied. BIM WT and 
BIM DM have been previously characterised by Walensky and co-workers.119 Czabotar 
and coworkers have studied stapled BIM peptides using the sequence labelled 
Czabotar BIM-WT,131 with the substitution positions of the unnatural amino acids the 
same as BIM-DM. The green residues are the key hydrophobic side chains.  
Hydrocarbon stapling of the BIM BH3 region has also been previously 
examined, with disubstituted amino acids replacing the native 94Arg and 98Glu 
residues.119, 131 Incidentally, the results of stapling of the BIM BH3 region by 
two different research groups have provoked a debate into the effectiveness of 
hydrocarbon stapling as a suitable therapeutic strategy. Walensky and 
coworkers demonstrated, in accordance with their previous work, that stapling 
the BH3 region of BIM improves helicity (20% to 81%), potency and cell uptake 
of the modified peptide.122 In contrast, the research of Czabotar and coworkers 
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shows that despite using the same position of the hydrocarbon stapling, a 
modest increase of helicity is observed (20% to 39%) with binding affinity and 
cellular uptake not improved.131  
A recent exchange of publications122, 131, 132, 187 has hypothesised that the 
sequence of the peptide is vital to its activity in vitro and in cellulo, but for the 
purposes of this investigation, the peptide sequence characterised by Walensky 
and coworkers was chosen.122 
The synthesis and purification of the BIM series of peptides was 
originally carried out by P. Rowell, who was able to effectively synthesise and 
purify the wild type peptide on a scale of 0.1 mmol with 17 mg of pure peptide 
obtained (41% crude yield, 6% purified), however, the unnatural variants were 
not effectively synthesised or purified.  
The peptides for hydrocarbon stapling were synthesised on a 0.075 or a 
0.1 mmol scale (BIM DM and BIM MM respectively) using analogous 
procedures to those reported in 3.5.1, where the first 8 residues were built 
using an automated peptide synthesiser. The unnatural amino acids were 
subsequently coupled manually, and the remaining 8 residues coupled using 
automated methods. After on-resin Grubbs' metathesis, the MM and DM BIM 
peptides were pleasingly obtained in high purity with no observed deletions. 
Semi-preparative HPLC afforded 21.5 mg of DM BIM (32%) and 9.2 mg of MM 
BIM (23% based on 40 mg crude purified). 
3.9 Circular Dichroism 
After the synthesis of the FITC labelled BID BH3 and BIM BH3 peptides, 
their secondary structure in aqueous solution was assessed to verify whether 
the FITC tag altered α-helicity of BID BH3 and whether α-helical character of 
BIM BH3 was improved after stapling.   
3.9.1 Circular Dichroism of FITC-BID Peptides  
It was confirmed that the FITC labelled peptides had a degree of helicity 
that was consistent with those observed in 3.6.1, with a slight decrease in % 
helicity seen for the stapled peptides, but with an increase of 10% of the wild 
type with respect to its unlabelled analogue (3.6.1). Whilst the CD profiles of 
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BID WT* and BID Aib* did not show an overriding random coil profile as 
previously observed, they are similar to those of the BID MU and DU (Appendix 
II, 6.2.1).  
 
 
Figure 3.20 – Circular dichroism of the FITC labelled peptides including their 
percentage helicities: BID WT* (black), BID MM* (blue), BID DM* (red) and BID Aib 
(purple).  
The maximum scanned wavelength was also increased to 500 nm, to 
observe any possible induced circular dichroism188 of the FITC tag with the BID 
peptides. The absence of a CD signal at 490 nm demonstrated that there was no 
induced circular dichroism, which suggested that the fluorophore was capable 
of moving freely, instead of forming hydrophobic contacts with side chains of 
the residues. 
3.9.2 Circular Dichroism of BIM BH3 Peptides     
Previously reported data into the helical content of the stapled BIM BH3 
peptides has been contradictory,119, 122, 131 so the circular dichroism experiment 
was designed so that the peptides were compared in buffer and buffer 
containing TFE in order to calculate the 'maximum helicity' of the wild type 
BIM BH3 peptide and to evaluate the extent to which hydrocarbon stapling 
introduces helical character.  
Peptide % Helicity 
BID WT* 23 
BID MM* 74 
BID DM* 70 









BIM WT 20 70 
BIM MM 57 61 
BIM DM 59 62 
 
Figure 3.21 – Circular Dichroism spectra of BIM BH3 peptides BIM WT (black), BIM DM 
(red) and BIM MM (blue) in a) 15% Acetonitrile in 40 mM sodium phosphate buffer 
and b) with 30% v/v TFE added to the buffer.  
The circular dichroism results are consistent in the helical nature of the 
wild type peptide, showing a random coil profile and a low helical percentage 
(20%). The two stapled peptides, BIM MM and BIM DM have equivalent helical 
contents, with 57% and 59% respectively. The addition of the TFE improved 
the helical content to 70% for the wild type, with a minimal increase of helical 
character seen for the MM and DM BIM peptides (61% and 62% respectively).  
In contrast with precedents,122 a moderate helicity was seen for both of 
the stapled peptides, but TFE does not vastly improve their helical contents, 
which demonstrates that the hydrocarbon staple rigidifies the peptide. 
Compared to BID, the moderate helicity of BIM DM and MM is somewhat 
surprising, considering that BID DM and MM possess high helical content in a 
peptide that is three residues longer (3.6.1). Nevertheless, the des-methyl 
amino acids were capable of matching the helical content of the disubstituted 





3.10 Inhibitor Selectivity Investigations: Competition 
Assays of Mcl-1/NoxaB* 
Stapled BID BH3 peptides were effective inhibitors of the Bcl-xL/BAK* 
PPI, but only marginal improvement in inhibitory potency was observed after 
constraining the peptide, contrary to literature precedent with anti-apoptotic 
Bcl-2. Therefore, with homologous anti-apoptotic Mcl-1 available,III the stapled 
BID BH3 peptides could be evaluated to provide insight into possible 
selectivities of a stapled ligand across a family of degenerate proteins. Also, 
with BIM BH3 in hand, the selectivity profile of different hydrocarbon stapled 
ligands could be constructed.  
 
Figure 3.22 – A routemap of the fluorescence anisotropy assays performed with the 
various members of the Bcl-2 family; a) Using Bcl-xL as the complete protein and b) 
Mcl-1 as the complete protein. 
Thus, a collaborative effort was made to establish a fluorescence 
anisotropy assay to test ligands for Mcl-1 affinity. With Dr. K Long and V. 
Azzarito, an assay with a FITC-labelled NoxaB* peptide (the 16-residue BH3 
region of pro-apoptotic NoxaB) was established for the testing of potential 
Mcl-1 ligands. A Kd of 18.7 ± 0.9 nM was calculated for the direct binding 
                                                        
III Mcl-1 was expressed by Dr. A. Bartlett or Dr. J. Miles in the laboratory of Dr. T. 
Edwards (University of Leeds). NoxaB* synthesised by Dr. P. Prabhakaran. 
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Mcl-1/NoxaB* assay, consistent with literature precedents (assay development 
is described in Appendix II, 6.2.2).172, 189   
3.10.1 BID BH3 Inhibitors of Mcl-1/NoxaB* 
After optimising the Mcl-1/NoxaB* competition assay conditions to use 
150 nM and 50 nM of Mcl-1 and NoxaB* respectively, all of the unlabelled BID 
BH3 peptides were titrated and afforded an expected decrease in anisotropy as 
NoxaB* was displaced from Mcl-1. The BID series gave a surprising series of 
potencies, with the wild type BID being the most potent inhibitor with an IC50 of 
0.38 µM compared to the IC50 values of 0.80 µM and 1.60 µM for DM and MM 
respectively. Interestingly, the value for the unstapled MU peptide was 2.80 µM, 
suggesting that the replacement of the native residues with the alkenyl 
unnatural amino acids is unfavourable to binding, but conformationally 
rigidifying the peptide provides a compensation in this binding penalty.  
 
Peptide IC50 (μM) 
BID WT 0.39 ± 0.08 
BID MM 1.60 ± 0.12 
BID DM 0.80 ± 0.07 
BID MU 2.80 ± 0.07 
Figure 3.23 – Inhibition curves for a selection of the BID BH3 peptides against the 
Mcl-1/NoxaB* interaction, with BID WT (black), MM (blue), DM (red) and MU (green) 
illustrated.  
 The results of the unlabelled BID BH3 peptides suggest there is partial 
selectivity of stapled peptides, where the constrained peptides are less potent 
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than unmodified BID WT for inhibiting Mcl-1/NoxaB*, but the potency range 
across the series is quite narrow.   
One caveat of the competition assays is that IC50 is more useful for 
comparing across a family of inhibitors, rather than a family of proteins, since 
Bcl-xL/BAK* is more tightly bound than Mcl-1/NoxaB* (3 vs 19 nM 
respectively). Therefore, direct binding experiments are vital to understanding 
whether hydrocarbon stapling modulates binding affinity with a family of 
proteins. 
3.10.2 BIM BH3 Inhibitors of Bcl-2 family PPIs 
So far, the hydrocarbon stapling of BID BH3 has afforded marginal 
improvement or diminishment of inhibitory potency of Bcl-2 family protein-
protein interactions. With the BIM BH3 stapled peptides in hand, the trends and 
selectivity of homologous hydrocarbon stapled ligands was open to 
investigation.   
 
Peptide IC50 vs Mcl-1/NoxaB* IC50 vs Bcl-xL/BAK* 
BIM WT 0.05 ± 0.002 μM 0.32 ± 0.07 μM 
BIM MM 1.77 ± 0.25 μM 11.9 ± 3.8 μM 
BIM DM 0.89 ± 0.15 μM 4.00 ± 0.62 μM 
Figure 3.24 - Fluorescence anisotropy competition curves of the BIM BH3 peptides; 
BIM WT (black), BIM MM (blue) and BIM DM (red) for their inhibition of a) Mcl-
1/NoxaB* and b) Bcl-xL/BAK* (right) protein-protein interactions.  
Against Mcl-1, the stapled BIM peptides possess similar IC50 values and a 
similar trend in inhibition (where DM is more potent than MM) compared to 
their BID BH3 peptides, but these peptides are clearly less potent than the wild 
type peptide (Figure 3.24a). Indeed, the IC50 of the wild type peptide surpasses 
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that of the wild type BID by an order of magnitude, which is surprising 
considering that a similar trend to the BID peptides was expected.  
Against Bcl-xL, the same trend is also seen, with BIM MM being the 
weakest peptide, with BIM DM being an order of magnitude weaker as an 
inhibitor than BIM WT (Figure 3.24b). These results are somewhat alarming, 
considering that literature precedent states that the BIM DM peptide has a 
threefold improvement of binding affinity compared to the wild type 
peptide.122 But, these results are consistent with the observations of Czabotar 
and co-workers,131, 132 where stapled BIM DM peptides are weaker ligands 
towards Mcl-1 and Bcl-xL (Table 3.3).131  
 Mcl-1 Bcl-xL 
Czabotar BIM DM Ki 3.4 nM Ki 300 nM 
Czabotar BIM WT Ki <1.4 nM Ki 11 nM 
Walensky BIM DM Kd 17 nM EC50 16.2 nM 
Walensky BIM WT - EC50 52.0 nM 
Table 3.3 - Summary of binding constants of reported BIM peptides against Mcl-1 and 
Bcl-xL from Czabotar131 and Walensky.119, 120 
However, the difference in the trends that have been observed may arise 
from the different methods that were used to calculate the Kd of the peptides. 
Walensky and coworkers calculated their Kd value based on a direct binding 
assay with FITC-labelled BIM peptides and by using a different Bcl-xL construct 
that retains its GST tag in the assay.119 Whilst it would have been expected to 
observe an IC50 value that is weaker than reported Ki values in the competition 
assay, considering that the BIM peptides are displacing a fluorophore with a Kd 
of 4 nM, it was surprising that the stapled peptides - especially in the case of the 
MM peptide - were considerably weaker than the unmodified control. 
BID and BIM BH3 share some sequence redundancies, but the 
hydrocarbon staple position was in the same location for both peptide series. 
The significant result from the competition assays - where stapling of BIM BH3 
in the investigated positions was detrimental to inhibitory activity -  
demonstrated that hydrocarbon stapled peptides must be designed on a per-
ligand, per-interaction basis, rather than assuming that the best stapling 
position of one ligand is the same across a homologous series of ligands. Future 
directions for the BIM peptide series will be the development of an orthogonal 
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biophysical assay, considering these results are contrary to the majority of 
published research in hydrocarbon stapling.   
3.11 Direct Binding Studies of FITC labelled BID BH3 
Peptides 
In competition assays, hydrocarbon stapling of BID BH3 peptides with 
either mono- or disubstituted amino acids had effectively no change of potency 
for inhibiting Bcl-xL/BAK*; stapled peptides were less potent for inhibiting 
Mcl-1/NoxaB* compared to unmodified controls. To explore further these 
findings, FITC-labelled BID BH3 peptides were employed in direct binding 
fluorescence anisotropy assays with Mcl-1 and Bcl-xL.  
3.11.1 Direct Binding of Mcl-1 and FITC-BID BH3 peptides 
3.11.1.1 Protein Titration of Mcl-1 
The first attempts at direct binding with all of the labelled peptides in 
the buffer used in all prior fluorescence anisotropy experiments (40 mM 
sodium phosphate, 200 mM NaCl, 0.02 mg mL-1 BSA, pH 7.50) displayed no 
change in anisotropy across the dilutions of Mcl-1. As a result, the buffer was 
altered to Tris (50 mM Tris, 140 mM NaCl, pH 7.50) which has been used within 
the Bcl-2 literature.3, 119 6, 189 After this modification, there was a clear change in 




Figure 3.25 – Slow equilibriation of the BID WT* peptide against Mcl-1 a) After 2 hours 
and b) after 20 hours incubation. It is noticeable that the lower anisotropy plateau 
settles after 20 h, but the measured intensity increases at lower protein 
concentrations.  
Interestingly, the equilibration of the labelled BID peptides was slower 
than NoxaB*, where the best results were often obtained after incubation of the 
plates at room temperature for 18-24 hours, particularly at lower 
concentrations of the titrated Mcl-1, suggesting that the larger BID peptides had 
slower binding kinetics than the smaller NoxaB*. It was also noteworthy that, 
similar to the Bcl-xL/BAK* titrations, the equilibration of the tracer with the 
protein (Figure 3.25) was slow, which was not observed with NoxaB*. As the 
incubation time increased, the lower anisotropy plateau settles, but the 
intensity began to change in a V-shaped profile. This suggested that the 
environment of the unbound FITC-labelled peptide was changing during the 





Peptide EC50 (nM) Kd (nM) 
BID WT* 98 ± 8.9 51 ± 19.9 
BID MM* 153 ± 12 141 ± 19.3 
BID Aib* 84 ± 13 66.2 ± 19.0 
BID DM* 129 ± 3.0 107 ± 23 
Figure 3.26 – Direct binding curves of FITC BID BH3 peptides with Mcl-1. a) and b) are 
the curves for BID WT* and BID DM* respectively, fit by the Kd model (orange) and 
logistic model (green); c) overlaid curves for all of the FITC BID BH3 peptides 
(100 nM), fitted with the logistic model.  
Interestingly, the trend observed in the direct binding studies showed 
that the Kd and the EC50 values of the stapled peptides are twofold weaker than 
those of the WT* and Aib* peptide, but the marginally more helical DM* peptide 
has an improved binding affinity compared to MM*. In spite of the weaker 
binding of the stapled peptides, this is a promising result, since the Kd values 
are in the same region as those previously reported and that the trend of Kd 
values match the IC50 trend observed in the inhibition of Mcl-1/NoxaB* 
(3.10.1).172, 189, 190  
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A problem in the calculation of the Kd values of the peptides was the 
difficult fitting of the data to a 1:1 Kd binding model, which either misinterprets 
the shape of the curve or overestimates the top plateau of the curve (which 
represents all of the tracer bound to the protein, and must therefore equal the 
tracer concentration). The origin of this may arise from non-specific binding or 
aggregation of the tracer prior to binding to the protein - a reasonable scenario 
considering the hydrophobic nature of the stapled crosslink and the FITC tag. 
As a result, EC50 values were also considered, which allow the slope of the curve 
to be accounted for.    
3.11.1.2 Peptide Titration of FITC-labelled peptides with Mcl-1 
In order to corroborate with the Kd values obtained for the protein 
titration with Mcl-1, the FITC-labelled peptides were titrated against a fixed 
concentration of Mcl-1 (100 nM). This experiment mirrors the protein titration 
whereby anisotropy is lower at higher concentrations of FITC labelled peptide. 
 
 
Peptide Kd (nM) 
BID WT* 70.6 ± 15.0 
BID MM* N.D. 
BID Aib* 15.4 ± 2.7 
BID DM* 17.2 ± 3.7 
Figure 3.27 – Peptide titration of BID WT* against Mcl-1 and a table of Kd values 
calculated from the peptide titrations of the other FITC labelled peptides (all curves 
are presented in Appendix II, 6.2.5). The Kd of MM* was not calculated because a 
bottom plateau was absent.    
The results for the peptide titration do not completely match those of 
the protein titration, which has been previously observed elsewhere.12, 141, 191 
The titration of the FITC-labelled peptide was hindered by the resolution of the 
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plate reader. At higher concentrations of the tracer, the decrease in anisotropy 
can be contributed by an unequal saturation of the polarised emission channels 
whereas at lower concentrations of the peptide, the poor signal to noise ratio 
obscured the rmax plateau.  
3.11.2  Protein titration of FITC-BID peptides with Bcl-xL. 
A protein titration was performed with the FITC-labelled BID peptides 
and Bcl-xL in an analogous manner to Mcl-1 to calculate binding affinities of 
these peptides.   
 
Peptide EC50 (nM) Kd (nM) 
BID WT* 79.3 ± 6.0 20.8 ± 6.6 
BID MM* 186 ± 24 246 ± 42 
BID Aib* 57 ± 16 59.5 ± 11 
BID DM* 159 ± 13 168 ± 19 
Figure 3.28 – Direct binding curves and EC50/Kd values of the FITC labelled BID 
peptides (100 nM) against Bcl-xL.   
Similar results were also obtained for Bcl-xL when compared to Mcl-1, 
with the unstapled peptides having the strongest affinity compared to the 
stapled peptides, but, the difference in the Kd values between the stapled 
peptides and the unmodified peptides against Bcl-xL is more prominent than 
those obtained against Mcl-1.   
This is not wholly reflected in the IC50 values of the unlabelled peptides 
against Bcl-xL/BAK*, which were broadly similar across the BID BH3 series. 
Similar to the direct binding assays with Mcl-1, there are some complications in 
the fitting of the binding data to a 1:1 binding model. In spite of this, the Kd 
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value of the WT* peptide was consistent with those previously reported.172 The 
Kd values obtained here demonstrate that hydrocarbon stapling had an adverse 
effect on binding affinity, which was not observed in the inhibition of 
Bcl-xL/BAK*. Given that Bcl-xL/BAK* has a Kd of 4 nM, the weaker BID BH3 
inhibitors would have a narrow distribution of IC50 values. Therefore, the direct 
binding experiments have been vital to assess how potency of the BID BH3 
peptide is modulated by hydrocarbon stapling.   
The reverse titration, with the concentration of the labelled peptide 
varied against a fixed concentration of Bcl-xL was also attempted for all FITC 
BID peptides (Appendix II, 6.2.5). However, the errors of fitting, in addition to 
the experimental restrictions of the peptide titration assay rendered the data 
unusable for the extraction of Kd. 
3.12 Structural Characterisation of BID BH3 
To complement the results from binding studies and to further reinforce 
the circular dichroism results from 3.6.1, the BID BH3 peptides required 
further structural characterisation.   
3.12.1 X-Ray Crystallography of BID MM and Mcl-1 
X-ray crystallography of ligands bound to their targets is seen as a gold 
standard of characterisation, which allows the confirmation of binding sites and 
the binding conformation of the ligand. Since BID MM was the weakest peptide 
in the BID BH3 series in direct binding studies, X-ray crystallography could 
confirm whether the hydrocarbon crosslink was interfering with the binding 
site in a similar way to the oestrogen receptor/coactivator interaction.129 
Dr. J. Miles performed crystal trials with BID MM and Mcl-1 to grow rod-
shaped crystals which were fluorescent under UV irradiation. X-ray scattering 
was performed at Diamond and solved to afford a complex of BID MM with Mcl-




Figure 3.29 – X-ray crystal structure of BID MM bound to Mcl-1 with the hydrocarbon 
staple coloured blue and the side chains omitted (top); Side-view of the BID BH3 
peptide bound to Mcl-1 with the key binding side chains coloured green (bottom).  
We were delighted to observe that the BID MM peptide is an α-helix and 
that the key binding side chains are buried into the hydrophobic pocket of 
Mcl-1 (Figure 3.29). Also, the hydrocarbon staple does not appear to be in 
contact with the surface of the protein, residing instead on the solvent exposed 
face of the BID BH3 peptide. Clearly, the binding conformation of the BID MM 
peptide is not distorted by the hydrocarbon staple and that helical character is 





Figure 3.30 – Expansion of the C-terminal and N-terminal regions of BID MM when 
bound to Mcl-1 
 Detailed examination of the crystal structure revealed that the alkene of 
the hydrocarbon staple was solely in the cis configuration. Examination of the 
remaining side chains revealed the possibility of a salt bridge between 84R and 
81D at the N-terminus, whilst 82I is forced into a polar surface region of Mcl-1. At 
the C-terminus, 95D and 99D both form contacts with basic regions of Mcl-1, 
whilst 100R appears to project into the solvent exposed face of the helix, rather 
than forming salt bridges with the acidic surface at the top edge of the BH3 
binding cleft.  
 
Figure 3.31 – Comparison of a) BID WT (PDB: 2KBW) and b) BID MM with Mcl-1. 
 Pleasingly, the orientation of the key side chains of BID MM when 
bound to Mcl-1 is similar to the reported solution state structure of BID WT 
with Mcl-1 (Figure 3.31). Further crystal trials with BIM MM and BID WT are 
underway to provide a direct comparison of BH3 ligands bound to Mcl-1 in the 
solid phase.  
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3.12.2 Solution Phase Structural Analysis 
3.12.2.1 Thermal Unfolding Experiments 
Preceding circular dichroism analysis of stapled peptides focused on the 
calculation of the % helicity of a constrained peptide with no analysis into the 
extent the peptide maintains its conformation when subjected to denaturation. 
Considering that stapled peptides are known for their resilience to proteolytic 
digestion, it was therefore interesting to examine their resistance to 
denaturation.  
 The unlabelled BID BH3 peptides were heated in the circular dichroism 
chamber and scanned in steps of 1 °C and their profiles examined. Initially, it 
was possible to compare the mean residue ellipticities (MRE) of the stapled 
peptides against the unfolded wild type at high temperature to evaluate the 
extent the constraint resists unfolding.  
Thermal unfolding of the BID BH3 peptides showed a minimal change in 
the mean residue ellipticity at 222 nm for the unstapled, Aib and wild type 
peptides. This is not surprising, since their structures were predominantly 
random coil (Figure 3.32). Unfolding of the stapled peptides showed that there 
was a minor transition to a random coil character, based on the change of the 
signal at 222 nm, and the presence of an isodichroic point at 203 nm. A classic 
marker for complete unfolding of a peptide to a random coil conformation is 
the presence of a minimum at 195 nm, which does not appear in the spectra of 




Figure 3.32 – Thermal unfolding circular dichroism spectra for a) BID DM and b) BID 
MM. The changes in MRE values with increasing temperature of the remaining BID 
peptides are shown in c).  
The stapled peptides both appear to begin forming a plateau in their 
degradation signal after 65   C, where the MRE does not reach the unfolded MRE 
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of unstapled peptides. Therefore, the hydrocarbon staple prevents complete 
unfolding of the peptides to a random coil, where the helical character of the 
peptides is 43% and 37% for MM and DM respectively at the highest 
temperatures studied.  
 
Figure 3.33 – a) An example thermal unfolding curve where a protein unfolds 
cooperatively upon heating. Tm is the point where the sigmoid inflects, where the 
fraction unfolded equals 0.5. b) and c) are the unfolding curves of BID DM and BID MM 
respectively, which do not unfold cooperatively.  
 To characterise the unfolding thermodynamics of the stapled peptides 
the fraction unfolded of the peptide was plotted against increasing temperature 
(Figure 3.33). Cooperative unfolding events are characterised by a sigmoid 
curve for this plot, whereby the midpoint of the transition is assigned as a 
melting temperature (Tm). Furthermore, at Tm, the free energy of folding is 0, 
which can allow the determination of thermodynamic properties of unfolding 
through Gibbs-Helmholtz and van't Hoff analyses.167, 192 The indication of a 
cooperative unfolding event is the presence of pre- and post-transition 
baselines (the asymptotes in Figure 3.33a).  
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In contrast, the profile of the plots in Figure 3.33b and Figure 3.33c 
begin linearly before starting to plateau after 65 °C. The gradual decrease of the 
amplitude of the trough at 222 nm as temperature increases, suggests that the 
peptide is unfolding through a non cooperative pathway. Significantly, whilst 
both of the stapled peptides retained a moderate level of helicity at higher 
temperatures, re-scanning the peptides at 20 °C after the temperature ramp 
gave the same MRE value to that at the start of the experiment. The unfolding 
event of the stapled peptides was therefore a reversible process and the 
refolding of the peptide into an α-helical enriched conformation was 
thermodynamically favourable.  
In the context of proteins, the stability of the native folded conformation 
is balanced between chain entropy penalties and stabilisation from non-
covalent contacts.193, 194 However, the overall stability of a folded (globular) 
protein is marginal, where usually ΔG is in the region of 10 kcal mol-1 (to 
compare, hydrogen bonds contribute around 2 kcal mol-1 to enthalpy).102 As 
temperature increases, the chain conformational entropy component increases, 
which leads to protein unfolding. With the stapled BID peptides, it appeared 
that the hydrocarbon staple maintained helical character by restricting 
conformational flexibility and preventing the scission of some intramolecular 
hydrogen bonds. The unfolding mechanism can therefore be envisaged as the 
termini of the peptide adopting a more random conformation ('fraying'), with 
the core of the peptide maintaining a rigid, helical conformation.  
      
3.13 Thermodynamic Contributions of Binding of BID 
BH3 Peptides to Bcl-xL and Mcl-1 
Given that there is a high α-helical character of hydrocarbon stapled BID 
peptides, it is expected that the entropic penalty of preorganisation is removed 
from the binding interaction thus improving affinity. Since this is not the case in 
our studies, understanding the interplay of enthalpy and entropy in the binding 
interaction would be of use for rationalising the improvement or reduction of 
binding affinity for hydrocarbon stapled peptides.  
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3.13.1 Isothermal Titration Calorimetry 
Isothermal titration calorimetry (ITC) is a method of studying 
biomolecular interactions, which involves the measurement of minute heat 
changes in a cell as one species is titrated into another.195 As thermal change 
occurs, the amount of power used to restore cell temperature is measured and  
is represented in the form of a peak, which reflects the enthalpy change. Over 
several injections of ligand to macromolecule, the heat change upon binding 
diminishes as the binding sites of the macromolecule become saturated. This in 
turn allows the calculation of a Kd, and ΔH, which in turn can be used to 
determine the thermodynamic contributions of binding events. A particular 
benefit of ITC is that labels are not required, and since experiments are often 
two-component systems, complicated equilibria observed in fluorescence 
anisotropy can be avoided.  
3.13.2 Isothermal Titration Calorimetry of BID peptides 
The ITC experiments were established by using the BID WT peptide and 
two of the anti-apoptotic members of the Bcl-2 family; Mcl-1 and Bcl-xL as used 
in previous fluorescence anisotropy assays. For Mcl-1, 385 µM of wild type BID 
was injected into 21.2 µM of Mcl-1, with care taken with the matching of 
buffers, considering that DMSO was required to solubilise the peptide. BID WT 
(385 µM) was also injected into Bcl-xL (25.1 µM). 
Protein N Kd (μM) ΔH (cal mol-1) ΔS (cal K-1 mol-1) 
Bcl-xL 0.910 ± 0.03 0.48 ± 0.01 -6041 ± 293 8.66 
Mcl-1 1.68 ± 0.04 0.97 ± 0.03 -6586 ± 247 5.42 
Table 3.4 - ITC data for the wild type BID peptides and anti-apoptotic members of the 
Bcl-2 family (Bcl-xL and Mcl-1).  
Pleasingly, clear isotherms were obtained for both of the interactions 
(Figure 3.34). Whilst the stoichiometry of the Mcl-1 data is wayward for a 1:1 
binding model, there are consistencies in the Kd values obtained for the Bcl-xL 
and Mcl-1 proteins, since it is reported that BID has a similar potency for both 
proteins, but the twofold improvement of the binding affinity of Bcl-xL over 
Mcl-1 mirrors that of the fluorescence anistropy data. Indeed, isothermal 
titration calorimetry of a truncated BID peptide with this Mcl-1 construct 
afforded a Kd value of 0.83 µM.190 Interestingly, the thermodynamics of the 
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binding are favourable in both enthalpy and entropy, with a larger entropic 
contribution in the binding of the BID peptide to Bcl-xL.  
 
Figure 3.34 – ITC thermograms of the wild type BID peptide against; a) Bcl-xL and b) 
Mcl-1.  
With these results in hand, ITC was performed with the BID DM and BID 
MM stapled peptides, with the objective of extracting thermodynamic data of 
the binding events. Unfortunately, no binding isotherm was detected with 
either of the stapled peptides (Appendix III), with precipitation observed in the 
barrel of the ITC syringe after the ITC run. Switching to tris buffer - which 
provided some successes in the fluorescence anisotropy assays - did not 
prevent the precipitation of the peptide in either case. Finally, the order of the 
reagents was reversed, with the smaller concentration of the stapled peptide in 
the cell and the proteins loaded into the syringe. In spite of this, no binding was 
observed, and reluctantly further ITC experiments were abandoned due to the 
uneconomical quantities of reagents that were required for each experiment. 
3.13.3 van’t Hoff Analyses of the FITC BID Peptides 
Considering that isothermal titration calorimetry was unsuccessful for 
some of the BID peptides, the thermodynamics of the binding interaction of the 
FITC labelled peptides were extracted using van't Hoff analysis of fluorescence 
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anisotropy binding assays. The van’t Hoff isotherm combines the equilibrium 
constant with thermodynamic parameters with varying temperature. 
Therefore, ΔH can be calculated from the gradient of the linear fit and ΔS can be 
calculated from the intercept of the line with the y-axis.   
     






As previously shown, the Kd calculation of the labelled peptides was not 
trivial and the fitting of the curves deviated substantially as the temperature 
was elevated. As such, the EC50 of the binding of the FITC-labelled peptides was 
considered to provide an indication of the thermodynamics of the binding 
interactions based on the trends of the change of EC50, for which some limited 
precedent does exist.196  
 
Figure 3.35 – van’t Hoff plots of the FITC labelled peptides against Mcl-1: BID WT* 
(black), BID Aib* (purple), BID DM* (red), BID MM* (blue).   
With Mcl-1, it appears that the entropic contributions to the binding are 
similar across the peptide series, but the intercept of MM* is exaggerated by its 
first data point. MM*, DM* both appear to have a favourable enthalpic 
contributions to binding, whilst Aib* appears to have a negligible enthalpic 
contribution. The surprising result is WT*, which has favourable entropy but 
appears to have the opposite trend of enthalpy compared to isothermal 
titration calorimetry. However, ITC used an unlabelled variant of the peptide 




Figure 3.36 – van’t Hoff analysis of the FITC BID peptides with Bcl-xL: BID WT* (black), 
BID Aib* (purple), BID DM* (red), BID MM* (blue).  
Against Bcl-xL (Figure 3.36), entropic contributions to binding were 
similar across the peptide series, but MM* appeared to have the most 
favourable entropic component. The surprising trend observed is the apparent 
disfavoured enthalpic contribution for DM*, whilst WT* and MM* retain their 
favourable binding enthalpies.  
The major caveat in these van't Hoff studies is the use of EC50 to indicate 
binding thermodynamics, rather than Kd.IV Since fitting the van't Hoff data 
requires a Kd fitting model that considers non-specific contributions to binding, 
it is possible that the thermodynamic trends observed may change.     
3.14 Preliminary in cellulo studies 
The in vitro binding studies of the BID BH3 stapled peptides suggested 
that the hydrocarbon staple has no improvement of the potency of the peptide 
as an inhibitor of two protein-protein interactions. Hydrocarbon stapled 
peptides have also been hypothesised to improve cell penetration properties 
from an increased hydrophobic character introduced by the  crosslink.2, 3 With 
Dr. J Levesley and Dr. L. Steele (Leeds Institute for Molecular Medicine), the BID 
BH3 peptides were tested in cellulo for their ability to penetrate cells, using the 
                                                        
IV A caveat with van't Hoff analysis is also the assumption that ΔH is constant 
over the temperature range that is studied. 
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FITC labelled BID peptides (Figure 3.20), and their ability to promote apoptosis 
using the unlabelled BID BH3 peptides. 
3.14.1 Cellular permeability studies 
SF188 paediatric glioblastoma cells were treated with FITC-labelled BID 
BH3 peptides, whose cell-penetrating properties were examined through FACS 
analysis, which measures fluorescence intensity of cells by flow cytometry. A 
fluorescently labelled peptide that is more cell penetrative therefore emits a 
more intense signal as the cells are passed through the detector. One caveat to 
FACS analysis is that the fluorescently labelled peptide could be bound to the 
cell membrane without penetrating it - localisation is therefore confirmed by 
confocal microscopy.    
 
Figure 3.37 – FACS analysis of FITC labelled BID Peptides; BID WT* (Black), BID Aib* 
(Green); BID MM* (blue) and BID DM* (purple) after 24 h incubation in serum free 
media. 'Events' on the y-axis refers to the number of fluorescent cells that are counted 
(Acquired by J. Levesley and L. Steele).   
When the fluorescently labelled BID peptides were treated with the cells 
in serum-free media, which was initially shown to improve the intensity of  
cellular fluorescence, the stapled BID peptides (DM* and MM*) both had 
greater fluorescence intensity compared to the Aib* and WT* peptides at 
concentrations of 10 µM. Whilst all of the peptides had an increased intensity 
compared to a DMSO control, it was very pleasing that both of the stapled 
peptides appeared to be more penetrative and that the MM* appeared to be as 
effective as the DM* stapled peptide. The next requirement is confocal 
microscopy, which would confirm that the stapled peptides are localising 
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within the cell. Nevertheless, the preliminary in cellulo results are very 
promising.  
3.14.2 Apoptosis studies 
The second in cellulo study was to examine the ability of the unlabelled 
BID peptides to induce apoptosis in SF188 pediatric glioblastoma cells, by the 
use of an MTT assay which quantifies cell death. In the case of a successful 
apoptosis initiator, the cell membrane begins to permeabilise and allows the 
uptake and enzymatic processing of MTT, which is measured using a 
spectrometer.  
 
Figure 3.38 – Apoptosis studies of 20 μM quantities of unlabelled BID BH3 peptides 
and ABT-263 after 72 h incubation in serum free media (acquired by J. Levesley and L. 
Steele).   
Disappointingly, the unlabelled BID peptides did not appear to promote 
any significant apoptosis of the cells up to a concentration of 20 µM in serum-
free conditions after 72 hours. To verify the sensitivity of the cell line to known 
inhibitors, ABT-263 (Navitoclax) was employed as a positive control as it is a 
known inhibitor of Bcl-2 and Bcl-xL.197-199 ABT-263 was capable of inducing 
apoptosis after 24 hours at concentrations of 20 µM, unlike all of the BID 
peptides which were unable to induce apoptosis at the same concentration.  
The in cellulo studies have provided an interesting insight into to 
biological capabilities of the stapled BID BH3 peptides. Whilst it was pleasing 
that stapling the peptides appears to improve penetration, it was surprising 




































line. Future studies could use the Jurkat T-Cell Leukaemia cell lines that have 
been previously used for BID DM.3     
3.15 Discussions and Conclusions 
The investigation into peptides functionalised with monosubstituted 
hydrocarbon staples revealed that, for the BID BH3 series, α-helical character 
was promoted and proved through crystallographic studies. In addition to this, 
monosubstituted stapled peptides demonstrated cell penetration properties 
similar to disubstituted stapled peptides, even if apoptosis was not induced by 
any of the BID BH3 peptides in SF188 cell lines.   
In the BID BH3 series, direct binding studies to Bcl-xL and Mcl-1 
demonstrated a moderate decrease in binding affinity for the stapled BID 
peptides compared to unmodified BID peptides. However, there appears to be 
no selectivity of stapled BID BH3 peptides for Bcl-xL over Mcl-1, given that the 
EC50 values for BID DM and BID MM are in the same region for both proteins.  
An attempt to understand the thermodynamics of the binding 
interaction of BID BH3 with Bcl-xL and Mcl-1 was undermined by practical 
complications with ITC and complex binding in fluorescence anisotropy. In 
spite of this, some preliminary conclusions can be made from van't Hoff 
analysis. BID MM* binds to Mcl-1 and Bcl-xL with favourable enthalpy, but BID 
DM* does not have a favourable enthalpic contribution for Mcl-1; entropy 
appears to be a larger driving force to binding.  
Given that stapling BID BH3 modulated potency and not selectivity 
across family members, transferring stapling methodology to another BH3 
ligand (BIM BH3) assessed how transferrable stapling is across a ligand series 
with sequence degeneracy. Inhibition assays with BIM BH3 demonstrated that 
stapled BIM peptides are dramatically weaker ligands compared to BIM WT 
and BID BH3.  
Based on this investigation, we can conclude that the original dogma of 
stapled peptides needs to be rigorously challenged. Whilst hydrocarbon 
constraints improve helical character when positioned correctly, this does not 
necessarily lead to an improved binding affinity. Clearly, there are 
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thermodynamic factors involved in the binding interaction as well as the 
entropic penalty of organising a ligand into an active conformation. For 
instance, the enthalpic benefit of forming a hydrogen bonded network as the 
peptide folds to an α-helix is overlooked in the original methodology.2 Also,  
non-covalent interactions within the peptide ligand and between the ligand and 
protein have only been considered in the instances where potency has fallen 
after hydrocarbon stapling.131  
We have found that hydrocarbon stapling cannot be used as a generic 
therapeutic strategy for a family of redundant proteins. Firstly, for the 
interactions we studied, whilst the proteolytic resistance and cell penetration 
properties were improved with hydrocarbon stapling, binding affinity and 
selectivity was not. Secondly, using the same staple position in a related ligand 
diminished binding affinity, so hydrocarbon stapling must be optimised for 
each ligand and thus for each target.  
To build on this work, an orthogonal binding assay would be necessary 
to quantify Kd of the BIM and BID BH3 series. Surface Plasmon Resonance 
spectroscopy (SPR) provides the kinetic parameters of the binding interaction, 
and has been previously used in hydrocarbon stapling to justify Kd observed for 
BIM BH3.131 Also, further structural studies of BIM BH3 and BID BH3 with Bcl-
xL and Mcl-1 would be indispensable to our understanding of the binding mode 
of the stapled peptides to further quantify our observed binding affinities. 
Detailed in cellulo experiments, particularly confocal microscopy would also be 
useful to determine whether the more penetrative stapled peptides localise to 




Chapter 3c - Investigation of a new 




Hydrocarbon stapling methodology furnishes a permanent covalent 
crosslink into a peptide with the aim of improving its biophysical properties.  
Reversible constraining methods, through non-covalent crosslinking, which 
stabilise a peptide through unnatural host-guest moieties,200 coordinative201, 202 
or π-π stacking203 of side chains has also been effective in reinforcing helical 
structure of polypeptides. However, non-covalent constraints generally require 
carefully balanced (or metal enriched) conditions that are not applicable to 
living systems.  
Reversible covalent crosslinking has already been described, through 
the stabilisation of peptides with intramolecular cystine dimers (1.2.2). We 
sought a reversible method of constraining peptides that was analogous to the 
research performed with the hydrocarbon staples (3.5).  
3.16 Synthesis of hCys- and Maleimide- constrained BID 
Baker and coworkers have described an effective protocol for the 
introduction of a maleimide linker into a peptide that contains native cysteine 
residues. The maleimide unit can then be functionalised to provide a handle for 
drug delivery, either through intramolecular cysteine residues (Figure 3.39)204 
or through intermolecular linkages of two peptides. 205  
 
Figure 3.39 - Maleimide bridging methodology used by Baker and coworkers for the in 
situ modification of the maleimide nitrogen of an intramolecular crosslink.204  
The maleimide-bridged peptide has been overlooked as a potential 
candidate for covalently constrained peptides and was worthy of further 
investigation alongside the hydrocarbon stapled BID BH3 peptide.  Installing 
homo-cysteine (cysteine with an additional methylene unit in the side chain) in 
the same positions as the olefinic amino acids previously studied, followed by 
bridging with 2,3-dibromomaleimide would afford an 8-atom crosslink that is 
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regioisomeric with the hydrocarbon stapled peptide. In addition to this, homo 
cysteine (hCys) analogues of the BID BH3 peptide provide access to 
investigations into the oxidised and reduced forms of hCys BID, to determine if 
conformation and binding affinities are changed under reversible oxidation 
conditions.  
 
Figure 3.40 - Peptide sequences of the homo cysteine (hCys) variants of the BID BH3 
peptide. 
  The synthesis of BID hCys was performed according to the same 
methods previously described, on a 0.1 mmol scale. After the cleavage and 
deprotection of the peptide, it was found that significant 91A and 95D deletion 
sequences were present. These deletions had come from the inefficiency of the 
Fmoc deprotection of the hCys residue prior to coupling, rather than the 
inefficiency of the coupling of 91A or 95D. In addition to this, fragmentations 
occurred during cleavage and deprotection to afford several other peptides that 
were not identified. Nevertheless, after rounds of purification, 6 mg (5 %) of 
hCys peptide was afforded.  
To perform the maleimide bridging, the hCys peptide was dissolved in 
40% acetonitrile:phosphate buffer and 5 equivalents of TCEP and 2,3-
dibromomaleimide was added. Pleasingly, the bridging reaction was complete 
after 4 hours with no evidence of intermolecularly bridged peptides observed, 
but attempts to purify the bridged peptide were unsuccessful.  
To circumvent the problem of two successive purifications, the 
maleimide-bridging reaction was performed using the crude BID hCys peptide 
after cleavage from resin. After 6 hours, the bridging was complete, but 
reduction of the maleimide to succinimide was observed and confirmed by 
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HRMS. Purification of the succinimide bridged BID hCys SUC peptide afforded 
4.1 mg (11% yield) of material.  
3.17 Biophysical analyses of hCys BID peptide series  
3.17.1 Circular Dichroism 
Ahead of circular dichroism, BID hCys OX was fully reduced to BID hCys 
RED by the addition of 5 equivalents of dithiothreitol (DTT) instead of TCEP, 
which absorbs strongly below 230 nm. 5 equivalents of diamide 
(1,1′-azobis(N,N-dimethylformamide) were employed to accelerate the slow 
oxidative conversion of BID hCys RED to BID hCys OX.  
 
Peptide % Helicity 
BID hCys OX 39 
BID hCys RED 33 
BID hCys SUC 45 
Figure 3.41 – CD spectra of BID hCys OX (blue), RED (red) and SUC (purple). 
Pleasingly, there were marginal increases in  helicity of the peptide after 
constraint with a disulfide and succinimide linker. In addition to this, the curve 
profile changes between RED, OX and SUC, where the minimum at 203 nm of 
RED moves to 208 nm for SUC. Crosslinking with cysteine and succinimide 
methodology appears to promote moderate helicity, compared to the high 
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helical content observed with the hydrocarbon stapled peptides (BID 
DM = 81%).  
3.17.2 Fluorescence Anisotropy Competition Assays 
In fluorescence anisotropy control experiments, diamide interfered with 
the assay, so BID hCys OX was afforded by air oxidation and confirmed by 
HRMS before starting the assays. TCEP did not interfere with the assay, so it 
was employed in the assay buffer to ensure that there was no oxidation of the 
peptide during incubation.   
 
Peptide IC50 Bcl-xL IC50 Mcl-1 
BID hCys OX 1.30 ± 0.07 µM 232 ± 17 nM 
BID hCys RED 5.42 ± 1.1 µM 268 ± 14 nM 
BID hCys SUC 0.34 ± 0.01 µM 186 ± 40 nM 
Figure 3.42 – Fluorescence anisotropy competition assays of a) Bcl-xL/BAK* and b) 
Mcl-1/NoxaB* with BID hCys OX (blue), BID hCys RED (red) and BID hCys BR (purple) 
employed as inhibitors. 
The competition assays yielded some interesting results for the hCys 
series of peptides. Against Bcl-xL/BAK*, there is a notable increase in potency 
for the bridged peptides over the reduced peptides – especially for the 
covalently bridged BID hCys SUC peptide. In contrast, against Mcl-1/NoxaB*, 
there is only a marginal difference in potencies across the series. In comparison 
to the hydrocarbon stapled BID BH3 peptides, constrained peptides have a 
slight improvement of potency over the wild type and unstapled peptides, but 
the order of magnitude difference between hCys SUC and hCys RED is the 




3.17.3 Preliminary BID hCys conclusions 
The inhibition results of the hCys BID peptides were particularly 
interesting, where covalently constrained BID hCys SUC outperformed 
reversibly constrained BID hCys OX and unconstrained BID hCys RED with the 
inhibition of Bcl-xL/BAK*. SUC and OX also possessed IC50 values that 
outperformed BID WT, in a similar result to the BID hydrocarbon stapled 
peptide series (3.6.3). It would appear that incorporating hCys into BID proved 
unfavourable for the inhibition of Bcl-xL/BAK*, but this was mitigated by 
constraint. Improvement of binding affinity through the SUC constraint was not 
transferred to the inhibition of Mcl-1/NoxaB*, echoing previous results with 
hydrocarbon stapling of BID.  
Whilst the reduction of BID hCys MAL to BID hCys SUC was unexpected, 
the results have been particularly fascinating and future investigation is 
worthwhile. Future expansion in this field shall focus on why the reduction 





Conclusions and Future Goals 
The original goals of the project had been changed as the project evolved 
through some of the difficulties encountered with the chemical synthesis of 
unnatural amino acids. Having found the synthesis of disubstituted olefinic 
amino acids for hydrocarbon stapling challenging, changing to a synthetic route 
for an overlooked monosubstituted amino acid opened a new avenue of 
research to expand the repertoire of secondary structure mimetics within the 
Wilson laboratory.  
Indeed, the overlooked monosubstituted unnatural amino acid was 
shown to be as effective as a surrogate for hydrocarbon stapling as 
disubstituted unnatural amino acids against two therapeutically relevant 
protein-protein interactions. The decreased potency of our hydrocarbon 
stapled peptides therefore triggered an investigation into why binding affinity 
was not improved after constraining the peptide into a biologically active 
helical conformation. The culmination of this investigation led to the 
quantification of the structure of hydrocarbon stapled peptides through solid 
and solution state techniques, but also provided insights into the selectivity of 
hydrocarbon stapled ligands within a degenerate family of proteins.  
Our findings into selectivity revealed that one stapled ligand (BID BH3) 
was unselective for Mcl-1 over Bcl-xL, but transferring the stapling 
methodology to a similar ligand, BIM BH3 resulted in a dramatic fall in potency. 
The main result here is that hydrocarbon stapling cannot be used as a generic 
therapeutic approach for reactivating apoptosis pathways in cells, since the 
appropriate hydrocarbon-stapled ligand requires specific design for one 
particular interaction.  
The hypothesis that hydrocarbon-stapled peptides are more potent 
ligands as a result of their increased α-helical character and reduced 
conformational flexibility has been challenged. Our thermodynamic studies 
suggest that there must be other thermodynamic penalties with binding to 




Future work with the stapled peptides would include orthogonal 
binding assays to reinforce Kd obtained from fluorescence anisotropy, 
particularly through the investigation of the kinetic parameters of binding 
(analogous to the on/off rate experiments performed by Czabotar and 
coworkers).131  
The stapled peptides investigation can be applied to future protein 
prosthesis studies, by replacing a helical section of a protein with a stapled 
peptidomimetic. Whilst the total synthesis of Im7 was not completed due to 
time constraints, the methodology has been established for future completion.   
Based on the deviation of the original project goals, the project has 
demonstrated that research evolves equally from design and serendipity. The 
research into the stapled peptides in particular, could have implications for the 
entire field of constrained peptides. As momentum has gathered with stapled 
peptides entering clinical trials, gathering an understanding into why the 
hydrocarbon stapling methodology is effective is a vital stage to the future 




Chapter 4  
Experimental 
4.1 Small Molecule Synthesis 
4.1.1 General Considerations 
Non-aqueous reactions were carried out in washed and oven-dried 
glassware. Solvents and reagents were used as received from major suppliers 
without prior purification unless stated. Anhydrous tetrahydrofuran, 
acetonitrile, dichloromethane and diethyl ether were obtained from the in-
house solvent purification system from Innovative Technology Inc. PureSolv®. 
Anhydrous dimethyl formamide, methanol and chloroform were obtained from 
major chemical suppliers equipped with a SureSeal™ (or equivalent). For 
reactions under non-anhydrous conditions, the solvents used were of HPLC 
quality and provided by Fisher or Sigma-Aldrich. Water in aqueous solutions 
and used for quenching was deionised, and water used for buffers and HPLC 
was ultra-pure 18 MΩ from an ELGA Purelab system. Mixtures of solvents are 
quoted as ratios and correspond to a volume:volume ratio. Drying of organic 
extracts was performed using sodium sulfate.  
Thin layer chromatography was performed on Merck Kieselgel 60 F254 
0.25 mm precoated aluminium plates. Product spots were visualised under UV 
light (λmax = 254 nm) and/or by staining with basic potassium permanganate. If 
any other TLC dip was used, it is stated under the specific experimental 
procedure of a molecule. Flash chromatography was performed using silica gel 
60 (0.043 – 0.063 mm VWR) using pressure by means of head bellows.  
1H NMR spectra were recorded on Bruker DPX 300 (300 MHz) or 
Avance 500 (500 MHz) spectrometers and referenced to either residual non-
deuterated solvent peaks or tetramethylsilane. 13C spectra were recorded on a 
Bruker Avance 500 (126 MHz) and referenced to the solvent peak. 1H spectra 
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are reported as follows: δH (spectrometer frequency, solvent): ppm to two 
decimal places (number of protons, multiplicity, J coupling constant in hertz, 
assignment). Chemical shifts are quoted in ppm with signal splitting recorded as 
singlet (s), doublet (d), triplet (t), quartet (q), quintet (quin.) multiplet (m), 
broad (br) and apparent (app.). Coupling constants, J, are measured to the 
nearest 0.1 Hz. Similarly, 13C spectra are reported as follows: δC (spectrometer 
frequency, solvent): ppm to one decimal place (assignment). Assignments of 
spectra were assisted by the results of DEPT, COSY, HMQC and HMBC 
experiments.  
Infrared spectra were recorded on a Perkin Elmer Fourier-Transfer 
spectrometer. Spectra were analysed neat and only structurally important 
absorptions are quoted. Absorption maxima (νmax) are quoted in wavenumbers 
(cm -1). 
HPLC/MS were recorded on a Bruker HCT ultra under the conditions of 
electrospray ionisation (ESI). HPLC separation was performed on an Agilent 
1200 series instrument equipped with a Phenomenex C18 column (50 × 2 mm) 
using acetonitrile:water as the eluent for positive ion spectra. Values are 
reported as a ratio of mass to charge. Nominal mass spectra and accurate (4 
d.p.) mass spectra were recorded on a Bruker Daltonics micrOTOF Premier 
Mass Spectrometer, or using a Bruker MaXisImpact Spectrometer under 
positive ESI conditions unless otherwise stated. 
Optical rotations were recorded on an Optical Activity AA-10 
polarimeter using the sodium D line (589 nm). [α]DT are reported in units of 
10-1 deg dm2 g-1.  
Melting points were determined on an Electrothermal digital melting 
point apparatus and are uncorrected. Microanalysis was performed by the 
School of Chemistry service, utilising a Carlo Erba 1108 Elemental Analyser. 
4.1.2 Procedures and data for monosubstituted 
unnatural amino acid synthesis 




(S)-Proline 41 (20.0 g, 174 mmol) and potassium hydroxide (19.5 g, 348 
mmol) were dissolved in 2-propanol (150 mL) and heated to 40 °C. Benzyl 
chloride (21 mL, 183 mmol) was added dropwise over 2 h at 40 °C. After 6 h, 
the suspension was diluted with aqueous hydrochloric acid (1M) to attain a pH 
of 5 (pH paper) and extracted with chloroform (3 × 200 mL). The aqueous 
suspension was filtered, washed with acetone (200 mL) and the combined 
organic fractions concentrated in vacuo. The colourless precipitate was found 
to be (S)-N-benzyl proline 43 (19.9 g, 97.5 mmol, 55%) that was used without 
further purification. The concentrated organic layers afforded (S)-N-benzyl 
proline benzyl ester 42 as a thin orange oil.V (S)-N-benzyl proline 43 m.p. 165-
166 °C (Lit: 167 °C)158; δH (500 MHz, DMSO-d6) 1.74-1.83 (1H, m, Pro-γH), 1.89-
1.97 (2H, m, Pro-βH and Pro-γ’H), 2.24-2.32 (1H, m, Pro-β’H), 2.96-3.03 (1H, m, 
Pro-δH), 3.25-3.31 (1H, m, Pro-δ’H), 3.90 (1H, dd, J = 9.6, J = 6.8, Pro-αH), 4.10 
(1H, d, J = 12.8, NCHHPh), 4.32 (1H, d, J = 12.8, NCHHPh), 7.36-7.42 (3H, m, 
ArCH), 7.45-7.49 (2H, m, ArCH); δC (125 MHz) 22.3, 28.2, 53.6, 57.3, 65.7, 128.6, 
128.8, 130.2, 132.9, 170.8; ESI-HRMS found m/z 228.0991 [M+Na]+, 
C12H15NO2Na requires 228.0994; [α]D25 (DMSO, c = 0.5) −28.1 (Lit: −28.4; 
MeOH, c = 1).158   
Hydrogenolysis of (S)-N-benzyl proline benzyl ester 42 
 
The (S)-N-benzyl proline benzyl ester 42 mixture (35.0 g, 118 mmol) 
was dissolved in degassed ethanol (250 mL) and 15% Palladium on Barium 
Sulfate (150 mg) was added. The reaction was left under positive pressure of 
hydrogen for 24 h, filtered through Celite® and washed with ethanol (400 mL). 
The ethanol was concentrated in vacuo and the residue of 43 washed with 
                                                        
V This also contained quaternary benzyl ammonium proline that was carried 
through to the hydrogenolysis step  
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acetone, dried in vacuo and used without further purification (16.0 g, 78.4 
mmol, 60%).  
(S)-2-[N-(N'-benzylprolyl)amino]-benzophenone 44 
 
(S)-N-benzyl Proline 43 (5.0 g, 24.5 mmol) was dissolved in 
dichloromethane (50 mL) under a nitrogen atmosphere. N-methyl imidazole 
(4.27 mL, 53.9 mmol) was then added dropwise, followed by the cooling of the 
reaction mixture to 0 °C and the addition of mesyl chloride (1.92 mL, 24.5 
mmol) over 2 h. The mixture was warmed to rt, and 2-aminobenzophenone 49 
(4.35 g, 22.1 mmol) dissolved in dichloromethane (40 mL) was added dropwise 
and the reaction heated to 40 °C for a further 12 h. The reaction was quenched 
with saturated ammonium chloride (200 mL) and extracted with 
dichloromethane (3 × 200 mL). The combined organic layers were 
concentrated in vacuo to afford (S)-2-[N-(N'-benzylprolyl)amino]-
benzophenone 44 as an amorphous, colourless solid (7.29g, 18.9 mmol, 86%). 
Rf = 0.8 (Chloroform:Acetone 5:1); δH (500 MHz, CDCl3): 1.77-1.89 (2H, m, Pro-
γH and γ’H), 1.96-2.04 (1H, m, Pro-βH), 2.24-2.34 (1H, m, Pro-β’H), 2.44 (1H, td, 
J = 9.6, 6.9, Pro-δH), 3.22-3.27 (1H, m, Pro-δ’H), 3.35 (1H, dd, J = 10.1, J = 5.0, 
Pro-αH), 3.63 (1H, d, J = 12.8, NCHHPh), 3.95 (1H, d, J = 12.8, NCHHPh), 7.12 
(1H, t, J = 8.0, ArH-6), 7.15-7.20 (3H, m, ArH-7, ArH-2, ArH-2’), 7.39-7.43 (2H, m, 
ArH-1, ArH-1’), 7.50-7.59 (4H, m, ArH-1, ArH-5, ArH-9, ArH-9’), 7.64 (1H, t, J = 
7.3, ArH-10), 7.81 (2H, d, J = 6.8, ArH-8, ArH-8’), 8.61, (1H, d, J = 8.2, ArH-4), 
11.5 (1H, br s, NH); δC (125 MHz, CDCl3): 24.2, 31.0, 53.9, 59.9, 68.3, 121.5, 
122.2, 125.3, 127.1, 128.2, 128.3, 129.1, 130.1, 132.5, 132.6, 133.4, 138.2, 138.6, 
139.2, 174.7, 197.9; ESI-HRMS found m/z 407.1729 [M+Na]+ C24H25N2O2Na 
requires 407.1729; [α]D25 (CHCl3 c = 0.5) −130.5 (Lit: −132.2, MeOH, c = 1).158        




(S)-2-[N-(N'-benzylprolyl)amino]-benzophenone 44 (1000 mg, 2.61 
mmol), Nickel (II) nitrate hexahydrate (908 mg, 3.13 mmol) and glycine (390 
mg, 5.22 mmol) were dissolved in anhydrous methanol (8 mL) and heated to 55 
°C. 25% w/v sodium methoxide in methanol (6.26 mL, 22.9 mmol) was added 
and the reaction diluted to 30 mL by the addition of anhydrous methanol. After 
1h, the solution was cooled to rt and acetic acid (1.7 mL, 29.6 mmol) was added, 
followed by dilution with water (100 mL). The solution was extracted with 
chloroform (3 × 50 mL), dried and concentrated in vacuo. Purification by silica 
gel chromatography (Chloroform:Acetone 5:1) afforded Gly-Ni-BPB 45 as a 
scarlet, glassy solid (1.25 g, 2.51 mmol, 96%): m.p. 211-213 °C (Lit: 208-209 
°C)158; Rf = 0.2 (Chloroform:Acetone 5:1); δH (500 MHz, CDCl3): 2.02-2.10 (1H, 
m, Pro-γH), 2.12-2.18 (1H, m, Pro-δH), 2.36-2.47 (1H, m, Pro-βH), 2.53-2.63 
(1H, m, Pro-βH), 3.29-3.39 (1H, m, Pro-δH), 3.46 (1H, dd, J = 10.7, J = 5.6, Pro-
αH), 3.64-3.74 (4H, m, Pro-γH, Gly-αH, NCHHPh, 4.48 (1H, d, J = 12.7, NCHHPh), 
6.70 (1H, t, J = 7.2, ArH-6), 6.79 (1H, dd, J = 7.9, J = 1.6, ArH-7), 6.96-7.00 (1H, m, 
ArH-8), 7.10 (1H, d, J = 7.2, ArH-12), 7.20 (1H, td, J = 8.7, J = 1.6, ArH-5), 7.30 
(1H, t, J = 7.2, ArH-1), 7.42 (2H, t, J = 7.6, ArH-2, ArH-2'), 7.48-7.56 (4H, m, ArH-
9, ArH-10, ArH-11), 8.07 (2H, d, J = 7.6, ArH-3, ArH-3'), 8.29 (1H, d, J = 8.3, ArH-
4). ESI-HRMS found m/z 520.1159 [M+Na]+, C27H25N3NiO3 requires 520.1142. 
(S)-Pent-4-enyl-gly-Ni-BPB 46 
 
Under an atmosphere of N2, Gly-Ni-BPB 45 (500 mg, 1 mmol) and 
1-bromopent-4-ene (151 mg, 0.77 mmol) was suspended in acetonitrile (15 
mL) and powdered sodium hydroxide (168 mg, 4.19 mmol) at  –22 °C 
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(Methanol–Ice). The reaction was gradually raised to rt and stirred for 20 h, 
before the addition of water (30 mL) and acetic acid (1 mL), and the solution 
extracted with chloroform (3 × 30 mL). The combined organic fractions were 
concentrated in vacuo and purified by silica gel chromatography 
(chloroform:acetone 8:1) to afford (S)-pent-4-enyl-gly-Ni-BPB 46 (392 mg, 
0.69 mmol, 69%) as a glassy, scarlet solid. Rf = 0.3 (chloroform:acetone 5:1); δH 
(500 MHz, CDCl3): 1.57-1.75 (2H, m, alkyl), 1.87-2.28 (6H, m, alkyl, Pro-γH), 
2.41-2.59 (1H, m, Pro-βH), 2.69-2.83 (1H, m, Pro-βH), 3.43-3.62 (4H, m, Pro-δH, 
NCHHPh, Gly-αH), 3.91 (1H, dd, J = 8.1, J = 3.3, Pro-αH), 4.44 (1H, d, J = 12.9, 
NCHHPh), 4.93-5.03 (2H, m, H2C=C), 5.64-5.79 (1H, m, H2C=CH), 6.61-6.69 (2H, 
m, ArH-8, ArH-12), 6.92 (1H, d, J = 8.1, ArH-7), 7.11-7.22 (3H, m, ArH-5, ArH-9, 
ArH-11), 7.35 (2H, t, J = 7.6, ArH-2, ArH-2'), 7.44-7.51 (3H, m, ArH-1, ArH-6, 
ArH-10  8.04 (2H, d, J = 7.2, ArH-3, ArH-3'), 8.12 (1H, d, J = 8.6, ArH-4). δC (126 
MHz, CDCl3): 23.6, 24.6, 30.8, 33.3, 34.8, 57.0, 63.1, 70.3, 70.4, 115.3, 120.8, 
123.7, 126.5, 127.2, 127.6, 128.9, 128.9, 129.7, 131.6, 132.1, 133.2, 133.8, 137.8, 
142.3, 142.3, 170.4, 179.4, 180.4; ESI-HRMS found m/z 566.1926 [M+H]+; 
C32H34O3N3Ni requires 566.1948; [α]D25 (CHCl3, c = 0.03) +2533 (Lit: CHCl3 c = 
0.033, +2560).4  
(S)-2-amino-hept-6-enoic acid  
 
(S)-pent-4-enyl-gly-Ni-BPB 47 (492 mg, 0.87 mmol) was dissolved in 
methanol (25 mL), which was added dropwise to a solution of aqueous 
hydrochloric acid (3 M, 7 mL) and heated to 50 °C until a colour change from 
scarlet to yellow/green was observed (after 15 min) when cooling to rt was 
followed by the evaporation of the solvent in vacuo. The resulting yellow/white 
residue was extracted with chloroform (3 x 25 mL) to remove the BPB ligand 
44 for re-use (44 was purified as described above). The aqueous fraction was 
loaded on a Dowex 50X2 100 H+ column (prewashed with H2O to pH 7), which 
was rinsed with methanol (50 mL) and water (50 mL) to remove residual 
nickel, amino acid 47 was then eluted with 20% ammonium hydroxide:ethanol 
1:1, where fractions containing 47 were identified by ninhydrin staining. 
Concentration of the fractions in vacuo afforded (S)-2-amino-hept-6-enoic acid 
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47 (118 mg, 95%) as a white, amorphous solid. m.p. 224-225 °C (Lit: 225 °C)4; 
δH (500 MHz, D2O): 1.31-1.43 (2H, m, H3), 1.71-1.83 (2H, m, H4), 1.97-2.05 (2H, 
m, H5), 3.64 (1H, t, J = 5.9, H2), 4.94 (1H, d, J = 10.3, H7 cis), 4.99 (1H, d, J = 17.5, 
H7 trans), 5.74-5.84 (1H, m, H6). δC (125 MHz, D2O): 23.5, 29.9, 32.5, 54.7, 
115.0, 138.6, 174.9. ESI-HRMS found 144.1044; C7H14NO2 [M-H]- requires 




(S)-2-amino-hept-6-eneoic acid 47 (186 mg, 1.30 mmol) and sodium 
carbonate (273 mg, 2.59 mmol) were dissolved in water (4 mL) and cooled to 
4 °C. 9-Fluorenylmethyl succinimidyl carbonate (657 mg, 1.95 mmol) was 
dissolved in 1,4 dioxane (8 mL) at 4 °C and added dropwise to the amino acid 
aqueous solution. After 1 h, the reaction was warmed to rt and allowed to 
continue for a further 14 h. The reaction suspension was diluted with water (15 
mL) and extracted with ethyl acetate (2 × 25 mL). The organic layers were 
back-extracted with saturated sodium hydrogen carbonate solution (20 mL), 
with the combined aqueous fractions acidified to pH 1 with 3M hydrochloric 
acid and extracted further with ethyl acetate (3 × 35 mL). The combined 
organic fractions were dried and concentrated in vacuo to afford a pale yellow 
oil. Purification by flash chromatography (Dichloromethane:toluene:methanol 
85:10:5) afforded (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)hept-6-
enoic acid 48 as a viscous, straw coloured oil (260 mg, 0.69 mmol,  53%). Rf = 
0.2 (Dichloromethane:methanol:acetic acid 95:4:1, visualised by ninhydrin 
(violet spot) and permanganate), δH (500 MHz, MeOD) 1.47 – 1.58 (2H, m, H3), 
1.67 – 1.76 (1H, m, H4), 1.84 – 1.92 (1H, m, H4), 2.09 – 2.15 (2H, m, H5), 4.17 
(1H, dd, J = 9.1, 4.8, H2), 4.26 (1H, t, J = 7.2, H10), 4.38 (2H, d, J = 7.2, H9), 4.99 
(1H, d, J = 9.9, H7 cis), 5.05 (1H, d, J = 17.1, H7 trans), 5.78 – 5.88 (1H, m, H6), 
7.33 (2H, t, J = 7.6, ArCH), 7.41 (2H, t, J = 7.6, ArCH), 7.65 – 7.72 (2H, m, ArCH), 
7.82 (2H, d, J = 7.6, ArCH); δC (125 MHz, MeOD): 26.3, 32.3, 34.3, 35.5, 48.3 
(identified by HMQC), 55.3, 68.0, 115.6, 121.0, 126.3, 128.2, 128.8, 139.4, 142.6, 
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145.1, 145.4, 158.7, 175.5; ESI-HRMS found 364.1590 [M-H]–; C22H22NO4 
requires 364.1554; [α]D22.4 (CHCl3, c = 1) +3.1. 
4.1.3 Procedures and Data for Disubstituted Unnatural 
Amino Acid Synthesis 
α-Benzoin oxime 31153, 163 
 
Benzoin 30 (20.0 g, 94.3 mmol) and sodium acetate (19.3 g, 235 mmol) 
were dissolved in ethanol (320 mL). Hydroxylamine hydrochloride (15.9 g, 230 
mmol) and water (60 mL) were added and the reaction heated to 75 °C to 
dissolve all of the solid. After 30 mins, the solution was cooled to rt and diluted 
with water (200 mL). The solution was extracted with dichloromethane 
(3 × 200 mL) and the combined organic layers washed with saturated sodium 
bicarbonate (2 × 150 mL) and water (200 mL). The organic solution was dried 
(Na2SO4) and concentrated in vacuo to afford α-benzoin oxime 31 as a 
colourless, sticky solid (21.9 g, 94.3 mmol, quant.): m.p. 151 – 152 °C (From 
H2O as pale yellow needles); (Lit 153 – 155 °C)153; δH (500 MHz, CDCl3): 3.85-
3.52 (1H, br s, OH), 5.59 (0.5H, s, E isomer), 6.24 (0.5H, s, Z isomer), 7.52-7.13 
(10 H, m, ArCH).  
2-amino-1,2-diphenylethanol 32153, 163 
 
Palladium on carbon (50 mg) was added to a solution of α-benzoin 
oxime 31 (1.00 g, 4.44 mmol) in degassed ethanol (30 mL) and concentrated 
hydrochloric acid (0.4 mL). The solution was stirred under a positive pressure 
of H2 for 7 h at rt. The suspension was filtered through Celite® and washed with 
methanol (100 mL). The solution was then concentrated in vacuo and the 
residue dissolved in dichloromethane (150 mL) and washed with saturated 
sodium bicarbonate (200 mL) to remove the hydrochloride salt. The organic 
layer was dried and then concentrated in vacuo to afford 2-amino-1,2-
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diphenylethanol 32 as a colourless, amorphous solid (900 mg, 4.26 mmol, 
96%). m.p. 145-146 °C (Recrystallised from H2O as colourless, stubby needles) 
(Lit: 142-145 °C)163; Found C 78.60%, H 7.10%, N 6.65%; C14H15NO requires C 
78.84%, H 7.09%, N 6.59%; δH (500 MHz, CDCl3): 2.40 – 1.60 (3H, br s, NH2 & 
OH), 4.17 (1H, d, J = 5.9, CHNH2), 4.75 (1H, d, J = 5.9, CHOH), 7.38 – 7.20 (10 H, 
m, ArH). 
(1S, 2R)-Ethyl-N-(1,2-diphenyl-2-hydroxyethyl)glycinate 34 
 
(1R, 2S)-2-amino-1,2-diphenylethanol 33 (1000 mg, 4.76 mmol) was 
dissolved in anhydrous tetrahydrofuran (25 mL) at rt. Ethyl bromoacetate (760 
μL, 7.1 mmol) and triethylamine (1.32 mL, 9.5 mmol) were then added 
dropwise to the solution. After 18 h, the suspension was passed through a 
sintered funnel to remove the  precipitated  triethylammonium bromide salt 
and the filtrate concentrated in vacuo to afford an off-white, amorphous solid. 
The solid was recrystallised from ethanol (15 mL) to afford (1S, 2R)-ethyl N-
(1,2-diphenyl-2-hydroxyethyl)glycinate 34 (1400 mg, 4.66 mmol, 98%) as 
white needles; m.p. 125-126 °C (Lit: 126-127 °C);206 Found C 71.85%, H 6.95%, 
N 4.50; C18H21NO3 requires C 72.22%, H 7.07%, N 4.68%; δH (500 MHz, CDCl3): 
1.20 (3H, t, J = 7.2, CH2CH3), 1.90 (1H, br s, NH), 2.84 (1H, br s, OH), 3.15 (1H, d, J 
= 17.5, NHCHH'CO2Et), 3.28 (1H, d, J = 17.5, NHCHH'CO2Et), 3.95 (1H, d, J = 6.0, 
OHCH), 4.11 (2H, q, J = 7.2, CH2CH3), 4.80 (1H, d, J = 6.0, NHCH), 7.16-7.22 (4H, 
m, ArCH), 7.23-7.31 (6H, m, ArCH); δC (126 MHz, CDCl3): 14.2, 48.4, 60.7, 68.3, 
126.9, 127.8, 127.9, 128.1, 128.3, 128.4, 128.4, 138.5, 140.2, 172.2; ESI-HRMS 
found m/z 300.1590 [M+H]+; C18H22NO3  requires 300.1594; [α]D24 (CHCl3, c = 
0.7) +23.7 (Lit: CH2Cl2, c = 1) +24.2.206  
(5S, 6R)-4-(t-Butoxycarbonyl)-5,6-diphenylmorpholin-2-one 35 
 
(1S, 2R)-Ethyl N-(1,2-diphenyl-2-hydroxyethyl)glycinate 35 (1310 mg, 
4.38 mmol) was dissolved in toluene (20 mL) and heated to 110 °C. Di-tert-
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butyl dicarbonate (1300 mg, 5.96 mmol) was added slowly as a solution in 
toluene (10 mL) to the reaction mixture over 1 h. After 12 h, 10 mL of toluene 
was distilled from the reaction at 130 °C at atmospheric pressure to remove 
any residual water. Fresh toluene (10 mL) and p-toluenesulfonic acid 
monohydrate (83 mg, 0.438 mmol) were added to the reaction mixture, which 
was heated at 110 °C for 1 h. 20 mL of toluene was then distilled from the 
reaction mixture over 2 h, followed by cooling to rt. The resulting solid was 
filtered and crystallised from hot ethanol to afford two rotamers (confirmed as 
rotamers by VT-NMR) of (5S, 6R)-4-(t-butoxycarbonyl)-5,6-
diphenylmorpholin-2-one 35 (1315 mg, 3.72 mmol, 85%) as colourless, fine 
needles. m.p. 204-205 °C (Lit: 207 °C)206; Found C 71.30%, H 6.55%, N 3.90%; 
C21H23NO4 requires C 71.37%, H 6.56%, N 3.96%; δH (500 MHz, CDCl3) 1.18 
(5H, s, tBu), 1.44 (4H, s, tBu), 4.31 (0.55 H, d, J = 18.2, H3), 4.45 (0.45H, d, J = 
17.9, H3), 4.60 (0.45H, d, J = 17.9, H3'), 4.86 (0.55H, d, J = 18.2, H3'), 5.03 
(0.55H, s, H5), 5.36 (0.45H, s, H5), 5.85 (1H, br s, H6). 6.62-6.80 (2H, m, ArCH), 
6.96-7.30 (8H, m, ArCH); δC (75 MHz, CDCl3) 27.9, 28.3, 44.8, 45.7, 58.7, 60.8, 
80.4, 81.1, 81.4, 81.8, 126.3, 126.4, 127.7, 127.8, 128.0, 128.2, 128.6, 134.0, 
134.3, 135.0, 136.0, 153.2, 153.5, 167.6, 168.0; νmax (neat) 3041, 2974, 2914, 
1741, 1687, 1604, 1455, 1432, 1362, 1343, 1273, 1240, 1196; ESI-HRMS found 
m/z 376.1474 [M+Na]+, C21H23NO4Na requires 376.1441. [α]D27 (CHCl3, c = 0.7) 




(5S, 6R)-4-(t-Butoxycarbonyl)-5,6-diphenylmorpholin-2-one 35 (2.57 g, 
7.28 mmol) was dissolved in tetrahydrofuran (50 mL) and cooled to –78 °C. 
Sodium bis-(trimethylsilyl)amide (7.78 mL, 7.74 mmol, 1M solution in 
tetrahydrofuran) was added dropwise to the reaction mixture. After 35 min, 
methyl iodide (4.66 mL, 75 mmol) was added dropwise at –78 °C. After 90 min, 
the reaction mixture was poured into water (150 mL) and the aqueous layer 
extracted with ethyl acetate (3 × 120 mL). The combined organic layers were 
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dried and concentrated in vacuo to afford an orange oil. Purification by flash 
chromatography (Chloroform:methanol 99:1) afforded two rotamers of (3S, 5S, 
6R)-3-methyl-4-(t-butoxycarbonyl)-5,6-diphenyl-morpholin-2-one 36 (2.09 g, 
5.68 mmol, 78%) as brown, stubby needles (after crystallisation from hot 
ethanol). Rf = 0.4 (Hexane:ethyl acetate 2:1); m.p. 198-200 °C; Found C 71.15%, 
H 6.85%, N 3.60%; C22H25NO4 requires C 71.91%, H 6.86%,  N 3.81%; δH (500 
MHz, DMSO-d6, 392 K): 1.23 (9H, br s, tBu), 1.72 (3H, d, J = 7.0, CH3), 4.88 (1H, q, 
J = 7.0, H3), 5.17 (1H, d, J = 3.1, H5), 6.15 (2H, d, J = 3.1, H6), 6.58 – 6.60 (2H, m, 
ArCH), 7.05 – 7.10 (5H, m, ArCH), 7.20 – 7.24 (3H, m, ArCH); δC (75 MHz, CDCl3): 
19.4, 28.7, 52.2, 60.3, 80.1, 125.4, 125.6, 126.3, 126.6, 126.7, 126.8, 127.0, 
127.1, 127.5, 127.6, 133.0, 135.3, 152.0, 169.7; ESI-HRMS found m/z 390.1689 
[M+Na]+; C22H25NO4Na requires 390.1676;154 [α]D26 (CHCl3, c = 0.7) –69.4 Lit: 





one 36 (2100 mg, 5.71 mmol) was dissolved in anhydrous tetrahydrofuran (42 
mL) and cooled to –40 °C (Liquid nitrogen in acetonitrile). 1-Iodopent-4-ene 
(2800 mg, 14.3 mmol) was added dropwise and the mixture was allowed to stir 
for 30 min. Potassium bis-(trimethylsilyl)amide (7.8 mL, 8.57 mmol,  0.91 M in 
tetrahydrofuran) was added dropwise and the reaction retained at –40 °C. After 
1 h, water (50 mL) was added at –40 °C and the suspension was raised to rt and 
extracted with ethyl acetate (3 × 100 mL). The organic layers were dried 
(Na2SO4) and concentrated in vacuo to afford an orange, amorphous solid. 
Purification by flash chromatography (Chloroform:acetone 99:1) afforded (3S, 
5S, 6R)-tert-butyl-3-methyl-2-oxo-3-(pent-4-enyl)-5,6-diphenylmorpholine-4-
carboxylate 37 as a colourless, amorphous solid (970 mg, 2.80 mmol,  49%). 
Rf = 0.6 (Hexane:ethyl acetate 2:1), δH (500 MHz, DMSO-d6, 392 K): 1.40 (9H, br 
s, tBu), 1.69 (3H, s, CH3), 1.45 – 1.57 (2H, m, CH2CH2CH2), 2.09 (2H, app q, 
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J = 7.3, CH2CH=CH2), 2.21 – 2.28 (1H, m, C(Me)CH2CH2), 2.43 – 2.45 (1H, m, 
C(Me)CH2CH2), 4.95 – 4.99 (1H, m, CH=CH2 cis), 5.03 (1H, dq, J = 17.2, 2.1, 
CH=CH2 trans), 5.57 (1H, d, J = 3.6, H5), 5.78 – 5.89 (1H, m, H4), 6.13 (1H, d, J = 
3.6, H6), 6.94 – 6.97 (2H, d, ArCH), 7.12 – 7.14 (3H, m, ArCH) 7.19 – 7.24 (5H, m, 
ArCH); δc (125 MHz, CDCl3): 24.1, 24.3, 25.2, 28.5, 33.6, 33.7, 57.6, 64.0, 67.3, 
80.5, 114.3, 115.4, 125.8, 127.8, 127.9, 128.1, 128.2, 128.3, 129.0, 129.9, 135.4, 
135.7, 135.9, 137.9, 172.5, 173.0; ν(max) 3066, 3034, 2976, 2931, 1747, 1694, 
1641, 1498, 1454; ESI-HRMS found 458.2303 [M+Na]+; C27H33NO4Na requires 
458.2302,  [α]D23.3 (CHCl3, c = 1) +29.9. 
(S)-2-(tert-butoxycarbonyl)amido-2-methylhept-6-enoic acid 38 
 
(3S, 5S, 6R)-tert-butyl-3-methyl-2-oxo-3-(pent-4-enyl)-5,6-
diphenylmorpholine-4-carboxylate 37 (950 mg, 2.18 mmol) was dissolved in 
anhydrous tetrahydrofuran (25 mL) and anhydrous ethanol (2 mL) and 
transferred via cannula to liquid ammonia (~50 mL) at –78 °C. Lithium wire 
(301 mg, 43.7 mmol) was washed in hexane and added to the reaction mixture 
in several portions. After the blue colour dissipated (15 min), saturated 
ammonium chloride was added dropwise, and the temperature allowed to rise 
to rt overnight, to ensure  evaporation of ammonia gas. The aqueous solution 
was extracted with ether (2 × 50 mL), acidified to pH 2 with 1M hydrochloric 
acid and extracted further with ethyl acetate (3 × 50 mL). The organic layers 
were combined, dried and concentrated in vacuo to afford a colourless solid. 
Purification by flash chromatography (dichloromethane : methanol 95:5) 
afforded (S)-2-(tert-butoxycarbonyl)amido-2-methylhept-6-enoic acid 38  as a 
colourless, amorphous solid (468 mg, 1.83 mmol, 84%). m.p. 230 °C 
(decomposes); Rf = 0.2 (dichloromethane:methanol 95:5, stained with 
ninhydrin (scarlet spot) and permanganate); δH (500 MHz, MeOD) 1.25 – 1.41 
(3H, m, H3 & H4), 1.45 & 1.46 (12H, 2 × br s, tBu & CH3), 1.75 – 1.85 (1H, m, H3), 
4.93 (1H, fine splitting obscured by residual peaks, H7), 4.98 (1H, d, J = 17.0, H7 
trans), 5.75 –5.95 (1H, m, H6); δC (125 MHz, MeOD) 24.3, 25.0, 28.9, 35.0, 37.3, 
61.0, 79.7, 115.0, 139.9, 156.4, 181.2; ν(max) 3411, 3355, 1667, 1620, 1485, 
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1454, 1405, 1367, 1170; ESI-HRMS found 280.1507 [M+Na]+; C13H23NO4Na 
requires 280.1519,  [α]D24.7 (MeOH, c = 1) +16.0. 
(S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-2-methylhept-6-
enoic acid 16 
 
(S)-2-(tert-butoxycarbonyl)amido-2-methylhept-6-enoic acid 38 (468 
mg, 1.82 mmol) was suspended in dichloromethane (6 mL) and trifluoroacetic 
acid (6 mL) was added slowly (2 mL/min) at rt. After 30 min, the solvents were 
removed in vacuo and dried on the high vacuum manifold until less than 2 
equivalents of trifluoroacetic acid remained by weight. The residue was then 
dissolved in water:acetone (1:1, 10 mL), cooled to 0 °C and then sodium 
carbonate (963 mg, 9.10 mmol) and 9-fluorenylmethyl succinimidyl carbonate 
(644 mg, 1.90 mmol) were added. After 1 h, the suspension was acidified to pH 
3 with 1M hydrochloric acid and extracted with ethyl acetate (3 × 120 mL). The 
combined organic layers were combined, dried and concentrated in vacuo to 
afford a yellow residue. Purification by flash chromatography (dry loaded, and 
eluted with 85:10:5 dichloromethane:toluene:methanol) afforded (S)-2-((((9H-
fluoren-9-yl)methoxy)carbonyl)amino)-2-methylhept-6-enoic acid 16 as a pale 
yellow oil (430 mg, 1.13 mmol, 62%). Rf = 0.2 (94:5:1 
dichloromethane:methanol:acetic acid), stained with ninhydrin (violet)), δH 
(500 MHz, MeOD) 1.29 – 1.42 (5H, m, CH3 and H3), 1.81 – 1.93 (2H, m, H4), 2.00 
– 2.08 (2H, m, H5), 4.19 (1H, t, J = 6.8, H10), 4.28  – 4.35 (2H, m, CH2O), 4.93 
(1H, d, J = 10.7, H7 cis), 4.99 (1H, d, J = 17.1, H7 trans), 5.71 – 5.89 (1H, m, H6), 
7.29 (2H, t, J = 7.3, ArCH), 7.36 (2H, t, J = 7.3 ArCH), 7.60 – 7.67 (2H, m, ArCH), 
7.77 (2H, d, J = 7.7, ArCH); δC (125 MHz, MeOD): 24.4, 34.8, 37.6, 49.6 (identified 
by HMQC), 60.8, 67.5, 115.2, 120.9, 126.2, 126.3, 128.2, 128.8, 139.6, 142.6, 
145.3, 158.1, 178.0; νmax 3331 (br), 3029, 2956, 1950, 1913, 1680, 1615, 1535, 
1421; ESI-HRMS found 402.1687 [M+Na]+; C23H25NO4Na requires 402.1676. 





4-Penten-1-ol (200 mg, 2.32 mmol), triphenyl phosphine (728 mg, 2.78 
mmol) and imidazole (237 mg, 3.48 mmol) were dissolved in dichloromethane 
(5 mL) at 0 °C. Iodine (703 mg, 2.78 mmol) was added and the solution allowed 
to stir at 0 °C for 1 h. The solution was allowed to warm to rt and quenched 
with saturated NH4Cl (15 ml) and extracted with dichloromethane (3 × 10 mL). 
The combined organic layers were washed with brine (20 mL), dried and 
concentrated in vacuo to afford a thin, colourless oil. Purification by silica gel 
chromatography (Ethyl acetate:hexane, 1:19) afforded 1-iodopent-4-ene 40 as 
a thin, volatile oil (270 mg, 1.40 mmol, 60%): Rf = 0.9 (Ethyl acetate:hexane 
1:19); δH (500 MHz, CDCl3): 1.92 (2H, quin, J 6.8, H2), 2.17 (2H, q, J 6.8, H3), 
3.20 (2H, t, J 6.8, H1), 5.02 (1H, d, J 10.3 H5 cis), 5.09 (1H, d, J 17.1, H5 trans), 
5.80 – 5.70 (1H, m, H4). δC (126 MHz, CDCl3): 6.7, 32.8, 34.7, 116.3, 137.0. 
4.2 Procedures regarding the synthesis of peptides 
4.2.1 General Regards 
All amino acids and resins were purchased from either Novasyn (Merck) 
or Sigma-Aldrich. All amino acids were N-Fmoc protected and side chains were 
protected with Boc (Lys, Trp); OtBu (Asp, Glu, Ser, Thr); Trt (Cys, Asn, Gln); Pbf 
(Arg). Synthesis of peptides was performed either manually using vaculate 
reservoirs and draining from a water aspirator or by the use of a microwave 
assisted automated peptide synthesiser (CEM Liberty). DMF used in peptide 
synthesis was of ACS grade from Sigma-Aldrich. Peptide identities were 
confirmed by the LCMS and HRMS machines stated in 4.1.1. Multiple charge 
states were used to reinforce the assignment of species observed by LCMS, and 
the monoisotopic mass used in 4 d.p. analysis.   
4.2.2 Methods for Manual Fmoc  Solid Phase Peptide Synthesis 
Method A: Resin Swelling 
The required quantity of resin was placed in a vaculate reservoir and 
CH2Cl2 (2 ml) was added and the resin was agitated on a blood spinner for 2 h 
to allow swelling of the resin. 
Method B: Deprotection of N-Fmoc protecting groups 
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N-terminal Fmoc protecting groups were removed by the addition of 
20% piperidine:DMF (5 × 2 mL × 2 min), followed by rinsing the resin with 
DMF (5 × 2 mL × 2 min). Successful deprotection was determined by a positive 
colour test (Methods C & D). 
Method C: Kaiser Test165  
The Kaiser Test was employed for the determination of the successful 
coupling or deprotection for most of the residues. A small number of resin 
beads were rinsed in ethanol and placed in a vial, followed by the addition of 
two drops of each of the three solutions in the following order: 
1) Ninhydrin (5% w/v) in ethanol;  
2) Phenol (80% w/v) in ethanol;  
3) 1 mM KCN(aq.) in pyridine (2% v/v). 
The solution was then heated to ca. 150 °C for 1 min. A successful 
coupling gave no change in the colour of the beads, whereas bright blue beads 
illustrate a successful deprotection. This colour test was useful for the 
identification of free primary amines, however inconclusive results are 
obtained for Asp, Ser, Pro and Asn residues. 
Method D: Chloranil Test207 
The chloranil test was also employed for the determination of successful 
couplings or deprotections of some residues. A small number of beads were 
rinsed in ethanol and placed in a vial, followed by the addition of two drops of 
each of the two solutions in the following order:  
1) Acetaldehyde (2% v/v) in DMF;  
2) p-Chloranil (2% w/v) in DMF. 
The solution was left at rt for 5 min. No change in colour of the beads 
showed a negative result, whereas the change of bead colour to pale 
green/bright blue illustrated a successful deprotection. This test was especially 
useful for Pro residues, where the bead colour became a very bright blue (often 
after 10 seconds) to show a free secondary amine. However, the length of time 
(often ~10 min for a primary amine) for the colour change made this colour 
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test less useful than the Kaiser test for the determination of free primary 
amines. 
Method E: Coupling of Amino Acids with Uronium Coupling Reagents 
The desired amino acid (5 equiv.), DIPEA (5 equiv.), HOBt (5 equiv.) and 
Uronium coupling reagent (Either HATU, HBTU or HCTU) (5 equiv.) were 
dissolved in DMF (2 mL) and added to the resin, followed by agitation for 1 h (2 
h for unnatural amino acids). For double couplings, this step was repeated. 
After draining the reagents, the resin was washed with DMF (3 × 2 mL × 2 min) 
and the success of coupling determined by a negative colour test (Methods C & 
D). Deprotection of the Fmoc-protected N-terminus then followed (Method B).   
Method F: Coupling of Cysteine and Thiazolidine (Thz) 
The desired amino acid (5 equiv.), 2,4,6-trimethylpyridine (5 equiv.) and 
HCTU (5 equiv.) were dissolved in  1:1 CH2Cl2:DMF (2 mL) and added to the 
resin, followed by agitation for 1 h. After draining the reagents, the resin was 
washed with DMF (3 × 2 mL × 2 min) and the success of coupling determined 
by a negative colour test (Methods C & D). 
Method G: N-terminal acetylation 
Acetic anhydride (10 equiv.) and DIPEA (10 equiv.) were dissolved in 
DMF (2 mL) and the solution was transferred to the resin. After 2 h, the resin 
was drained, washed with DMF (3 × 2 mL × 2 min) and successful capping 
determined by a negative colour test (Methods C & D).  
Method H: N-terminal FITC labelling172 
Fluorescein isothiocyanate (1.2 equiv.) was dissolved in 12:8:5 
Pyridine:DMF:CH2Cl2 (2 mL) and the solution transferred to the resin in the 
dark. After 18 h, the resin was washed with DMF (5 × 2 mL × 2 min) ahead of 
cleavage and deprotection (Method K). The solvents were of anhydrous grade 
and the pyridine distilled prior to use.   
Method J: On-Resin Olefin Metathesis 
After the completed peptide elongation and N-terminal acetylation, on-
resin olefin metathesis was completed by the preparation of a 10 mM solution 
of Grubbs First Generation Catalyst in degassed dichloroethane (2 mL), which 
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was added to the resin beads and allowed to agitate gently for 2 h, after which 
time the metathesis procedure was repeated for another 2 h. N-terminally 
acetylated peptides were then cleaved from the resin (Method K). For FITC 
labelled peptides, metathesis was performed before labelling (Method H).  
Method K: Cleavage and deprotection of Rink Amide MBHA and Wang 
resins 
After elongation and N-terminal acetylation was complete, the resin was 
washed with DMF (5 × 2 mL × 2 min), CH2Cl2 (5 × 2 mL × 2 min) and then Et2O 
(3 × 2 mL × 2 min). Peptides were then simultaneously cleaved and side-chain 
deprotected with cleavage 'Reagent K' TFA:EDT:Thioanisole:Phenol:H2O, 
82:3:5:5:5 (3 × 2 mL × 1 h). The resin was washed with fresh TFA 
(2 mL × 2 min) and the solution concentrated in vacuo.  
The resulting oil was precipitated with ice-cold ether (10 mL) and 
placed in a centrifuge (3000 rpm × 0.5 min). The supernatants were removed, 
the precipitate rinsed with ice-cold ether (3 × 10 mL) and dried in vacuo. 
Method L: Cleavage of TGT Resins to Afford Side-chain Protected 
Peptides 
After rinsing with DMF (5 × 2 mL × 2 min), CH2Cl2 (5 × 2 mL × 2 min) 
and then Et2O (3 × 2 mL × 2 min), the peptides were cleaved from the resin 
with a cleavage cocktail of TFA:CH2Cl2, 1:199 (2 × 2 mL × 1 h). The resin was 
rinsed with fresh cleavage cocktail (2 × 2 mL × 2 min) and the solution 
concentrated in vacuo. 
Method M: C-terminal thioesterification of protected peptides 
The side-chain protected peptide was dissolved in anhydrous DMF (to a 
concentration of 0.0575 M) under N2, and BnSH (20 equiv.) was added at rt. 
After 30 mins, PyBOP (2 equiv.) was added, followed by DIPEA (2 equiv.) after a 
further 15 min. After 2 h, PyBOP (2 equiv.) and DIPEA (2 equiv.) was added. 
The reaction was monitored by LCMS by removing an aliquot of the reaction 
mixture and adding TFA:TIPS:H2O (92.5:2.5:5) deprotected the side chains to 
allow the peptide to ionise. After 15 h, the solvent was evaporated in vacuo and 
the peptidyl thioester globally deprotected using 'Reagent K' 82:3:5:5:5 
TFA:EDT:Phenol:Thioanisole:H2O (5 mL) under N2 for 2 h. The solution was 
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concentrated in vacuo and the peptide precipitated with ice cold ether (10 mL) 
and placed in a centrifuge (3000 rpm × 0.5 min). The supernatants were 
removed, the precipitate rinsed with ice-cold ether (10 × 10 mL) and dried 
under a nitrogen jet. 
Method N: Peptide Purification 
Peptides were purified by preparative scale HPLC using a Jupiter Proteo 
preparative column (reversed phase) on an increasing gradient of acetonitrile 
to water (plus 0.1% formic acid v/v in both solvents) at a flow rate of 20 mL 
min-1. Crude peptides were suspended in either dimethylsulfoxide or 1:1 
acetonitrile:water at an approximate concentration of 15 - 20 mg mL-1. 
Purification runs injected a maximum of 2.5 mL of crude peptide solution and 
were allowed to run for 35 min, with acetonitrile increasing from 5 to 95%, and 
the eluent scanned with a diode array at 220, 254, 280 and 490 nm. Fractions 
were checked by LCMS, concentrated in vacuo and lyophilised. For semi-
preparative purification, a Jupiter Proteo Semi-Preparative (reversed phase) 
column was used, with the injection reduced to 250 µL and the flow rate 
reduced to 3 mL min-1. For peptides with crude UV traces that were unsuitable 
for collection by chromatogram, purification was performed on a semi-
preparative scale using a mass directed chromatography software Masshunter 
by ChemStation (Agilent). Mass directed chromatography allows the collection 
of the desired peptide by mass, with the eluent split into an Agilent 6120 
Quadrupole LCMS which triggers collection of eluent at a programmed m/z. 
The column used with this apparatus is an Agilent XBridge 5 µM 10×50 mm C18 
semi preparative column. Injections were 250 µL and flow rate 5 mL min-1.   
4.2.3 Cycles for automated peptide synthesis  
Peptides that were built on the microwave assisted Liberty CEM Peptide 
Synthesiser followed this cycle: 
Resin Loading 
Clean reaction vessel; wash with DMF; wash with CH2Cl2; transfer resin 
to reaction vessel; wash with DMF; wash with CH2Cl2; transfer resin to reaction 
vessel; wash with DMF; wash with CH2Cl2; vessel draining. 
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Deprotection and coupling 
Clean resin dip tube, wash with DMF (15 mL), add 20% piperidine in 
DMF (6 mL), microwave method (30 sec), wash with DMF (15 mL), add 20% 
piperidine in DMF (6 mL), microwave method (30 sec), wash with DMF 
(15 mL), clean resin dip tube, wash with DMF (15 mL), add amino acid 
(2.5 mL), add coupling reagent (1 mL), add activator base (0.5 mL), microwave 
method (5 min), wash with DMF (15 mL), drain.  
For methods that did not use microwave assistance, the reaction cycle 
was the same, except the microwave method for deprotection and coupling was 
replaced by agitation of the resin at rt for 10 min and 90 min respectively. 
After the final residue, the resin is ejected from the reaction vessel and 
cleavage/deprotection was performed manually using Methods K-M.  
4.2.4 Specific protocols for the use of Dawson resin 
Method O: Loading of Dawson Resin 
After swelling of the resin (4.2.2, Method A) and deprotection of the 
Fmoc-Dbz group (4.2.2, Method B), the first coupling was done by the addition 
of Fmoc-Ala-OH (5 equiv.), HBTU (5 equiv.), HOBt (5 equiv.) and DIPEA (10 
equiv.) in DMF (2 mL) and the resin agitated for 1.5 h. The resin was drained, 
and the coupling repeated. After the first residue was successfully coupled by 
determination from LCMS, the following residues were deprotected and 
coupled by the methods described above (4.2.2, Methods B & F). 
Method P: The final coupling of Dawson resin 
Boc-Met-OH (5 equiv.), HBTU (5 equiv.), HOBt (5 equiv.) and DIPEA (5 
equiv.) was dissolved in DMF (2 mL) and agitated at rt for 1 h. After 
determination of a successful coupling (4.2.2, Method D), the resin was washed 
with DMF (5 × 2 mL × 2 min) and CH2Cl2 (5 × 2 mL × 2 min). 
Method Q: Activation of Dawson resins to C-terminal N-
acylbenzimidazolinone 
After purging the resin beads with a stream of N2, p-
nitrophenylchloroformate (5 equiv.) was dissolved in anhydrous CH2Cl2 (2 ml) 
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and agitated at rt, sealed under N2 for 2 h. The resin was drained, and DIPEA 
(10 equiv.) in DMF (2 mL) was added and the resin agitated for a further 60 
min. After confirming the completion of the activation by LCMS, the peptide 
was cleaved from the resin using 'Reagent K'; (82:3:5:5:5 
TFA:EDT:Phenol:Thioanisole:H2O) for 2 × 2 h. The peptidyl solution was 
concentrated in vacuo and precipitated with ice cold ether (10 mL) and placed 
in a centrifuge (3000 rpm × 0.5 min). The supernatants were removed, the 
precipitate rinsed with ice cold ether (3 × 10 mL) and dried in vacuo. 
4.2.5 Native Chemical Ligation 
Fragment 3 and Fragment 2 were separately dissolved in freshly 
prepared, degassed ligation buffer (6M guanidinium hydrochloride, 0.1 M 
sodium phosphate, 200 mM 4-mercaptophenyl acetic acid, 20 mM tris(2-
carboxyethyl) phosphine, pH 7.0) to a concentration of ~ 2 mM. The peptidyl 
solutions were centrifuged (10000 rpm × 2 min) and the concentration of the 
supernatant verified by UV-Vis spectroscopy. The supernatants were then 
mixed to equimolar concentrations of Fragment 3 and 2 under nitrogen and the 
ligation monitored by LCMS.  
The N-terminal Thz residue on the ligated Fragment 2-3 was 
deprotected by the addition of 200 mM methoxyamine hydrochloride and 
20 mM tris(2-carboxyethyl) phosphine (TCEP) and the pH adjusted to ~4. The 
deprotection was monitored by LCMS.  
Fragment 1 Nbz was then dissolved in ligation buffer to a concentration 
of ~2 mM and centrifuged (10000 rpm × 2 min). The supernatant was then 
added to the Fragment 2-3 ligation mixture to have an equimolar mixture of 
Fragment 1 and Fragment 2-3, with the ligation monitored by LCMS. 
4.2.6 Maleimide Bridging of hCys BID peptides 
hCys BID was dissolved to a 200 μM concentration in degassed bridging 
buffer (2.5:37.5:60 dimethylformamide:acetonitrile: 40 mM phosphate buffer) 
with 5 eq. TCEP and 5 eq. dibromomaleimide added and the pH adjusted to 
~6.5. After 12 h, the reaction mixture was washed with ethyl acetate and the 
concentrated in vacuo. 
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4.3 Specific Peptide Synthesis Procedures - p53 and 
Bcl-2 family 
4.3.1 p53 peptide series 
The p53 series of peptides (p53 MM and p53 MU) were built on Rink 
Amide MHBA Resin (Capacity 0.79 mmol g-1) on a scale of 0.05 mmol, using 
Methods A-G, J and K. The coupling reagent was HCTU and double couplings 
were employed for 29Asn and 30Asn. Purification of the peptides using 
preparative HPLC (Jupiter Proteo Preparative column) on a gradient of 20-60% 
acetonitrile over 20 mins afforded 7 mg (13%) and 6 mg (11%) of p53 MM and 
p53 MU respectively. 
4.3.2 Unlabelled BID peptides 
The unlabelled BID series (BID WT, BID MM, BID MU, BID DM, BID DU 
and BID Aib) were synthesised on Rink Amide MBHA LL Resin 
(Capacity ~0.45 mmol g-1) on a 0.1 mmol scale using manual and automated 
SPPS methods. Residues 91AXVGDX were coupled manually, with the 
surrounding residues coupled using non-microwave assisted automated 
synthesis. The coupling conditions followed Method E with HCTU as the 
coupling reagent, with the following residues double-coupled with HCTU: 82I, 
83I, 84R, 85N and 103W. The Fmoc groups of 92X and 96X were deprotected as in 
Method B, but with each deprotection lasting 5 min. 91A and 95D were double 
coupled using 10 equivalents of HATU, with the first coupling proceeding for 
1 h and the second coupled overnight. For the synthesis of BID MM and BID DM, 
the peptide was divided into two halves, with one cleaved (Method K) to afford 
BID MU or DU, and the other half metathesised (Method J) before cleavage 
(Method K) to afford BID MM or DM. 
 Purification was performed using a Jupiter Proteo semi-preparative 
column outlined in Method N. The employed gradient was 0-40-60-95% 
acetonitrile with 0.1% formic acid at times 0-5-25-30 mins with the elution 
between 17-19 minutes for WT BID and Aib BID peptides and 19-21 minutes 
for MM, MU, DM and DU BID. The purified yields of peptides were: BID WT 24.1 
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mg (11%); BID MM 13.1 mg (10%); BID MU 3.9 mg (4%); BID DM 7.2 mg (7%); 
BID DU 4.7 mg (5%); BID Aib 9.1 mg (10%).    
4.3.3 FITC Labelled BID Peptides 
FITC labelled BID peptides (BID WT*, BID Aib*, BID MM* and BID DM*) 
were synthesised on a 0.05 mmol scale in the same manner described in 4.3.2. 
The N-termini were functionalised with 6-aminohexanoic acid (BID WT*) or 
β-alanine (BID Aib*, MM*, DM*) which were coupled using Method E with 
HCTU as the activator. Then, on-resin Grubbs metathesis (Method J) was done 
for BID MM* and BID DM* before Fmoc deprotection (Method B) and labelling 
with FITC (Method H). Cleavage and deprotection was performed as Method K, 
with the exception of the peptide being kept in the dark to prevent 
photobleaching of the FITC tag.  
Purification of the BID WT*, MM* and DM* peptides was performed by 
semi-preparative HPLC (Method N) using a Jupiter Proteo semi-preparative 
column with a gradient of 5-40-60-95% acetonitrile (with 0.1% formic acid) at 
time 0-5-25-30 mins. The peptides generally eluted between 20-22 minutes. 
BID Aib* was purified using the mass-directed semi-preparative method 
(Method N) on an Agilent XBridge column, using a gradient of 40-60% 
acetonitrile (with 0.1 % formic acid) over 20 minutes. BID Aib* eluted at 6 
minutes. The purified yields of the peptides were: WT* 6.5 mg (7%); Aib* 
9. 9 mg (10 %), MM* 23 mg (21 %) and DM* 9.25 mg (10%). 
4.3.4 hCys BID 
hCys BID was synthesised on Rink Amide MBHA LL Resin (Capacity 
0.36 mmol g-1) on a 0.05 mmol scale, following the same procedure as outlined 
in 4.3.2, but without the double couplings of 82I, 83I, 84R and 85N.  
Purification was performed using semi-preparative HPLC using an 
Agilent XBridge column using a gradient of 30-50% acetonitrile (with 0.1% 
formic acid) over 25 minutes. The peptide eluted at 17-18.5 minutes to afford 
6 mg (5 %) of pure hCys BID.   
4.3.5 hCys BID MAL and hCys BID SUC 
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hCys BID was converted into hCys BID SUC using the protocol described 
in 4.2.6. 30 mg of crude hCys BID (cleaved from the resin) was reacted and 
purified using semi-preparative HPLC using an Agilent XBridge column using a 
gradient of 35-55% acetonitrile (with 0.1% formic acid) over 25 minutes. The 
peptide eluted at 7.0-8.5 minutes to afford 4.1 mg (11%) of hCys BID SUC. hCys 
BID MAL was identified as being present in the reaction mixture and as a 
shoulder in some HPLC fractions, but was not isolated.   
4.3.6 BIM Peptide Series  
The BIM series of peptides (BIM MM and BIM DM) were synthesised on 
Rink Amide MBHA LL resin (Capacity 0.36 mmol g-1) on a scale of 0.1 (BIM MM) 
and 0.075 (BIM DM) following Methods A-E, with HCTU employed as the 
coupling reagent. The peptide was synthesised on the automated peptide 
synthesiser without microwave assistance, except for the residues 
encompassing 152RXIGDX which were coupled manually. The Fmoc groups of 
153X and 157X were deprotected as Method B, but with each deprotection lasting 
5 min. 152R and 158D were double coupled using 10 equivalents of HATU, with 
the first coupling proceeding for 1 h and the second coupled overnight. On-
resin Grubbs metathesis followed Method J prior to cleavage and deprotection 
(Method K).  
Purification was performed using semi-preparative HPLC with a Jupiter 
Proteo semi-preparative column on a gradient of 0-35-52-95% acetonitrile 
(with 0.1% formic acid) at times 0-7-27-31 mins with BIM DM and MM eluting 
at 16-18 minutes. The purified yields of peptides were: BIM MM 9.2 mg (23% 
based on 40 mg purified) and BIM DM 21.6 mg (32% of 0.038 mmol purified).          
4.3.7 Im7 Fragment 3 
Im7 Fragment 3 was synthesised on Fmoc-Gly-Wang resin 
(Capacity 0.79 mmol g-1) on a 0.08 mmol scale, using manual SPPS synthesis 
(Methods A-F) and HCTU as the activator in Method F. Residues 68I, 69V, 71E, 72I 
and 79N were double coupled before cleavage and deprotection was done 
following Method K.  
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Purification of Im7 Fragment 3 was done using a Jupiter Proteo 
preparative HPLC column on a gradient of 5-40-60-95% acetonitrile at time 
0-10-30-35 mins with the peptide eluting at 18-19 mins. The purified yield was  
48 mg (19%).  
4.3.8 Im7 Fragment 2 
Im7 Fragment 2 was synthesised on a scale of 0.1 mmol on Fmoc-Ser 
NovaSyn TGT resin (Capacity 0.20 mmol g-1) using automated non-microwave 
assisted synthesis following Methods A-F, with HCTU as the coupling reagent. 
Residues 41F and 57P were double coupled and the N-terminal 29Thz residue 
was coupled manually (Method F). Cleavage followed Method L to afford 
333 mg (77%) of the crude side-chain protected peptide, which was 
thioesterified on its C-terminus (Method M). Global deprotection of the side 
chain protecting groups then followed Method K. 
Purification was done using semi-preparative HPLC using an Agilent 
XBridge column (Method N), on a gradient of 35-50% acetonitrile (with 0.1% 
formic acid) over 20 minutes. The peptide eluted between 12-14 minutes. The 
purified yield was 10 mg (15%).  
4.3.9 Im7 Fragment 1 (C-terminal Acid) 
Im7 Fragment 1 was built on a 0.05 mmol scale on Fmoc-Ala NovaSyn 
TGT resin (Capacity 0.21 mmol g-1), with the automated non-microwave 
assisted synthesis performed for all of the peptide couplings (Methods B & F) 
and HCTU used as the coupling reagent. The eight N-terminal residues were 
double coupled (Method E) before cleavage from the resin (Method L) to afford 
the crude side-chain protected peptide (257 mg, 83% crude). 
4.3.10 Im7 Fragment 1 (C-terminal Nbz) 
Im7 fragment 1 with C-terminal Nbz group was built on a 0.1 mmol scale 
on Dawson Dbz TGR resin (Capacity 0.22 mmol g-1) following Methods O, F and 
P with HBTU used as the coupling agent. After peptide elongation was 
complete, activation of the resin (Method Q) was followed by cleavage and 
deprotection of the peptide (Method K). 
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Purification of the peptide was performed by semi-preparative HPLC 
using a Jupiter Proteo column (Method N) on a gradient of 5-25-45-95% 
acetonitrile (with 0.1% formic acid) at times 0-5-25-30 minutes. The peptide 
eluted between 18-20 minutes and required immediate evaporation of the 
solvent to prevent hydrolysis of the Nbz activating group. The purified yield 
was 10 mg (25%).  
4.4 Peptide Data 
4.4.1 High Resolution Mass Spectrometry Data 
Below is a tabulation of the HRMS data of the peptides that have been 
synthesised. Peptide identity was confirmed by the inspection of multiple 
charge states and are quoted as the monoisotopic peak for the Expected (Expd) 
and Observed (Obsd) masses. 
4.4.1.1 p53  
Peptide  [M+H+Na]2+Obsd  [M+H+Na]2+Expd  
p53 U 1111.5335 1111.5318 
p53 M  1097.5137 1097.5135 
 
4.4.1.2 Unlabelled BID peptides 
Peptide  [M+2H]2+ Obsd  [M+2H]2+ Expd  [M+3H]3+ Obsd  [M+3H]3+ Expd  
BID WT  1359.7318  1359.7253  906.8313  906.8193  
BID-Aib  1337.2347  1337.2328  891.8258  891.8243  
BID-DU  1391.2777  1391.2798  927.8572  927.8556  
BID-DM  1377.2529  1377.2641  918.5114  918.5118  
BID-MU  1377.2619  1377.2641  918.5161  918.5161  
BID-MM  1363.2338  1363.2485  909.1673  909.1673  
 
4.4.1.3 hCys BID 
Homocysteine BID peptides were oxidised to an intramolecular disulfide 
in the presence of Diamide (5 equiv.) or reduced to the free thiols by TCEP (5 
equiv.). 
Peptide  [M+3H]3+ Obsd  [M+3H]3+ Expd  [M+4H]4+ Obsd  [M+4H]4+ Expd  
BID hCys OX 912.4684  912.4677 684.6083  684.6028 
BID hCys RED  913.1407  913.1396 685.1077  685.1067 
BID hCys MAL 944.1281 944.1341 708.3517 708.3524 
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BID hCys SUC 944.8036 944.8046 708.8556 708.8563 
 
4.4.1.4 FITC labelled BID peptides 
Peptide  [M+4H]4+ Obsd  [M+4H]4+ Expd  [M+5H]5+ Obsd  [M+5H]5+ Expd  
BID WT*  795.3939 795.3942 636.5157 636.5169 
BID Aib* 773.6356 773.6362 619.1093 619.1105 
BID DM* 793.6513 793.6518 635.1209 635.1230 
BID MM* 786.6422 786.6440 629.5143 629.5166 
 
4.4.1.5 BIM BH3 peptides 
Peptide  [M+3H]3+ Obsd  [M+3H]3+ Expd  [M+4H]4+ Obsd  [M+4H]4+ Expd  
BIM WT  894.4736 894.4735 671.1072 671.1069 
BIM DM 882.8175 882.8150  662.3624 662.3662 
 
Peptide  [M+3H]3+ Obsd  [M+3H]3+ Expd  [M+2H]2+ Obsd  [M+2H]2+ Expd  
BIM MM 873.4713 873.4712 1309.7027 1309.7032 
 
4.4.1.6 Im7 peptides 
Peptide  [M+3H]3+ Obsd  [M+3H]3+ Expd  [M+4H]4+ Obsd  [M+4H]4+ Expd  
Fragment 3 1077.2106 1077.2168 808.1551 808.1597 
 
Peptide  [M+3H]3+ Obsd  [M+3H]3+ Expd  [M+4H]4+ Obsd  [M+4H]4+ Expd  
Fragment 2 
Acid 
1154.2286 1154.2233 - - 
Fragment 2 
Thioester 
1189.2355 1189.2351 892.1781 892.1793 
 
Peptide  [M+3H]3+ Obsd  [M+3H]3+ Expd  [M+4H]4+ Obsd  [M+4H]4+ Expd  
Fragment 1 
Acid 
1408.0194 1408.0186 1056.2665 1056.2656 
 
Peptide  [M+6H]6+ Obsd  [M+6H]6+ Expd  [M+5H]5+ Obsd  [M+4H]4+ Expd  
Fragment 1 
Nbz 
731.0200 731.0201 877.0232 877.0227 
 
4.5 Biophysical Analysis Protocols 
4.5.1 Enzymatic Degradation 
Peptides were dissolved in PBS Buffer (0.01 M, pH 7.47) at 
concentrations of 200 μM, from the dilution of a main stock of the peptide in 
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DMSO (typically 1-5 mM). Trypsin (Promega, Sequencing Grade) was made into 
a 0.01 nM stock. 60 μL of each stock were added and mixed and the digestion 
monitored by HPLC at 25 °C, with aliquots removed after 0, 5, 12, 21, 45 and 90 
minutes and the digestion quantified by the integration of the peak at 220 nm 
corresponding to undigested peptide. The HPLC used an Ascentis Analytical 
Peptide Column (20 μL injection, 0.5 mL min-1 flow rate, 5-95% 
acetonitrile:water gradient, 5.5 min run time). Experiments were done in 
duplicate, and assume first order kinetics. The HPLC time points were 
converted into a percentage of the original substrate (S), and plotted as a 
natural logarithm (lnS) against time (t) in minutes. Half lives (t1/2) were 
calculated by dividing –ln(2) by the slope of the graph, plotted in Origin 8. 




    
 
 
4.5.2 Circular Dichroism 
4.5.2.1 Fixed temperature CD 
Circular Dichroism was performed on an Applied Photophysics 
ChiraScan Apparatus and Software. For each scan, the following parameters 
were used: 180-260 nm range; point time 1 s; 1 nm per point; step = 1; 
bandwidth 5 nm; path length 10 mm; temperature 20 °C. Scans were done in 
triplicate. Samples were dissolved in 1:4 acetonitrile:50 mM sodium phosphate 
buffer pH 7.50 to concentrations between 5 - 20 μM. DMSO stocks of peptides 
were not used for CD due to its high absorbance below 230 nm. The raw 
circular dichroism data obtained for the peptides was processed by the 
subtraction of the solvent signal and converted into a mean residue ellipticity: 
     
 
      
 
        
   




Where θ = circular dichroism at a given wavelength, c = molar 
concentration, l = path length in cm, R = number of residues in the peptide 
sequence. 
Calculation of % Helicity was performed by the following equation:167 
          
  
  
       
 
  
   
Where: Θ = Theoretical MRE for 100% helicity at 222 nm, Θ(0) = 
Theoretical MRE for 100% helicity at 222 nm at 0 °C = -44000, (∂Θ/∂T) = 
temperature dependence of infinite helix = +250, T = temperature in °C, x = 3, 
Nr = number of residues in a peptide. 






4.5.2.2 Temperature ramped CD 
The apparatus and settings were the same as those in 4.5.2.1, except for 
the temperature, which increased in steps of 1 °C, with an equilibration time of 
3 minutes between the rising of the temperature to the reading of the 
spectrum. The temperature was increased to a maximum of 72 °C with a final 
reading taken after the chamber had cooled to 20 °C to verify the reversibility 
of the unfolding. The data was processed into mean residue ellipticity as 
described in 4.5.2.1, with the following additions for the calculations of the 
fraction of the unfolded peptide: 
   
        
      
 
Where α = Fraction Unfolded; Θf = MRE at T = 20 °C; Θu = MRE at 
T = 72 °C.  
4.5.3   Fluorescence Anisotropy 
4.5.3.1 General regards 
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The buffers used for fluorescence anisotropy were either phosphate 
buffer (40 mM sodium phosphate, 200 mM sodium chloride, 0.02 mg ml-1 
bovine serum albumin, pH 7.50) or Tris buffer (50 mM Tris, 140 mM sodium 
chloride, pH 7.50). Phosphate buffer was used for all competition assays and 
the direct binding assays for NoxaB*/Mcl-1, BAK*/Bcl-xL and p53*/hDM2. Tris 
buffer was used for all FITC labelled BID peptides in direct binding experiments 
with Mcl-1 and Bcl-xL.  
Assays were run in 96 or 384 well Optiplates and were scanned using a 
Perkin Elmer EnVisionTM 2103 MultiLabel plate reader. Fluorescein labelled 
peptides used an excitation and emission wavelength of 490 nm and 535 nm 
respectively whilst BODIPY labelled peptides used an excitation and emission 
wavelength of 531 nm and 595 nm respectively, with a bandwidth of 5 nm.  
4.5.3.2 96 well plate competition assay protocol 
For competition assays using 96 well plates and a 2/3 dilution regime, 
solutions were added into 6 rows, 3 assay and 3 control wells: 
1) 50 µL buffer added to all wells 
2) 100 µL of inhibitor added to the first well of a row and 100 µL mixed 
and transferred to the adjacent well to achieve a serial dilution 
3) 50 µL of fluorescently labelled peptide to each of the 'assay' wells 
4) 50 µL of buffer to the 'control' wells 
5) 50 µL of protein to every well.  
4.5.3.3 384 well plate direct binding assay protocol 
For a 2/3 dilution regime of a direct binding assay in 384 well plates, the 
following volumes of solutions were added to 3 'assay' rows and 3 'control' 
rows. 
1) 20 µL buffer added to all wells 
2) 40 µL of titrant added to the first well of a row, with 40 µL transferred 
down the row to achieve a serial dilution. 
3) 20 µL of fixed component to each of the 'assay' wells 
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4) 20 µL of buffer to the 'control' wells 
In 'protein titrations' the protein is the titrant, with the fluorescently 
labelled peptide the fixed component in the assay. These roles are reversed in a 
'peptide titration'. For a 3/4 dilution regime, which was employed in some of 
the FITC BID assays, 60 µL of titrant was added and serially diluted. 
4.5.3.4 384 well plate competition assay protocol 
 For competition assays using 384 well plates and a 2/3 dilution regime, 
solutions were added into 6 rows, 3 'assay' and 3 'control' wells: 
1) 20 µL buffer added to all wells 
2) 60 µL of inhibitor added to the first well of a row and 60 µL mixed and 
transferred to the adjacent well to achieve a serial dilution 
3) 20 µL of fluorescently labelled peptide to each of the 'assay' wells 
4) 20 µL of buffer to the 'control' wells 
5) 20 µL of protein to every well. 
4.5.3.5 Processing of fluorescence anisotropy data 
After reading the plates, the fluorescence anisotropy data was processed 
using Microsoft Excel to calculate intensity, anisotropy and fraction bound: 
        
   
    
 
 
    
        
                     
 
r = anisotropy, I = total intensity, P = perpendicular intensity, S = parallel 
intensity, Lb = fraction ligand bound, λ = Ibound/Iunbound , G = 1= instrumental 
factor.     
This data was then transferred into Origin 8 which could fit the data to 
either a logisitic model (for the calculation of IC50 and EC50) or to the Kd model 
for the extraction of Kd values: 
         
          





                                    
 
 
Where for the logisitic model; y = r = anisotropy, xo = mid-point of the 
curve between the rmax and rmin plateaux.  
For the Kd model; y = Lb*[FL], K = Kd, [FL] = Concentration of fluorescent 
ligand.  
4.5.3.6 van't Hoff analysis of fluorescence anisotropy data 
The van't Hoff analysis of the fluorescently labelled BID peptides was 
done by following the protocol outlined in 4.5.4.4. After incubation of the plates 
until the lower anisotropy plateau had equilibrated (between 4-24 hours), the 
plates were scanned at 20 °C, then the temperature in the plate reader 
increased in steps of 5 °C, with a 5 minute equilibration time before the plate 
was read at each increasing temperature. Between 45 and 50 °C, the plate 
reader was at its limit for heating, therefore the plate was read at the maximum 
temperature that the plate reader could reach after 15 minutes, to reduce the 
evaporation of the buffer in the wells.  
The data was processed as described in 4.5.3.5 and plotted as its EC50 
against 1/T.  
4.5.4 Specific protocols for fluorescence anisotropy assays 
4.5.4.1 p53*/hDM2 competition assays 
p53*/hDM2 competition assays were performed in 96 well plates as 
outlined in 4.5.3.2 in phosphate buffer. The concentration of the inhibitor 
started at 100 µM and was diluted over 24 wells to a final concentration of 10 
nM, with the maximum concentration of hDM2 and p53* being 162 nM and 54 
nM respectively in individual wells. Plates were read after 1 h of incubation. 
4.5.4.2 NoxaB*/Mcl-1 direct binding assays 
NoxaB*/Mcl-1 direct binding assays were performed in 96 well plates as 
outlined in 4.5.3.2 in phosphate buffer. In protein titrations, [Mcl-1] started 
from 10 µM and was diluted over 24 wells, with [NoxaB*] fixed at 25 nM. In 
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peptide titrations, [NoxaB*] started at 5 µM and was diluted over 24 wells with 
[Mcl-1] fixed at 25 nM. Plates were read after 1 h of incubation.  
4.5.4.3 BAK*/Bcl-xL direct binding assays 
BAK*/Bcl-xL direct binding assays were performed in phosphate buffer 
in 384 well plates (4.5.3.3). In the protein titration, [Bcl-xL] started from 3 µM 
and was diluted over 24 points with [BAK*] fixed at 25 nM. In the peptide 
titration, [BAK*] started at 3 µM and was diluted over 24 points with [Bcl-xL] 
fixed at 25 nM. Plates were read after 4 hours of incubation. 
4.5.4.4 BID*/Mcl-1 and BID*/Bcl-xL direct binding assays 
For all variants of the labelled BID peptides (WT*, MM*, DM* and Aib*), 
the direct binding assays were performed in Tris Buffer in 384 well plates as 
described in 4.5.3.3. In protein titrations, the protein concentration started 
from between 1-10 µM and was diluted over 24 points in a 3/4 dilution regime, 
with the concentration of the labelled peptide fixed at 25-100 nM. In the 
peptide titrations, the concentration of the labelled peptides started from 5 µM 
and were diluted in a 2/3 regime over 24 points, with the concentration of the 
protein fixed at 50 nM. Plates were read after 2 hours of incubation, and read 
again after 4 and 18 hours to ensure complete equilibration. 
4.5.4.5 NoxaB*/Mcl-1 competition assays 
NoxaB*/Mcl-1 competition assays were performed in either 96 well 
plates (4.5.3.2) or 384 well plates (4.5.3.4) in phosphate buffer, with the 
concentration of the inhibitor typically starting from 5-100 µM, diluted over 24 
points in a 2/3 regime and with [NoxaB*] and [Mcl-1] fixed at 50 nM and 
150 nM respectively. Plates were read after 1 h. 
4.5.4.6 BAK*/Bcl-xL competition assays 
BAK*/Bcl-xL competition assays were performed in 384 well plates in 
phosphate buffer (4.5.3.4) with the concentration of the inhibitor typically 
starting from 5-50 µM, diluted over 24 points in a 2/3 regime with [BAK*] and 
[Bcl-xL] fixed at 43 nM and 131 nM respectively. Plates were read after 1 h of 
incubation.        
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4.5.5 Isothermal Titration Calorimetry 
Mcl-1 or Bcl-xL were dialysed in phosphate buffer containing DMSO 
(40 mM sodium phosphate, 200 mM sodium chloride, 1% v/v DMSO, pH 7.50) 
and the BID peptides were dialysed in the same buffer at a concentration ~15× 
higher than that of the protein. Dialysis was performed at 4 °C overnight, and 
the final concentration of the protein and peptides verified by UV-Vis 
Spectrophotometry. A calorimetric run was performed with one injection of 0.5 
μL after 90 seconds, followed by twenty injections of 2 μL and a 120 second gap 
between injections against water as a reference at 25 °C with the cell contents 
were stirred at 1000 rpm. 60 μL of peptide solution was prepared in the 
syringe, with 200 μL of protein solution in the cell. ITC experiments also 
included a control of peptide being injected into phosphate buffer to account 
for heat changes associated with dilution. Measurements were done on a micro-
iTC 200 from Microcal (GE Healthcare) provided by the Wellcome Trust. The 
thermodynamic calculations and curve fitting was done using ITC-Origin 
software. 
4.6 Protein Expression of Bcl-xL 
The pGEX Bcl-xL ‘no loop’ construct was kindly provided by Prof W. D. 
Fairlie (The Walter and Eliza Hall Institute for Medical Research, Victoria, 
Australia). The pGEX Bcl-xL ‘no loop’ construct was over-expressed in the E.coli 
strain Rosetta 2. 15 ml of overnight starter culture was used to inoculate 1 L 2 
xYT containing 100 μg mL-1 Ampicillin. Cultures were grown at 37 °C plus 
shaking until OD600 ~ 0.6 – 0.8, the temperature was then switched to 18 °C and 
protein expression induced by the addition of 0.8 mM IPTG. Induced cultures 
were grown at 18 °C plus shaking overnight before harvesting by 
centrifugation. Cells were resuspended in 20 mM sodium phosphate, 140 mM 
NaCl, pH 7.5 containing 0.1% Triton X-100 and lysed by sonication in the 
presence of 10 μL of 1 U.ml-1 DNase I per litre of over-expression culture and 
5 mM MgCl2. DTT was then added to the lysed cells to give a final concentration 
of 1 mM. The cell lysate was centrifuged (Beckman JA25.50 rotor, 17000 rpm, 
30 min, 4 °C) and the supernatant filtered (0.22 μM syringe filter) before mixing 
with 5ml of Glutathione Superflow (SuperGlu) resin (Generon) at 4 °C for 1 
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hour. The resin had previously been equilibrated with 5 column volumes (CV) 
of 20 mM Sodium Phosphate pH 7.5, 140 mM NaCl, 1 mM DTT (low salt buffer). 
The cleared cell lysate was then allowed to flow through the SuperGlu resin 
under gravity flow. The resin was then washed with 5 CV of low salt buffer 
followed by 7 CV of 20 mM sodium phosphate pH 7.5, 1 M NaCl, 1 mM DTT 
(high salt buffer) and a further 7 CV of low salt buffer.  
One half of the fusion protein was retained for future experiments and 
the remaining GST-Bcl-xL fusion protein was cleaved on the resin. 10 ml of low 
salt buffer was added to the resin along with 3 x 100 μL aliquots of PreScission 
protease (prepared by H. Kyle). The resin was mixed gently at 4 °C overnight. 
To remove any cleaved Bcl-xL ‘no loop’ protein the column was washed with 6 
CV followed by 5 CV of low salt buffer. The resin was then washed with 6 CV of 
20 mM sodium phosphate pH 7.5, 140 mM NaCl, 20 mM reduced glutathione to 
remove the GST tag. The eluent from each step was collected and samples run 
on a 15% SDS-PAGE gel.  
The eluent fraction containing cleaved Bcl-xL ‘no loop’ was concentrated 
(Amicon Ultra centrifugal filter, MWCO 3500) to approximately 5 ml. The 
sample was then filtered before being loaded onto a Superdex 75 column (GE 
healthcare) equilibrated in 40 mM sodium phosphate, 140 mM NaCl, 5% 
glycerol, 1 mM DTT, pH 7.5. The purified Bcl-xL ‘no loop’ was concentrated to 
and stored at – 80 °C. From a 10 L growth, 9.1 mg of GST-Bcl-xL 'no loop' and 
4.9 mg of Bcl-xL 'no loop' was afforded. 
4.7 X-Ray Crystallography 
4.7.1     Alkylated Ni-Gly-BPB Complex 46 
Diffraction and solving was performed by Dr. C. Pask at the School of 
Chemistry XRD service at the University of Leeds. Measurements were carried 
out at 100K on an Agilent Supernova diffractometer equipped with an Atlas 
CCD detector and connected to an Oxford Cryostream low temperature device 
using graphite monochromated Cu K radiation ( = 1.54184 Å) from a 
Microfocus Nova X-ray source. The structure was solved by direct methods 
using SHELXS208 and refined using SHELX97. 
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The compound crystallised as orange plates in a monoclinic cell and was 
solved in the P21 space group, with two molecules in the asymmetric unit. Most 
non-hydrogen atoms were located in the Fourier Map and refined 
anisotropically. There was disorder around the aromatic ring of one of the 
benzyl groups (C34 to C39). This was refined as two rings each with 50% 
occupancy. C34, C35A to C39A and C35B to C39B were refined isotropically. All 
hydrogen atoms were placed in calculated positions and refined isotropically 
using a “riding model”. 
During the data collection and reduction, Friedel pairs were unmerged, 
allowing determination of the stereochemistry of the complex. The Flack 
parameter,209 -0.005(12) indicates the correct stereochemistry has been 
determined.     
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Chapter 6  
Appendix I 
HPLC and MS Data for all peptides 
The mass spectra were obtained from the LCMS facilities described in 
4.2.1, where the reported peak is the most abundant isotope. In this instance, 





Figure 6.6.1 - MS data shows [M+H+Na]2+ at 1112.0. The peaks at 1526.4 and 674.1 are 





BID BH3 Series 
BID WT 
 
Figure 6.2 - p53MM HPLC and MS data. The MS shows [M+H+Na]2+ at 1097.8. The 


































Figure 6.8 - MS data shows [M+4H]4+ at 696.73, [M+3H]3+ at 928.48 and [M+2H]2+ at 
1392.05.  











Figure 6.10 - The HPLC trace has been broadened and appears to have breaks in the 
peak, which may have arisen from the use of mixed isomers of FITC for this peptide. 













Figure 6.12 - MS data shows the [M+4H]4+ at 635.46, [M+3H]3+ at 794.18 and [M+2H]2+ 
at 1058.37. 
hCys BID Series 
BID hCys OX 
 
 
Figure 6.13 - MS data shows [M+4H]4+ at 685.05 and [M+3H]3+ at 913.08. 





Figure 6.14 - MS data shows [M+4H]4+ at 685.51 and [M+3H]3+ at 913.73. 
BID hCys SUC 
 
 
Figure 6.15 - MS data shows [M+4H]4+ at 709.33 and [M+3H]3+ at 945.49. 




Figure 6.16 -MS data of isolated BID hCys MAL, but the purity of the peptide was 
insufficient for complete characterisation. Data shows [M+4H]4+ at 708.86 and 
[M+3H]3+ at 944.73. 







Figure 6.17 -On Analytical HPLC, BIM WT appeared to have two UV peaks, but further 
analysis with LCMS and altering the HPLC gradient did not separate these peaks out 
further. Using Loop and LCMS identified only the target peptide with no other species 










Figure 6.19 - MS Data shows [M+3H]3+ at 883.35 and [M+2H]2+ at 1324.30. 






Figure 6.20 - MS Data shows the [M+5H]5+ at 647.1,[M+4H]4+ at 808.5 and [M+3H]3+ at 
1077.6. 
Fragment 2 C-terminal acid (crude trace) 
 
 
Figure 6.21 - The MS data was obtained after the deprotection of the side chains of the 
peptide with TFA, with the HPLC trace being the fully protected peptide. MS data 
displays [M+4H]4+ at 866.0 and [M+3H]3+ at 1154.3.  





Figure 6.22 - MS data displays [M+4H]4+ at 892.87 and [M+3H]3+ at 1190.19. 





Figure 6.23 - The MS data was obtained after the deprotection of the side chains of the 
peptide with TFA, with the HPLC trace being the fully protected peptide. MS data 
displays [M+6H]6+ at 707.5, [M+5H]5+ at 848.7 and [M+4H]4+ at 1060.6.  
Im7 Fragment 1 C-terminal Nbz 
 
 
Figure 6.24 - MS data shows [M+5H]5+ at 731.52,[M+4H]4+ at 877.71 and [M+3H]3+ at 
1096.83, with traces of the Nbz group hydrolysing during the MS - this is also visible 





Appendix II  
6.1 Unstapled BID BH3 Peptide Biophysical Data 
The unstapled BID BH3 peptides were assessed for their secondary 
structure in solution, enzymatic degradation resistance and inhibition potency 
of Bcl-xL/BAK* (experimental procedures reported: 4.5).  
The unstapled peptides generally possessed a random coil conformation 
in aqueous solution (30% acetonitrile in 40 mM phosphate buffer, pH 7.5) with 
low helical content, but the profile of the CD curve of BID DU appeared to be 
more helical than BID MU – suggesting that there is some helical induction of 
the peptide by the quaternary disubstituted amino acid. BID DU and MU were 
effective inhibitors of Bcl-xL/BAK*, but their potencies were weaker than the 
BID WT and stapled BID peptides, which suggested that changing the native 
peptide sequence with olefinic amino acids is unfavourable to binding, but 
constraining the peptide mitigates this binding penalty. This was consistent 
with the stapled p53 investigation. The unstapled peptides also had a slight 
improvement of proteolytic resistance compared to BID WT, but this was less 
than the BID Aib peptide.   
Peptide % Helicity IC50 Bcl-xL/BAK* Trypsin t1/2 
BID MU 17  2.48 ± 0.11 μM 25.1 mins 





Figure 6.25 – Circular Dichroism, Bcl-xL/BAK* assay and proteolytic degradation data 
of the unstapled MU and DU BID BH3 peptides. 
6.2  Additional Fluorescence Anisotropy Data 
6.2.1 Complications in Ki calculation  
The fluorescence anisotropy assays have an intrinsic limitation that precludes 
the calculation of a dissociation constant or inhibition constant (Kd or Ki) in 
competition mode. The assay does not occur in a two state equilibrium between 
174 
 
the free tracer/inhibitor or protein and protein-ligand complex. Additional 
contribution to anisotropy arise from homo-aggregates of the tracer (r1, Figure 
6.26 a) and hetero tracer-inhibitor aggregates (r2, Figure 6.26 a). In the direct 
binding experiment, the contribution from r1 is added to the theoretical 
minimum (r0) to give a higher than expected experimental minimum (rmin, 
green curve, Figure 6.26 b).  
 
Figure 6.26 - Complex equilibria preclude Kd determination. a) Cartoon of the 
equilibria in the assay and highlighting the anisotropy contributions; b) Experimental 
(green) and theoretical (red) anisotropies in a direct binding experiment, which 
highlight the contribution of r1 to rmin; c) anisotropy of the competition assay 
highlighting the r0 and r2 contributions to r'.  
 In competition mode, the anisotropy of hetero-aggregates (r2) adds to 
the overall minimum r'. Since r2 < r1, the competition assay minimum r' differs 
from rmin, which precludes the correct determination of the anisotropy limits to 





6.2.2 Establishing Mcl-1/NoxaB* direct binding assays 
The assay development of Mcl-1/NoxaB* was performed in 
collaboration with Dr. K. Long and V. Azzarito. To test inhibitors of Mcl-1 
protein-protein interactions, a direct binding assay was established that 
avoided the complications of the long equilibration time that was experienced 
with the labelled BID and BAK peptides. NoxaB*, a 16mer BH3 peptide, 
required no prior addition of DMSO before its dilution into assay buffer. The 
protein titration experiment of Mcl-1 using 25 nM of NoxaB* afforded a Kd of 
18.7 ± 0.9 nM, which is consistent with what has been previously reported.6, 189 
Unlike the BID* and BAK* BH3 peptides, NoxaB* required only 1 hour of 
incubation with Mcl-1 – where longer incubation times did not affect the 
observed anisotropy plateaux. In this experiment, deviation of the pH of the 
assay buffer from 7.0−8.0 abolished the binding of NoxaB* to Mcl-1. 
 
Figure 6.27 – Protein Titration of Mcl-l into NoxaB* displaying: a) Anisotropy change; 
b) Kd model curve. Peptide Titration of NoxaB* into Mcl-1 displaying c) Anisotropy 
change; d) Kd model curve. 
The peptide titration afforded a Kd of 13.0 ± 2.29 nM but this experiment 
was complicated by the saturation of the plate reader detector at higher 
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concentrations of NoxaB* and increased noise at lower concentrations of 
NoxaB*. This direct binding experiment was transferred for the testing of 
inhibitors of Mcl-1/NoxaB*.   
6.2.3 Testing of BAD, BAK and NoxaB peptides 
The Wilson laboratory had previously synthesised other BH3 domains of 
proteins of the Bcl-2 family, which have selective binding to certain members of 
the Bcl-2 pro-apoptotic proteins. These BH3 peptides were tested against Mcl-1 
and Bcl-xL to confirm their reported specificities. The assays were performed as 
described in 4.5.4.  
 
Figure 6.28 – a) Specificities of the BH3 protein family, including the pan-BH3 binding 
BID and BIM proteins; b) Sequences of the fluorescently labelled and unlabelled BAK, 





BH3 Peptide IC50 Bcl-xL/BAK* IC50 Mcl-1/NoxaB* 
NoxaB No Inhibition 0.70 ± 0.03 μM 
BAD 0.14 ± 0.01 μM No Inhibition 
BAK > 50 μM No Inhibition 
Figure 6.29 – a) Competition assay curves for the inhibition of Bcl-xL/BAK* with NoxaB 
(black), BAD (red) and BAK (blue); b) Competition curve of Mcl-1/NoxaB* inhibited by 
NoxaB and c) Assay results of the inhibition of Mcl-1/NoxaB* by BAK (blue) and BAD 
(red). 
The competition assay results confirmed that BAD and NoxaB are 
selective for Bcl-xL and Mcl-1 respectively. The surprising result was the poor 
inhibition of Bcl-xL/BAK* with unlabelled BAK, considering that BODIPY 
labelled BAK* binds to Bcl-xL with a Kd of 4 nM (3.6.3.1). Also, BAK did not 
inhibit Mcl-1/NoxaB* despite literature precedent suggesting that the BAK 
protein is capable of binding to Mcl-1.  
In the instances of the unlabelled peptides that did not inhibit a protein-
protein interaction in the competition assays, a labelled analogue was used in 




Figure 6.30 – Negative controls of a) CF-BAD* with Mcl-1; b) BODIPY-BAK* with Mcl-1 
and c) FITC-NoxaB* with Bcl-xL 
The direct binding assays confirmed the selectivity profiles of NoxaB 
and BAD, whilst the labelled BAK* peptide did not bind to Mcl-1 in a similar 
result to the Mcl-1/NoxaB* competition assay with unlabelled BAK.  
6.2.4 CF-BAD Direct Binding Assays 
Direct binding assays were attempted with carboxy-fluorescein labelled 
BAD (CF-BAD), but assay development was hampered by the critical 
insolubility of the peptide. Assay stocks of CF-BAD at a 1 mM concentration 
required 20% DMSO to maintain a solution. Protein titrations performed in 
phosphate buffer did not show any change in anisotropy, which led to the 
change of assay buffer to Tris, which had proven successful for the labelled BID 
peptide series. The assay in Tris buffer gave some evidence of a transition in 
anisotropy, but turbidity of the solutions in the wells at higher concentrations 
of Bcl-xL led to the anisotropy signal falling. Therefore, neither Kd nor EC50 were 




Figure 6.31 – Protein titration of Bcl-xL into CF-BAD, with a) phosphate buffer (40 mM 
sodium phosphate, 200 mM NaCl, 0.02 mg ml-1 BSA, pH 7.50) and b) Tris buffer (50 
mM Tris, 140 mM NaCl, pH 7.50).  
6.2.5 FITC-BID Peptide Titration Experiments 
As referred in 3.6.3 and 3.11, direct binding fluorescence anisotropy 
experiments are performed with two different titrations; protein and peptide 
titrations. Generally, the anisotropy minima and maxima of a ligand:protein 
interaction are extracted from the protein titration, which are transferred into 
the peptide titration to calculate Kd (4.5.3.5). However, the peptide titration is 
limited by the saturation of the plate reader detector at high concentrations of 
fluorophore and poor signal-to-noise ratio at low concentrations of 
fluorophore. As a result, the Kd values for the FITC labelled BID peptides and 
Mcl-1 or Bcl-xL were calculated from the protein titration.  
The protein concentration in the experiments was set at 100 nM, and the 
FITC labelled peptides were titrated from a concentration of 5 μM, with the 
experiment performed in Tris buffer. Plates were read after 2 h of incubation 
and rechecked after 18 h.   
6.2.5.1 BID WT* Peptide Titrations 
BID WT* demonstrated the problem with saturation and signal-to-noise 
in the Mcl-1 peptide titration, but a transition was observed and Kd calculated 
as 70.6 ± 15.0 nM (protein titration: 51 ± 19.9 nM). Against Bcl-xL, there were 




Figure 6.32 – a) Anisotropy and b) Kd data of BID WT*/Mcl-1 direct binding 
experiments; c) anisotropy of BID WT*/Bcl-xL 
6.2.5.2 BID Aib* Peptide Titrations 
BID Aib* provided the best data for the peptide titration experiments 
with Mcl-1, with a clear transition observed and a Kd calculated at 15.4 ± 2.7 nM 
(protein titration: 66.2 ± 19 nM). Whilst the peptide titration with Bcl-xL has 
evidence of a change in anisotropy, the Kd model did not fit well, with a Kd 




Figure 6.33 – a) Anisotropy and b) Kd data for the Mcl-1/BID Aib* peptide titration; c) 
anisotropy and d) Kd data for the Bcl-xL/BID Aib* peptide titration. 
6.2.5.3 BID DM* Peptide Titration Experiments 
The peptide titration of BID DM* with Mcl-1 allowed a Kd of 17.2 ± 3.7 
nM to be calculated (protein titration: 107 ± 23 nM) and 14.0 ± 2.7 nM with 
Bcl-xL (protein titration: 168 ± 19 nM). Considering the large difference in the 
Kd values calculated between the protein and peptide titration, the Kd  values 
from the protein titration were used in the discussions of the peptides, since 




Figure 6.34 – a) Anisotropy and b) Kd data for Mcl-1/BID DM* peptide titration; c) 
anisotropy and d) Kd data for the Bcl-xL/BID DM* peptide titration.  
6.2.5.4 BID MM* Peptide Titration 
For BID MM*, there was no observed transition in the anisotropy data 
for either Mcl-1 or Bcl-xL which precludes the calculation of Kd. This particular 
peptide suffered from poor signal-to-noise below 100 nM, which is the 




Figure 6.35 - a) Anisotropy of Mcl-1/BID MM* peptide titration. and b) expansion of 
the region beween 10-10000 nM; c) anisotropy of Bcl-xL/BID MM* peptide titration.  
6.2.6   Raw Anisotropies of FITC BID Protein Titrations 
The anisotropies of the protein titrations of the FITC BID series (3.11.1.1 
and 3.11.2) are included below. It was evident that the rmax and rmin obtained in 
the protein titration experiment were different to those from the peptide titration 
experiment, which rendered the two assays incompatible to calculate Kd together. 




Figure 6.36 – Protein titration anisotropy curves for: a) BID WT*/Mcl-1; b) BID 
WT*/Bcl-xL; c) BID Aib*/Mcl-1; d) BID Aib*/Bcl-xL; e) BID DM*/Mcl-1; f) BID DM*/Bcl-






Additional Biophysical Data 
6.3 Thermal Ramping Circular Dichroism Data 
The circular dichroism curves of BID WT, Aib, DU and MU are included 
below during the thermal ramping experiment (Figure 6.37). BID WT, MU and 
Aib displayed little change in their profiles at higher temperatures, which is not 
surprising considering that their CD profiles at 20 °C were predominantly 
random coil. At 20 °C, BID DU appeared to have a CD profile that suggested an 
α-helical conformation (6.1) but its % helicity was 20%. As the temperature of 
the measurement chamber increased, this apparent helical content did decay to 
a random coil profile, but, like the BID MM and BID DM peptides, the unfolding 









6.4 Isothermal Titration Calorimetry (ITC) 
ITC was attempted for BID DM, BID MM and BID WT*, following the 
conditions as described in 4.5.5. The precipitation of BID DM and BID MM in the 
syringe was responsible for the poor data observed, which was not improved 
by performing the experiment with peptide present in the cell and the protein 
in the syringe.  
Figure 6.38 – ITC thermograms of BID MM (300 μM) with a) Mcl-1 (30 μM) and b) Bcl-





Figure 6.39 – ITC thermograms of BID DM (250 μM) with a) Mcl-1 (30 μM) and b) Bcl-
xL (35 μM).  
 
Figure 6.40 – ITC thermograms of BID WT* (300 μM) with a) Mcl-1 (30 μM) and b) Bcl-






Protein Expression Data 
To supplement sections 3.5.2 and 4.6  
 
Figure 6.41 – SDS-PAGE Gel of the expressed GST-Bcl-xL (no loop); The flow through 
was the loading of the GST Superflow resin; W1 and W3 were ‘low salt’ washes (20 mM 
sodium phosphate pH 7.5, 140 mM NaCl, 1 mM DTT); W2 was a ‘high salt’ wash (20 
mM sodium phosphate pH 7.5, 1 M NaCl, 1 mM DTT); GT was the elution with 20 mM 
reduced glutathione to afford GST-Bcl-xL fusion protein cleanly; ‘cut’ was the mixture 
after the use of PreScission Protease to remove the GST tag from Bcl-xL. 
 
 
Figure 6.42 – SDS-PAGE Gel of the gel filtration column fractions of Bcl-xL ‘no loop’ 





Additional in cellulo data 
The following data complements the findings described in 3.14.  
 
Figure 6.43 - FACS analysis of paediatric glioblastoma cells treated with FITC-labelled 
BID peptides in serum-free media for a) BID WT*; b) BID Aib*; c) BID DM*; d) BID 
MM*. The curves represent DMSO vehicle (red), 2 h incubation (black), 4 h incubation 
(green) and 24 h incubation (blue). 
 SF188 paediatric glioblastoma cells were incubated with FITC-labelled 
WT and modified BID peptides for 2, 4 or 24 hours in serum-free media 
(10µM), followed by washing, digestion with trypsin and FACS analysis to 
assess cellular fluorescence.  Cells treated with all FITC-labelled peptides 
displayed increased cellular fluorescence compared to cells treated with vehicle 
only (0.1% (v/v) DMSO) despite a 20 minute digestion with 1x trypsin at 37°C 
in order to reduce non-specific binding of peptides to cell surface proteins. 
However, cells treated with stapled derivatives did display increased cellular 
fluorescence compared to cells treated with BID WT*, particularly after 24 
hours. As described in 3.14, confocal microscopy is required to validate cell 




Figure 6.44 - Effect of unlabelled BID peptides on glioblastoma cell viability in serum 
containing (top) and serum-free media (bottom).  
The stapled BID DM and BID MM peptides had a limited effect on cell 





6.5 X-ray Crystallographic Data 
6.5.1 Alkylated Ni-Gly-BPB complex 46 
The diffraction and structure solving was performed by Dr. C. Pask at the 
School of Chemistry X-ray service at the University of Leeds. 
Empirical formula  C32H33N3NiO3  
Formula weight  566.32  
Temperature/K  99.9(3)  
Crystal system  monoclinic  
Space group  P21  
a/Å  11.07980(8)  
b/Å  21.99770(13)  
c/Å  11.88015(9)  
α/°  90.00  
β/°  102.0025(7)  
γ/°  90.00  
Volume/Å3  2832.25(3)  
Z  4  
ρcalcmg/mm3  1.328  
m/mm-1  1.284  
F(000)  1192.0  
Crystal size/mm3  0.15 × 0.07 × 0.04  
Radiation  CuKα (λ = 1.54184)  
2Θ range for data collection  7.6 to 133.2°  
Index ranges  -13 ≤ h ≤ 12, -26 ≤ k ≤ 26, -14 ≤ l ≤ 14  
Reflections collected  21899  
Independent reflections  10002 [Rint = 0.0253, Rsigma = 0.0327]  
Data/restraints/parameters  10002/1/693  
Goodness-of-fit on F2  1.037  
Final R indexes [I>=2σ (I)]  R1 = 0.0274, wR2 = 0.0688  
Final R indexes [all data]  R1 = 0.0285, wR2 = 0.0696  
Largest diff. peak/hole / e Å-3  0.36/-0.23  






6.5.2 BID MM in complex with Mcl-1 
N.B. The optimisation of the resolved structure was still being performed 
at the time of writing.  
The crystal growth and diffraction was performed by Dr. J. Miles. 
Structure solution was perfomed by Dr. J. Miles, Dr. T. Edwards and D. 
Monteiro. The Mcl-1 in complex with BID was at 12 mg mL-1. The trays were 
stored at 4 °C. Crystals were optimised in a 1:1 drop of 18% PEG 20,000, 0.1 M 
Tris, pH 8.0, and the crystals were cryoprotected with 30% glycerol. 
 Diffraction data was collected from Diamond Light Source to 1.43 Å. The 
structure was solved using molecular replacement and the staple built as 
previously described in the literature.  
Parameters:  
 The unit cell dimensions are 80.83 Å, 37.020 Å and 56.920 Å.  
 The angles are 90.0°, 90.0° and 90.0°.  
 The space group is P 21 21 2.  
 The R factor is 0.179 with an R free of 0.2072. 
  The resolution is 1.43 Å. 
 
